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1.1 Inflammation and cancer 
The  relationship  between  inflammation  and  cancer  was  described  for  the  first 
time in 1863, when Rudolf Virchow observed leukocyte infiltration in 
neoplastic  tissues  (“lymphoreticular  infiltration”)  and  hypothesized  that  the 
origin of cancer was at site of chronic inflammation. In the last decade several 
lines of evidences  – based on a range of findings from epidemiological studies 
of patients to molecular studies of genetically modified mice – demonstrated the 
critical  role  of  infection  and  chronic  inflammatory  diseases  in  tumorigenesis, 
and some of the underlying molecular mechanisms have been elucidated [1-3]. 
Inflammation is a well-coordinated process fundamental either in physiological 
conditions or in protecting body against different exogenous and/or endogenous 
treats. Any disorder in tissue homeostasis activates innate immune cells that are 
a  first  line  of  defense  designed  to  “heal”  the  afflicted  tissue.  In  response  to 
chemotactic cytokines, the innate immune cells (macrophages, mast cells, 
dendritic cells and natural killer cells) migrate from the venous system to sites 
of  damage,  where  initiate  the  inflammatory  response  by  releasing  cytokines, 
chemokines,  matrix-remodeling  proteases,  and  reactive  oxygen  and  nitrogen 
species, leading to the elimination of pathogens and repair of tissue damage [4].  
The key concept is that physiological inflammation, for example inflammation 
associated with wound healing, is a strictly controlled and self-limiting process; 
however,  any  deregulation  in  the  specific  control  of  immune  components  can 
lead  to  chronic  inflammation  that  may  favor  the  initiation  and  progression  of 
cancer. In this scenario, a sustained inflammatory microenvironment provides a 
constant supply of a variety of factors (i.e. cytokines, chemokines and growth 
factors)  which  can  counteract  cell  death  and/or  repair  programs,  resulting  in 
genomic instability and predisposes tissues for cancer development [5, 6].  
Hence,  the  mediators  and  cellular  effectors  of  inflammation  are  important 
components of the local environment of tumors. It is estimated that 20% of all 
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cancers  is  associated  with  chronic  infection  and  inflammation  [7],  indicating 
inflammation as the “Seventh hallmark of cancer” (Fig. 1) [8, 9].  
 
 
         
 
Figure 1: Inflammation as the seventh hallmark of cancer.  
In  2000,  Hanahan  and  Weinberg  proposed  a  model  to  define  the  six  hallmarks  that  a  tumor 
acquires: unlimited replicative potential, ability to develop blood vessels, evasion of 
programmed cell death, self-sufficiency in growth signals, insensitivity to growth inhibitors and 
tissue  remodeling  and  metastasis.  Next  studies  suggest  that  this  model  should  be  revised  to 
include cancer-related inflammation as an additional hallmark [10]. 
 
The connection between inflammation and cancer can be viewed as consisting 
of two pathways; in some types of cancer, inflammatory conditions are present 
before  a  malignant  change  occurs  (extrinsic  pathway)  [7,  11].  Conversely,  in 
other types of cancer, an oncogenic change induces an inflammatory 
microenvironment that promotes the development of tumors (intrinsic pathway) 
[12, 13]. These two pathways converge, resulting in the activation of 
transcription factors, among which nuclear factor-κB (NF-κB), signal transducer 
and activator of transcription 3 (STAT3) and hypoxia-inducible factor 1α 
(HIF1α)  play  a  central  role  in  tumor  cell  biology.  These  factors  recruit  and 
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activate various leukocytes, most notably cells of the myelo-monocytic lineage, 
and  activate  the  same  key  transcription  factors  in  inflammatory  cells,  stromal 
cells and tumor cells, resulting in more inflammatory mediators being produced 
and  a  cancer-related  inflammatory  microenvironment  being  generated.  This 
uncontrolled and non self-limiting cancer-related inflammation has many tumor-
promoting effects; in fact, it aids in the proliferation and survival of malignant 
cells, promotes angiogenesis and metastasis, subverts adaptive immune 
responses and alters responses to chemotherapeutic agents [3, 7].  
However, despite these evidences, genetic studies of mouse models have 
demonstrated  that  innate  immune  cells  activate  an  adaptive  immune  response 
capable of eliminating rising tumors [14]. It is generally accepted that immune 
cells  continuously  recognize  and  destroy  nascent  tumor  cells  but,  due  to  the 
genetic, epigenetic and metabolic instability that characterizes neoplastic cells, 
the  arising  of  new  variants  able  to  evade  the  immune  surveillance  results  in 
tumor  establishment  and  progression  (immunoediting  process)  [15].  Several 
studies  have  emphasized  that  the  “smouldering”  inflammation  associated  with 
tumors is mainly oriented to tune the adaptive immune response. Thus, tumor-
infiltrating  lymphocytes  have  functional  roles  in  promoting  tumor  immune 
escape by producing immunosuppressive cytokines and generating 
immunosuppressive networks. Indeed, myelo-monocytic cells recruited in 
tumors express an alternative M2 functional phenotype mainly oriented towards 
the suppression of the adaptive immune response [16, 17]. In agreement, clinical 
studies suggest that an established type-2 “suppressive” immunological profile 
correlates  with  poor  prognosis,  as  shown  in  colorectal,  hepatocellular  and 
pancreatic carcinomas and in Hodgkin’s lymphoma [18].  
Hence, the immune system plays a dual role in cancer: not only it can suppress 
tumor progression by destroying cancer cells or inhibiting their outgrowth, but it 
can also promote tumor development by establishing favorable conditions 
within the tumor microenvironment that facilitate tumor growth and metastasis 
[19].  
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1.2 Myeloid cells in cancer 
Myeloid cells are the most abundant hematopoietic cells in the human body and 
are a collection of distinct cell populations with different function. All myeloid 
cells arise from multipotent hematopoietic stem cells (HSCs) that develop into 
mature  myeloid  cells  through  sequential  steps  of  differentiation.  The  three 
groups of terminally differentiated myeloid cells (macrophages, dendritic cells 
(DCs) and granulocytes) are essential for the normal functions of the innate and 
adaptive immune systems [20].  
Steady-state myelopoiesis is a continuous homeostatic process, occurring in the 
bone marrow, for replacing hematopoietic cells that are lost to normal 
programmed cell death. In contrast, emergency (or stress) hematopoiesis is an 
episodic  modification  of  the  magnitude  and  composition  of  the  hematopoietic 
output that occurs during immunological stress, including tumor progression, to 
ensure proper supply of immune cells to increased demand [21].  
In this scenario, compelling evidences in literature indicate that dynamic 
changes in myeloid cell functions occur in parallel to tumor development and 
that cancer fuels myeloid cells heterogeneity by promoting sustained 
myelopoiesis. It is well recognized that tumor-derived factors (TDFs), such as 
cytokines, chemokines, metabolites and inflammatory messengers like 
prostaglandins, act in paracrine or systemic manner to induce tumor-
reprogrammed myeloid cells not only to create a widespread tolerogenic 
environment  by  blocking  T  cell  functions  and  proliferation,  but  also  to  drive 
tumor  growth  by  promoting  cancer  stemness,  angiogenesis,  stroma  deposition 
and metastasis formation. Consequently, chronic exposure of the bone marrow 
microenvironment to non-physiologic levels of ordinarily tightly regulated 
myelopoietic-like  growth  factors  corrupts  the  normal  process  of  myeloid  cell 
development and differentiation [8, 20]. This phenomenon drives the increase of 
circulating  myeloid  cells  in  tumour-bearing  hosts  and  it  is  associated  with  a 
partial blockade of myeloid cell differentiation and a consequent accumulation 
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of  highly  immunosuppressive,  immature  myeloid  cells  (iMCs).  Indeed,  many 
TDFs are myelopoietic factors making the myeloid compartment a major target 
of this ‘tumor reconditioning’ [22]. For example, granulocyte colony-
stimulating factor (G-CSF) and granulocyte/macrophage colony-stimulating 
factor (GM-CSF) were reported to drive “emergency” myelopoiesis by securing 
supply of neutrophils and macrophages from bone marrow and extra-medullary 
hematopoietic stem cell niches (HSCs) [23, 24].  
In addition, the macrophage colony-stimulating factor (M-CSF) promotes 
macrophage  differentiation  from  marrow  precursors  cells  and  is  required  for 
differentiation and expansion of tissue macrophages involved in tissue 
homeostasis  and  tumor  progression  [25].  Investigation  of  signaling  pathways 
controlling hematopoiesis revealed that G-CSF-induced granulopoiesis is 
mediated through the transcription factors c-EBPβ [26, 27], SOCS3 [28], Bcl3 
[29] and STAT3 [30], whereas M-CSF supports monocyte differentiation 
through activation of the transcription factors PU.1 and IRF8 [31]. Of relevance, 
interleukin-17A (IL-17A) promotes G-CSF- and stem-cell-factor-mediated 
neutrophilia [32] and supports G-CSF-driven ‘‘emergency’’ myelopoiesis [33].  
Importantly, reciprocal regulation of macrophage versus neutrophil/granulocyte 
differentiation  might  control  tissue  homeostasis;  indeed,  depletion  of  tissue 
macro- phages leads to exacerbated G-CSF-mediated granulopoiesis [34]. Thus, 
investigation  of  the  molecular  networks  that  dictate  this  reciprocal  regulation 
appears to be crucial, as it may affect tissue homeostasis during cancerogenesis. 
Myeloid  deficiencies  can  occur  at  developmental  and/or  functional  levels  in 
essentially  all  myeloid  lineages.  To  distinguish  “normal”  myeloid  cells  from 
their  dysfunctional  counterparts,  the  latter  populations  have  been  variously 
renamed myeloid-derived suppressor cells (MDSCs), tumor-associated 
macrophages (TAMs), tumor-associated neutrophils (TANs), immature DCs or 
tolerogenic  DCs  [35].  Among  these,  TAMs  and  MDSCs  represent  the  major 
orchestrators of the immunosuppressive circuits arising in tumor bearers (Fig. 2) 
[36, 37]. 
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Figure 2: Myeloid cells in cancer.  
Factors produced in the tumor microenvironment by tumor cells and stromal cells promote the 
aberrant differentiation of myeloid lineage cells. The dotted lines show the normal pathways of 
myeloid cell differentiation from immature myeloid precursor cells to dendritic cells, 
macrophages and granulocytes. The solid bold lines indicate the aberrant pathways of myeloid 
cell  differentiation  that  occur  in  cancer,  in  which  the  tumor  environment  can  promote  the 
development of various immunosuppressive populations, including monocytic MDSCs, 
polymorphonuclear MDSCs, suppressive DCs and TAMs and TANs [20].   
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1.3 Myeloid-derived suppressor cells 
MDSCs are a heterogeneous population of cells of myeloid origin that 
comprises myeloid progenitor cells and immature macrophages, immature 
granulocytes  and  immature  dendritic  cells  [38].  They  expand  during  cancer, 
inflammation  and  infection  and  have  a  remarkable  ability  to  suppress  T-cell 
responses.  In  particular,  MDSCs  are  generated  in  the  bone  marrow  and,  in 
tumor-bearing hosts, migrate to peripheral lymphoid organs and tumor tissues 
contributing  to  the  formation  of  the  pro-tumor  microenvironment  [39,  40]. 
Although initial observations and most of the current information on the role of 
MDSCs  in  immune  responses  has  come  from  studies  in  the  field  of  cancer 
research, accumulating evidence has shown that MDSCs also regulate immune 
responses during bacterial and parasitic infections, acute and chronic 
inflammation and sepsis [38].  
 
1.3.1 MDSCs phenotype  
MDSCs  are  characterized  by  a  morphological  mixture  of  granulocytic  and 
monocytic cells lacking the expression of cell-surface markers associated with 
fully differentiated monocytes, macrophages or dendritic cells [41]. In 
particular, MDSCs include a group of immature mononuclear cells, which are 
morphologically  and  phenotypically  similar  to  monocytes  (M-MDSCs),  and 
immature  polymorphonuclear  (PMN)  cells,  which  are  morphologically  and 
phenotypically  similar  to  neutrophils  (PMN-MDSCs).  In  mice,  MDSCs  are 
identified by co-expression of myeloid lineage differentiation antigens Gr-1 and 
CD11b [42]. The two major subsets of MDSCs can be distinguished by different 
expression  of  the  Gr-1  marker  (Gr1 high  cells  are  mostly  PMN-MDSCs  and 
Gr1low cells are mostly M-MDSC). However, the Gr-1 marker is a combination 
of  the  Ly6C  and  Ly6G  markers,  so  these  subsets  can  be  more  accurately 
identified based on Ly6C and Ly6G expression (M-MDSCs as 
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CD11b+Ly6ChighLy6Glow and PMN-MDSCs as CD11b+Ly6G+Ly6Clow). In 
humans, MDSCs are identified in the mononuclear fraction as cells that express 
the  CD33  marker  but  lack  the  expression  of  markers  of  mature  myeloid  and 
lymphoid cells and the HLA-DR. The identification of human MDSCs subsets 
is,  actually,  really  difficult  because  of  their  heterogeneity.  However,  human 
PMN-MDSCs  are  defined  as  CD14 –CD33+CD15+  HLA-DR–/low cells and  M-
MDSCs as CD14 +HLA-DR–/lowCD33+CD15- cells [43-46]. These cells represent 
≈0.5% of peripheral blood mononuclear cells in healthy individuals with a 10-
fold  increase  in  cancer  patients,  such  as  those  with  renal  cell  carcinoma  and 
colorectal carcinoma [47].  
Several biochemical and genomic features distinguish MDSCs from neutrophils 
and monocytes. In particular, MDSCs are characterized by increased expression 
of of NADPH oxidase (Nox2), resulting in increased production of ROS [48]; 
increased  expression  of  arginase  1  (arg1)  and  nitric  oxide  synthase  2  (nos2) 
genes, resulting in increased production of Arg1 and NO [49]; increased 
expression  of  the  transcriptional  factors  c/EBPβ  [27]  and  STAT3  [50]  and 
decreased  expression  of  IRF8  [51].  As  a  result,  MDSCs  display  decreased 
ability to differentiate into mature myeloid cells and their immune suppressive 
effects are due to the hyper production of ROS, NO and Arg1 [20]. 
 
1.3.2 Mechanisms of MDSCs suppressive activity  
MDSCs exert their immunosuppression through several mechanisms. In 
particular, they can mediate suppression of T-lymphocytes in an antigen-
specific and -nonspecific manner, deploying strategies that can be either direct 
or indirect, leading to the generation or expansion of regulatory cell populations, 
such as CD4+CD25+ Tregs. Main mechanisms of action include:  
- ARG1, iNOS and peroxynitrite: the  suppressive  activity  of  MDSCs  has  been 
associated  with  the  metabolism  of  L-arginine,  which  serves  as  a  substrate  for 
two  enzymes:  iNOS,  which  generates  NO,  and  arginase,  which  converts  L-
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arginine into urea and L-ornithine. MDSCs express high levels of both arginase 
and iNOS, and the direct role for both of these enzymes in the inhibition of T-
cell function is now well established [52]. In fact, high levels of Arg1 
expression by MDSCs can accelerate the depletion of L-arginine in the tumor 
microenvironment, which subsequently promotes T cell proliferation arrest and 
functional  inhibition  by  down  regulation  of  the  CD3ζ  chain  in  the  T  cell 
receptor (TCR) complex. [53]. NO suppresses T-cell function through a variety 
of different mechanisms that involve the inhibition of JAK3 and STAT5 in T 
cells [54], the inhibition of MHC class II expression [55] and the induction of T-
cell  apoptosis  [56].  NO  is  mainly  produced  by  M-MDSCs  while  both  subsets 
express Arg1. More recently, it has emerged that reactive nitrogen species, such 
as  peroxynitrite  (ONOO-),  are  byproducts  of  the  combined  activity  of  iNOS, 
ARG1  and  NOX2  that  can  alter  the  formation  of  a  correct  peptide-MHC 
complex in MHCI molecules and interfere with T cell migration and viability. 
In  fact,  they  induce  the  nitration  and  nitrosylation  of  the  amino  acids  cystine, 
methionine, tryptophan and tyrosine in many types of T cells, driving their un-
responsiveness  to  tumor  antigens  [57],  and  modify  trafficking  of  leukocytes 
through aromatic amino acid nitration and nitrosylation of chemokines (CCL2, 
CCL5, CCL21, CXCL12) or chemokine receptors (CXCR4) [58].  
- Reactive oxygen species (ROS): ROS production is the major regulator of the 
suppressive  activity  of  the  PMN-MDSCs  in  both  murine  models  and  human 
cancers; it affect T-cell fitness by down regulating CD3ζ chain expression and 
reducing cytokine secretion [59]. 
- TGFβ: TGFβ is an immunosuppressive cytokine that has been associated  with 
MDSCs  functions  and  with  the  regulation  of  tumor  induction  and  expansion 
[60]. 
-  Induction  of  regulatory  T  cells  (Tregs):  emerging  evidence  indicates  that 
MDSCs are involved in Tregs recruitment and differentiation through the 
production of several chemokines (acting on CCR5 and CCR6) and cytokines 
(i.e.  IFN-γ,  IL-10)  and/or  through  direct  cell-cell  contacts  (including  CD40-
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CD40L interactions) [61]. Moreover, to sustain the immune-suppressive 
environment,  MDSCs  also  skew  TAMs  activation  towards  an  M2  polarized 
phenotype, characterized by impaired production of functional IL-12 supporting 
immune escape and tumor growth, through a cell contact–dependent mechanism 
[40]. MDSCs also promote immune dysfunction by expressing membrane 
surface  ligands  of  T  cell–inhibitory  receptors,  such  as  programmed  cell  death 
ligand  1/2  (PD-L1/2),  which  bind  programmed  death  1  (PD-1),  and  B7-1/2, 
which bind to cytotoxic T lymphocyte antigen 4 (CTLA4) and CD28 as well as 
FASL [62, 63].   
Hence,  in  tumor-bearing  hosts  MDSCs  inhibit  the  immune  response  through 
four processes: 1) driving the differentiation of immune cells toward regulatory 
cells;  2)  interfering  with  T  cell  migration;  3)  altering  T  cell  functionality  by 
production of NO, ROS and RNS; and 4) depleting essential metabolites for T 
lymphocyte fitness.  Several studies indicate that M-MDSCs are highly 
immunosuppressive  and  exert  their  effects  largely  in  an  antigen-nonspecific 
manner, whereas PMN-MDSCs are moderately immunosuppressive and 
promote T cell tolerance via antigen-specific mechanisms (Fig. 3) [41].  
 
             
 
Figure 3: Mechanisms of MDSC’s suppression  
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MDSCs suppress the immune system by distinct mechanisms including increased Tregs 
proliferation,  direct  actions  of  MDSC  on  T  cells  by  increased  NO,  nitrotyrosine  and  ROS 
secretion, and decreased l-arginine production [64].  
 
 
1.3.3 Expansion and activation of MDSCs in cancer  
 
Accumulating evidence from tumor-bearing mice and human cancers indicates 
that  the  expansion  and  activation  of  MDSCs  in  the  tumor  microenvironment 
requires  the  integration  of  at  least  two  types  of  signals:  signals  promoting 
accumulation of immature myeloid cells, followed by signals providing for the 
pathological activation of these cells [43].  
MDSCs  are  generated  in  the  bone  marrow  from  common  myeloid  progenitor 
cells (CMP). The expansion of immature myeloid cells is mediated largely by 
granulocyte-macrophage CSF (GM- CSF), macrophage CSF (M-CSF), 
granulocyte CSF (G-CSF) and other factors, such as pro-inflammatory 
cytokines and damage-associated molecular pattern molecules (DAMPs), 
produced by tumor cells and stroma (e.g. cyclooxygenase 2, prostaglandins, IL-
6, IL-17, C5a, VEGF) [65-70]. MDSCs expansion is facilitated by triggering a 
cascade through the signaling molecules that regulate cell survival, 
proliferation, differentiation and apoptosis, which are known as family members 
of  Janus  tyrosine  kinase  and  STAT3  [71].  In  recent  years,  more  evidence  has 
emerged regarding the mechanism of MDSCs regulation by STAT3. Indeed, it 
was  reported  that  MDSCs  from  tumor-bearing  mice  have  markedly  increased 
levels of phosphorylated STAT3 compared with Immature Myeloid Cells 
(IMCs) from naive mice. Several evidence in  vitro indicate also that the 
exposure  of  hematopoietic  progenitor  cells  to  the  supernatant  from  tumor-cell 
cultures  activate  JAK2  and  STAT3  in  parallel  with  an  expansion  of  MDSCs, 
and that this expansion is abrogated when STAT3 expression in hematopoietic 
progenitor  cells  is  inhibited  [72].  Moreover,  ablation  of  STAT3  expression 
through  the  use  of  conditional  knockout  mice  or  selective  STAT3  inhibitors 
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markedly reduced the expansion of MDSCs and increased T-cell responses in 
tumor-bearing mice [73].  
The  effect  of  STAT3  on  MDSCs  accumulation  is  mediated  by  C/EBPβ  and 
IRF8  and  is  associated  with  increased  survival  and  proliferation  of  myeloid 
progenitor cells, probably through the up-regulation of the expression of B-cell 
lymphoma  XL,  cyclin  D1,  MYC  and  survivin.  So,  abnormal  and  persistent 
activation  of  STAT3  in  myeloid  progenitor  cells  prevents  their  differentiation 
into mature myeloid cells and thereby promotes MDSCs expansion [27, 51].  
However,  the  activity  of  MDSCs  does  not  only  require  factors  that  promote 
their expansion but also activating factors that exert their effect through multiple 
signaling  pathways  including  STAT6,  STAT1  and  NF-κB.  These  factors  are 
mainly produced by activated T cells and tumor stromal cells and include IFN-γ, 
ligands for TLRs, IL-13, IL-4 and TGF-β [20]. STAT1 is the major transcription 
factor that is activated by IFN-γ and drives the up-regulation of Arg1 and iNOS 
expression in MDSCs within the tumor microenvironment. MDSCs from 
STAT1-knockout  mice  could  not  up-regulate  Arg1  and  iNOS  expression  and 
subsequently  had  no  inhibitory  effect  on  T  cells  [74,  75].  Moreover,  also  the 
signaling  pathway  that  involves  IL-4  receptor  α-chain  (IL-4Rα)  and  STAT6 
(which  is  activated  by  the  binding  of  either  IL-4  or  IL-13  to  IL-4Rα)  is 
important for MDSCs activation, but probably only in some tumor models [76]. 
Hence,  the  impact  of  MDSCs  in  cancer  is  characterized  both  by  an  abnormal 
myelopoiesis and recruitment of MDSCs into the tumor site, resulting from the 
persistent  stimulation  of  the  myeloid  compartment  with  signals  coming  from 
tumors, and by an active MDSCs cytokine production and cell–cell interactions 
within the environment that promote tumor immune evasion by limiting T-cell 
responses and infiltration into the tumor microenvironment [39, 77]. 
MDSCs  are  also  capable  of  supporting  tumor  growth  through  nonimmune-
related  mechanisms  designed  to  remodeling  tumor  microenvironment.  They 
have been shown to produce several mediators implicated in the 
neoangiogenesis  and  tissue  invasion  [78].  In  the  tumor  microenvironment  in 
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fact, MDSCs promote the angiogenic switch, by producing proteases (cathepsin 
and matrix metallo-proteinases 9 (MMP9)) and enhancing VEGF bioavailability 
[79].  In  addition,  MDSCs  also  play  an  active  role  in  promoting  the  spread  of 
distal tumor cells. In a murine model of melanoma, it was reported that MDSCs 
promote cancer cell dissemination by inducing epithelial–to-mesenchymal 
transition  (EMT)  through  the  production  of  TGF-β  in  primary  tumor  [80]. 
Moreover, mouse models have shown that MDSCs appear in the lungs as early 
as two weeks prior to the appearance of metastases in parallel with decreased 
immune function in the lungs. Importantly, myeloid-specific deletion of MMP9 
essentially  eliminated  metastasis,  suggesting  indispensable  role  of  MDSCs  in 
the establishment of the premetastatic niche [81-83]. 
 
1.3.4 Therapeutic strategies targeting MDSCs  
The fact that MDSCs strongly contribute to the establishment of an 
immunosuppressive  tumor-microenvironment  has  stimulated  the  search  for  a 
way to therapeutically target these cells in order to allow for increased antitumor 
immunity. Several therapeutic strategies are currently being tested in clinic with 
the aim to elimination, deactivation, or skewing of myelopoiesis away from the 
accumulation of MDSCs [43, 84].  
MDSCs can be eliminated with some first-generation chemotherapeutic agents, 
probably  because  these  cells  are  more  sensitive  than  tumor  cells  to  low-dose 
chemotherapy [85]. In this scenario, gemcitabine has been shown to specifically 
deplete splenic MDSCs in tumor-bearing mice, resulting in enhanced antitumor 
response and prolonged survival [86, 87].  
Similar success in selectively MDSCs targeting has been achieved with a single 
administration of 5-fluorouracil, which resulted in increased CD8+ T-cell 
responses [88]. Moreover, it was shown that selective up regulation of TRAIL 
receptor DR5 on mouse MDSCs induce their depletion selectively, resulting in 
tumor growth inhibition [89]. 
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MDSCs can be functionally inactivated by targeting their suppressive 
machinery. In particular, the up regulation by a synthetic triterpenoid of Nf-E2–
related factor 2 (NRF2), that plays an important role in protecting cells against 
free  radical  damage, has  been  shown  to  reduce  the  production  of  ROS  by 
MDSCs ex vivo [90]. Moreover, phosphodiesterase-5 (PDE-5) inhibitor  is able 
to  inhibit  MDSCs  functions  by  decreasing  their  production  of  both  Arg1  and 
iNOS restoring the  in vitro T-cell proliferation in multiple myeloma and head 
and neck cancer patients [91, 92].  
Finally,  also  nitroaspirin  has  been  shown  to  down  regulate  NO  and  ROS 
production and thus eliminates the suppressive functions of MDSCs [93].   
Other compounds have been reported to affect MDSCs accumulation in cancer; 
for example all-trans-retinoic acid (ATRA) at therapeutic levels has been shown 
to  induce  MDSCs  differentiation  into  DCs  and  macrophages,  leading  to  a 
subsequent  reduction  in  the  number  of  MDSCs  in  renal  and  lung  carcinoma 
patients  and  mice  [94,  95].  Additionally,  sunitinib,  which  inhibits  STAT3, 
VEGF, c-kit, and M-CSF signaling, has been shown to reduce MDSCs 
accumulation  in  renal  cell  carcinoma  patients  and  may  provide  a  strategy  for 
improving antitumor immunity in these patients [96].   
Therefore,  different  approaches  have  been  explored  to  harness  the  potency  of 
the  immune  system  to  target  cancer.  However,  till  now,  efforts  to  actively 
stimulate  the  immune  system  against  tumors  in  patients  have  been  largely 
disappointing  despite  substantial  evidence  that  peripheral  immune  responses 
against tumor antigens can be generated. Moreover, immune-modulating 
activities of chemotherapeutic agents are often very complex to understand, in 
fact,  the  same  molecules  may  play  opposite  roles  depending  on  tumor  type, 
immune contexture, and/or precise therapeutic strategy. For example, 
gemcitabine and 5-fluorouracil, have been reported to deplete 
immunosuppressive MDSCs but also to induce the release of cathepsin B from 
lysosomes  and  the  activation  of  the  NLRP3  inflammasome  and  caspase-1, 
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which causes IL-1β secretion from MDSCs, resulting in IL-17 production by T-
cells and promotion of tumor growth [97].  
These complexities underscore the need for an ever more profound 
comprehension of the dynamic changes in the tumor microenvironment and in 
systemic immune responses as tumors evolve, progress, and respond to therapy, 
in order to facilitate the rational design of highly efficient, synergistic regimens 
that combine anticancer agents and immunotherapies.  
 
1.4 Tumor-associated macrophages  
Macrophages  are  a  group  of  terminally  differentiated  tissue-resident  myeloid 
cells found in all tissues, derived from monocytes circulating in peripheral blood 
[98].  They are key players in tissue homeostasis maintenance, tissue repair and 
immune  surveillance,  with  important  functions  in  both  innate  and  acquired 
immunity.  Resident  macrophages  provide  immediate  defense  against  foreign 
pathogens contributing to the balance between antigen availability and clearance 
through  phagocytosis  and  subsequent  degradation  of  senescent  or  apoptotic 
cells,  microbes  and  possibly  neoplastic  cells.  Macrophages  also  coordinate 
leukocyte  infiltration  and  their  role  is  essential  for  triggering,  instructing  and 
terminating the adaptive immune response [99].  
Macrophages  are  the  most  plastic  cells  of  the  hematopoietic  system  able  to 
finely  modulate  their  programs  in  response  to  different  microenvironmental 
conditions [100].  In the last decade, there have been numerous reports about the 
relationship between macrophages and tumors. In fact, tumor-associated 
macrophages (TAMs) represent the major population of leucocytes infiltrating 
tumors  and,  despite  their  potential  anti-tumor  activities,  there  is  an  extensive 
literature demonstrating that in both mouse and man, TAMs are co-opted during 
malignancy to facilitate tumor development and invasion [101].   
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1.4.1 Macrophage polarization  
Macrophages  are  highly  plastic  cells  that  can  adopt  different  phenotypes  or 
activation states in response to different microenvironmental signals (e.g. 
cytokines,  pathogen-associated  molecular  patterns,  danger  stimuli)  [102,  103]. 
This plasticity increases the heterogeneity of macrophage populations in a given 
tissue  and  in  particular,  the  M1/M2  dichotomy  is  the  widely  used  model  for 
describing their different functional states (Fig. 4) [104, 105].  
 
             
Figure 4: M1 and M2 macrophages. 
In the presence of IFN–γ, LPS and other microbial products, monocytes differentiate into M1 
macrophages.  In  the  presence  of  macrophage  colony-stimulating  factor  (CSF-1),  IL-4,  IL-13, 
IL-10  and  immunocomplexes  in  association  with  either  IL-1R  or  TLR-ligands,  monocytes 
differentiate  into  M2  macrophages.  M1  and  M2  subsets  differ  in  term  of  phenotype  and 
functions. M1 cells have microbial activity, immuno-stimulatory functions and tumor 
cytotoxicity. M2 cells have high scavenging ability, promote tissue repair and angiogenesis and 
favour tumor progression [106].  
 
“Classical activated” M1 macrophages are potent antigen presenter cells 
involved in T helper 1 (Th1)-cell-mediated immune resolution of infection and 
exert  their  cytotoxic  activities  by  secreting  nitric  oxide  and  ROS.  Typical 
drivers of M1 activation are Th1 cytokines such as IFN-γ and microbial 
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products  (LPS).  These  signals  trigger  the  activation  of  NF-κB-  and  STAT1- 
pathways  with  subsequent  transcription  of  NF-κB-  and  STAT1-  dependent 
proinflammatory cytokines (e.g. IL-12, IL- 23 and TNFα) [107, 108].  
On the contrary the “alternative activated” M2 macrophages secrete anti-
inflammatory cytokines and are involved in scavenge debris, tissue remodelling 
and repair, angiogenesis and humoral immunity and are able to tune 
inflammatory response [109]. They show strong activation of arginase pathway 
with generation of ornithine and polyamines. Important drivers of M2 activation 
are the Th2 cytokines, such as IL-4 and IL-13, the anti-inflammatory cytokines 
IL-10  and  TGF-β,  hormones  (e.g.  glucocorticoids),  and  immune  complexes. 
These  M2-polarizing  signals  generally  inhibit  the  expression  of  M1  cytokines 
and chemokines. These inhibitory effects principally relay on STAT-3 
dependent mechanisms and the direct inhibition of NF-κB [110].  
In vivo,  macrophages  can  be  exposed  to  a  large  number  of  stimuli  that  may 
induce opposing signaling pathways and thus result in mixed functional states. 
Nevertheless,  there  is  considerable  plasticity  between  distinct  types.  For  this 
reason macrophage activation should not be seen as existing of discrete states 
M1 and M2, but rather as a continuum that emphasize the extremes of 
macrophage  plasticity  (Fig.  5)  [109].  M1  and  M2  extremes  exhibit  specific 
characteristic  expression  of  metabolic  enzymes  (iNOS  vs.  ARG1),  cytokines 
(IL-12highIL-10low vs. IL-12 lowIL-10high), chemokines (CXCL9 and CXCL10 vs. 
CCL17 and CCL22), as well as transcription factors (NF-κB, STAT1 and IRF5 
vs. STAT6, MYC, IRF4 and PPARγ) [104].  
A large body of literature indicates that monocytes and macrophages associated 
with  established  tumors  show  an  immunosuppressive,  M2  phenotype  which 
supports immune escape, tumor growth and malignancy exerting crucial tumor-
promoting functions [109, 111]. However, when applied to TAMs the M1/M2 
dichotomy  is  too  simplistic  since  their  phenotype  varies  significantly  between 
tumors or even among different areas of the same tumor [112, 113]. Monocytes 
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from  patients  with  renal  cell  carcinoma  indeed  coexpress  proinflammatory 
genes,  such  as  TNFα,  together  with  tumor-promoting  genes  VEGFA,  MMP9 
and CXCR4 [44]. Moreover, similar mixed phenotypes have been observed in 
various  other  tumor  models  [114].  Thus,  defining  TAMs  polarization  status 
require  integration  of  a  multiparameter  analysis  of  cell  surface  markers,  and 
comparison of the TAMs transcriptome with the gene profile of resident 
macrophages isolated from the same tissues [17, 104].   
 
                     
 
Figure 5: M1 and M2 macrophages are the extremes of a continuum [109].  
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1.4.2 Origin, recruitment and activation of TAMs  
As mentioned above, TAMs are the main orchestrators of inflammation 
associated  with  cancer  and  constitute  the  dominant  myeloid  cell  population, 
both  in  terms  of  number  and  functions,  in  most  solid  tumors.  However,  the 
details  regarding  TAMs  origins  and  the  stimuli  that  drive  their  differentiation 
and functional states are still being defined [25, 105, 115].  
It has long been held that macrophages originate from the blood compartment 
and that chemotactic signals originating from tumor cells or from normal cells 
present  in  the  cancer  microenvironment  recruit  monocytic  precursors  at  the 
primary and metastatic tumor sites [116]. Recent studies, however, have shown 
that most tissue macrophages, although with some exceptions such as intestine, 
arise  during  early  embryonic  development  from  yolk  sac  and  do  not  require 
input from the bone marrow (BM) but rather maintain their populations via local 
proliferation.  In  contrast,  macrophages  involved  in  pathogen  responses  appear 
to come from circulating BM monocytes (Fig. 6) [98, 117-120].  
 
 
Figure 6: Macrophage ontogeny in mice.  
The mononuclear phagocytic system in adults derives from at least three sources. The first is the 
yolk  sac  (YS)  that  results  in  progenitors  that  populate  all  tissues  and  their  progeny  persist 
throughout life as F4/80 bright resident macrophages. These lineages are largely regulated by 
CSF1R. The second from the fetal liver is less well defined but seems to contribute to adult LCs 
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perhaps  through  a  progenitor  derived  from  the  YS.  The  third  lineage  derives  from  the  bone 
marrow (BM) to give circulating monocytes and their progeny F4/80 low macrophages and DCs. 
In this case the Ly6C + monocytes give rise to classical DCs under the regulation of FLT3 and 
these  are  continuously  replenished.  Other  macrophages  that  are  F4/80 low also  emanate  from 
Ly6C+ monocytes and in some cases such as kidney and lung, co-exist with those derived from 
YS  to  give  chimeric  organs.  The  exact  role  of  the  patrolling  Ly6C + macrophages  remains 
unclear, as is the contribution of fetal liver to adult tissue macrophages [98].  
 
Hence, in light of these recent findings, macrophage ontogeny in carcinogenesis 
has been revisited. A relevant question is whether TAMs are derived from the 
local tissue macrophage pool or whether they are newly recruited BM-derived 
cells. To date, developmental origins of TAMs have been best studied in mouse 
tumor  models  of  the  breast  and  lung  and  experimental  indications suggest  a 
monocyte  origin  for  TAMs  [112,  121-124].  In  this  regard,  a  recent  study  by 
Franklin  et al.,  conducted  in  the  polyoma  middle  T  (PyMT)  oncogene-driven 
mouse  model  of  breast  cancer  (MMTV-PyMT),  showed  that  these  monocyte-
derived  TAMs  are  continuously  replaced  via  peripheral  recruitment.  In  fact, 
they pointed out that the major TAMs population (MHCII highCD11blow), as well 
as the mammary tissue-resident macrophage population ((MTMs) 
MHCIIhighCD11bhigh) originates from Ly6C highCCR2+ monocytes. However, the 
role of local renewal cannot be excluded, since they observed that TAMs also 
expand their population through in situ proliferation [122].  In line with these 
results,  in  another  spontaneous  breast  cancer  model  MMTV-Neu,  two  TAMs 
populations were identified (CD11bhighF4/80lowMHCIIhigh and 
CD11blowF4/80highMHCIIint)  and  both  were  also  found  to  be  derived  from 
monocytes, with the CD11blow population heavily dependent on in situ 
proliferation [123]. 
Recent experimental evidences conducted in mouse models of lung carcinoma, 
suggest that TAMs also in the lung tumor are monocyte-derived, similar to their 
counterparts  in  breast  cancers  [121,  124].  A  study  by  Cortez-Retamozo  et al. 
showed that in the genetic KrasLSL–G12D/+p53fl/fl lung carcinoma model, 
fluorescently tagged monocyte precursors were found to differentiate into 
macrophages  in  developing  tumors.  Furthermore,  this  study  suggested  that 
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instead of coming directly from the BM, a substantial fraction of TAMs arise 
from extra-medullary hematopoiesis within the spleen, which may function as a 
reservoir  that  continuously  supplies  the  tumor  with  fresh  progenitors  [121], 
although the relative contribution of BM and spleen to the monocyte reservoire 
and tumor trafficking is not clear and might be tumor dependent [125].  
Together,  these  findings  suggest  that  TAMs  can  arise  from  tissue-resident 
macrophages, originating either from embryonic precursors which seed 
peripheral  locations  and  self-sustain  or  from  circulating  monocytes,  that  may 
undergo a change in phenotype and/or activation state during carcinogenesis, or 
from inflammatory Ly6C+ circulating monocytes that undergo a distinct 
differentiation step to become macrophages in response to tumor 
microenvironment, and that these two populations may both be present 
simultaneously  in  the  tumor  microenvironment  potentially  having  differential 
roles.  
TAMs differentiation and localization is not a defined and preserved track but 
depends on both anatomical location and the tumor stage: cancers with different 
histology  are  infiltrated  by  TAMs  with  phenotypic  and  functionally  distinct 
properties [112]. Interestingly, TAMs heterogeneity may be due to the nature of 
the monocytic precursor that is recruited to the tumor. Clear indications 
emerging  from  several  tumor  models  suggest  that  Ly6Chigh  monocytes,  which 
rely on the CCL2-CCR2 axis, are the major precursor of TAMs [112, 121, 122, 
126].  
In addition, a smaller subset of TAMs, encompasses monocytes that express the 
angiopoietin-2 receptor TIE2, may arise from Ly6C lowCCR2- monocytes. These 
pro-angiogenic TAMs, known as Tie2-expressing monocytes (TEMs), are 
recruited  to  the  tumor  by  angiopoietin-2,  localize  preferentially  in  areas  of 
angiogenesis,  aligned  along  the  abluminal  surface  of  blood  vessels,  and  play 
important non-redundant roles in tumor neovascularization [114, 127].  
The  development  of  macrophages  from  monocytes  is  regulated  by  several 
cytokines, such as IL-6, and myelopoietic growth factors, such as M-CSF and 
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GM-CSF [128]. Among these, M-CSF, also known as colony stimulating factor 
1 (CSF1), is the major lineage regulator of macrophages regardless their arising 
from  the  yolk  sac  or  BM,  and  in  addition  it  is  a  chemotactic  factor  for 
macrophages [129]. In this regard, in several models of cancer, genetic deletion 
of CSF1 or CSF-1R signaling inhibition with anti-CSFR1 antibodies, results in 
reduced number of TAMs recruited in the tumor microenvironment associated 
with slowed tumor initiation or decreased disease progression and distal 
metastatic spread [130-132]. Indeed, elevated CSF1 levels correlated with 
marked  macrophage  infiltration  in  human  metastatic  breast  cancer  [25].  In 
addition,  the  transcription  factor  PU.1,  which  among  other  functions  controls 
the expression of CSF1R, regulates differentiation of progenitors to the 
macrophage lineage [133]. 
Moreover, in a xenograft model of skin cancer, it was reported that also VEGFA 
recruits  macrophage  progenitors  that  then  differentiate  to  TAMs  under  IL-4 
influence and that loss of these VEGF-recruited TAMs inhibited tumor growth, 
angiogenesis  and  invasion  [134].  These  observations  indicate  that  CSF1  and 
VEGFA  can  be  independent  recruiters  of  macrophages  to  tumors  in  mouse 
models  and  that  this  effect  could  be  explicated  via  recruitment  of  monocytes 
and/or through proliferation of recruited or resident cells.  
Compelling evidence indicate that these growth factors act collaboratively in the 
tumor microenvironment with locally synthesized TDFs, such as cytokines (e.g. 
IL-10, IL-4, IL-13, IFN-γ,  IL-1β), chemokines (e.g. CCL2, CXCL12, CCL5) as 
well as growth factors and noncanonical chemotactic peptides (e.g. TGF-
β, PGE2), to drive the monocyte-to-macrophage differentiation and the 
macrophage activation state inside tumors [122, 126, 135-137].  
Several  factors  controlling  TAMs  phenotype  coincide  with  signals  driving 
"alternative" macrophage activation such as IL-10, IL-4 and IL-13. These latter, 
bind different receptors sharing the IL-4Rα chain that is responsible for 
recruiting and phosphorylating STAT6, which induces the transcription of genes 
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involved in the immune-suppressive program [138]. Recently, genetic evidence 
in the mouse suggested that complement components, C5a in particular, play an 
important role in recruitment and functional polarization of TAMs [139]. 
Interestingly, macrophages may also be affected by the metabolic environmental 
signals that are associated with malignant neoplasms. The tumor 
microenvironment is typically hypoxic and characterized by a high 
concentration of lactate due to the ‘Warburg effect’ namely the metabolic shift 
occurring in highly proliferating cells which predominantly convert glucose into 
lactate even in the presence of oxygen (aerobic glycolysis) [140]. This results in 
substantial  production  of  lactic  acid,  which  was  recently  shown  to  polarize 
TAMs activation toward an M2 state and to influence their spatial dissemination 
within specific areas of tumors [141]. In particolar, TAMs accumulate 
preferentially in poorly vascularized regions of tumors, suggesting that oxygen 
availability  has  a  role  in  guiding  their  localization  and  function.  Hypoxia 
promotes the metabolic adaptation of TAMs through the activation of hypoxia-
inducible  factors  HIF-1α  and  HIF-2α.  HIF-1α  influences  the  positioning  and 
function of tumor cells, stromal cells and TAMs by up-regulating their 
expression  of  CXCR4.  Moreover,  HIF-1α  activation  can  have  a  role  in  the 
induction  of  the  CXCR4  ligand  CXCL12,  a  chemokine  involved  in  cancer 
metastasis [142-144].  
Despite  these  several  indications,  the  detailed  mechanisms  for  the  recruitment 
and tumor-promoting function of TAMs are not fully understood; thus, further 
investigation is required to identify new targets for cancer immunotherapy. 
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1.4.3 Pro-tumoral mechanism of TAMs 
For  decades,  solid  tumors  have  been  known  to  be  strongly  infiltrated  by 
inflammatory leukocytes and accumulating evidences have clearly demonstrated 
in various mouse and human malignancies, that despite high levels of 
infiltration, macrophages are unable to stimulate an effective antitumor response 
and are instead generally associated with poor patient prognosis [4, 145, 146]. 
One  of  the  most  important  characteristic  of  TAMs  include  their  ability  to 
directly affect tumor growth through promotion of tumor angiogenesis as well 
as the survival and metastasis of tumor cells [147, 148].  
As already discussed, in terms of cytotoxicity and expression of inflammatory 
cytokines, we can say that TAMs resemble the M2 macrophages: both are poor 
producers of NO and of ROIs [149]; both are poor antigen presenting cells and 
not  only  they  are  unable  to  trigger  Th1  polarized  immune  responses,  but  also 
they  induce  Treg  cells  and  suppress  T  cell  activation  and  proliferation  [111]. 
Moreover, TAMs express high levels of both scavenger receptor-A (SR-A) and 
the  mannose  receptor  (MR)  together  with  other  M2  markers  like  Arginase  I, 
YM1, FIZZ1 [150].  
In agreement with the M2 signature, TAMs were reported to express low levels 
of inflammatory cytokines (e.g. IL-12, IL-1β, TNFα, IL-6) [109].  
Activation of the transcriptional factor NF- κB is a necessary event promoting 
transcription of several proinflammatory genes. TAMs display a defective NF-
κB activation in response to M1 polarizing signals LPS and TNFα [151]. The 
defect in NF-κB was shown to be due to the over expression of nuclear p50 NF-
κB homodimers which inhibit the transcription of proinflammatory genes [152]. 
The defective NF-κB activity was seen in TAMs isolated from tumors 
characterized by advanced stages and is in apparent contrast with TAMs NF- κB 
dependent pro-tumorigenic functions observed in murine models of 
inflammation-associated liver and colorectal cancer [153, 154]. This 
discrepancy  might  reflect  a  dynamic  change  in  the  tumor  microenvironment 
  27 
during  the  transition  from  early-neoplastic  events  to  advanced  tumor  stages, 
which would result in progressive modulation of the NF- κB activity expressed 
by infiltrating inflammatory cells and progressive conversion of the TAMs from 
an M1 to an M2 macrophage phenotype (Fig. 7) [15].  
   
 
 
Figure 7: Macrophage polarization in tumor immunoediting and progression.  
During  tumor  progression  a  gradual  switching  of  macrophage  polarization,  M1  versus  M2,  is 
paralleled by the gradual inhibition of NF-κB activity. These events concur to establish 
permissive conditions for tumor growth and spread [100]. 
 
Interestingly, over-expression of p50 NF-κB has also been reported in 
endotoxin  tolerant  human  monocytes  which  show  defective  TNFα  production 
but overexpress IL-10, similar to the TAMs [155]. However, while in sepsis the 
over-expression  of  the  p50  NF- κB  represents  a  protective  response  against 
deregulation  of  the  inflammatory  process,  in  cancer  it  may  be  part  of  the 
immunosuppressive mechanisms associated with tumor growth [37].  
TAMs favor tumor growth through non-immune and immune processes. 
Angiogenesis  is  an  M2-associated  function,  which  represents  a  key  event  in 
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tumor progression. Indeed, in several human cancers, TAMs accumulation has 
been associated with angiogenesis and with the production of angiogenic factors 
such  as  VEGF  and  platelet-derived  endothelial  cell  growth  factor  [1,  156]. 
Additionally, TAMs participate to the proangiogenic process by producing the 
angiogenic  factor  thymidine  phosphorylase,  which  promotes  endothelial  cell 
migration  in  vitro  and  whose  level  of  expression  is  associated  with  tumor 
neovascularization [157].  
TAMs  also  play  an  active  role  in  promoting  the  spread  of  distal  tumor  cells. 
They  express  enzymes  that  regulate  the  digestion  of  the  extracellular  matrix, 
such  as  MMPs,  plasmin,  urokinase-type  plasminogen  activator  [158]  and  the 
uPA  receptor.  In  mammary  tumors,  TAMs  promote  metastatic  diffusion  via  a 
paracrine  loop  involving  CSF1  and  EGF,  which  induces  macrophages  and 
tumor cells to cluster around blood vessels, where macrophages create a gate for 
tumor cell intravasation into the circulation, thus producing a tumor 
microenvironment for metastasis [35, 148, 159, 160]. 
As  mentioned  above,  the  most  important  pathogenic  activity  of  TAMs  is  the 
suppression of anticancer immune responses. This ability is due at least partially 
on  their  reduced  immunostimulatory  properties.  For  instance,  TAMs  produce 
low levels of IL-12, which triggers tumoricidal actions of natural killer cells and 
the generation of cytotoxic CD4+ T-cells, and high levels of immunosuppressive 
factors  such  as  IL-10,  TGFβ   and  PGE2,  which  recruit  Treg-cells  [150].  In 
particular, TAMs-derived IL-10 negatively regulates the production of IL-12 by 
tumor-associated myeloid cells and thus indirectly stimulates the differentiation 
of  Th2  cells  that  release  high  levels  of  IL-4  and  IL-13  reinforcing  TAMs 
protumor phenotype [161].  
TAMs  can  also  direct  suppress  the  cytotoxic  functions  of  T-cells  and  this 
immunosuppression  is  mediated,  at  least  in  part,  by  nitrosylation  of  T-cell 
receptors  via  ARG1,  iNOS  and  peroxynitrite,  inducing  T  cell  apoptosis  [20, 
162, 163]. Moreover, TAMs may also promote apoptosis of T-cells by 
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expressing on their cell surface the inhibitory B7 family molecules PD-L1 and 
B7-H1, which trigger checkpoint blockade in T cells [164]. 
Finally,  TAMs  maintain  the  cancer  cell  reservoir  by  providing  a  niche  for 
cancer  stem  cells  (CSC).  Indeed,  TAMs  can  sustain  CSC  proliferation  by 
releasing proinflammatory cytokines such as TNF-α and IL-6, which reinforce 
tumor cell proliferation through NF-κB and STAT3 signaling pathways, and by 
producing milk fat globule EGF factor 8 (MFGE8), which favored CSC 
reservoir survival during chemotherapeutic treatment [165-167]. 
 
   
  
 
Figure 8: Pro-tumoral mechanisms of TAMs [101].   
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1.4.4 TAMs as therapeutic targets 
It is now clear that cells of the monocyte-macrophage lineage are an essential 
element of the inflammatory component in the tumor contest that play a key role 
in supporting cancer development [168, 169]. In addition to these pro-tumoral 
activities, TAMs can also modulate the efficacy of various form of anticancer 
therapy [162, 170]. Based on this, both the recruitment and activation of TAMs 
are considered putative targets for therapeutic intervention. In particular, current 
therapeutic approaches affecting TAMs compartment are aimed either at 
reeducating  their  functional  activation  to  an  antitumor,  M1-like  phenotype  or 
inhibiting their recruitment and/or survival in tumors [171].  
As mentioned above, mediators involved in macrophage recruitment in tumors 
include for instance CCL2, CCL5, complement components, CSF-1 and VEGF 
and  the  inhibition  of  these  molecules  with  specific  monoclonal  antibodies  or 
antagonist prevent TAMs recruitment, reducing tumor growth and 
dissemination [122, 126]. Indeed, compelling evidences indicate that inhibition 
of CCL2 with specific antibodies reduced tumor growth in several experimental 
models  such  as  prostate,  melanoma,  breast  and  lung  cancer;  moreover,  when 
administered in combination with chemotherapy, anti-CCL2 antibodies 
improved the therapeutic efficacy [172-174]. However, it has been also shown 
in a breast cancer mouse model, that recession of anti-CCL2 treatment increased 
the mobilization and recruitment of circulating monocyte, thus accelerating lung 
metastasis [175]. 
Analysis  of  leukocyte  migration  in  colon  cancer  (CRC)  metastasis  revealed 
overproduction of CCL5, a TAMs attractant also responsible for their functional 
skewing. Recent clinical studies reveal that treatment with a CCR5 antagonist 
result in biological and clinical responses in a small cohort of advanced CRC 
patients,  indicating  the  CCL5-CCR5  axis  another  possible  therapeutic  target 
[176]. 
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The CSF-1 receptor (CSF-1R) is exclusively expressed by the monocytic 
lineage, thus representing an obvious target to hit TAMs; accordingly, anti-CSF-
1R  neutralizing  antibodies  or  small  molecule  inhibitors  interfering  with  this 
pathway have been developed and tested in preclinical models [177, 178]. Ries 
et  al.  reported  that  treatment  with  anti-CSF-1R  antibody  (RG7155)  strongly 
reduced TAMs infiltration in tumors accompanied by an increase of the 
CD8+/CD4+ T cell ratio, in animal models; in addition, administration of 
RG7155 to diffuse-type giant cell tumor (Dt-GCT) patients led to reductions of 
macrophages in tumor biopsies [131]. 
Moreover,  TAMs  depletion  by  anti-CSF1  antibodies  enhanced  the  efficacy  of 
combination chemotherapy (cyclophosphamide, methotrexate, and 5-fluoro-
uracil) in chemoresistant, human breast cancer xenografts grown in 
immunodeficient mice [162]. Similarly, TAMs depletion improved the efficacy 
of paclitaxel in a transgenic mouse model of mammary adenocarcinoma [179]. 
Small  molecule  inhibitors  to  CSF1R  have  also  been  shown  to  deplete  some 
populations of TAMs and to dramatically enhance responses to chemotherapy. 
This effect is at least in part consequent to the removal of macrophage-mediated 
immunosuppression leading to the increased of CD8 + T cell infiltration during 
the tumor recovery period [162, 170]. 
Trabectedin is an anticancer drug licensed in Europe and several other countries 
for the treatment of soft tissue sarcoma patients and ovarian carcinoma patients; 
it  was  initially  identified  for  its  potent  cytotoxic  and  antiproliferative  activity 
against malignant cells [180]. Further clinical and experimental evidences 
indicate  that  trabectedin  not  only  hits  neoplastic  cells  but  also  importantly 
modulate tumor microenvironment; in particular, it activates a caspase-
dependent  pathway  of  apoptosis  selectively  in  cells  of  the  monocyte  lineage, 
causing  a  partial  depletion  of  circulating  monocytes  and  TAMs.  In  murine 
tumors and in human sarcomas Trabectedin-induced TAMs reduction was 
associated  with  decreased  angiogenesis  and  increased  T-cell  infiltration  [62, 
181, 182].  
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The contribution of TAMs to the modulation of tumor responses to 
chemotherapy  can  vary  markedly  among  different  cytotoxic  agents  and  tumor 
models and intriguingly, increasing data suggest that the efficacy of some forms 
of  immunotherapy  may  also  depend  on  effective  reprogramming  of  TAMs 
toward an M1-like phenotype. For example, the antitumor activity of the taxane 
docetaxel  involves  the  depletion  of  immunosuppressive  (M2-like)  TAMs  and 
the concomitant activation or expansion of antitumoral (M1-like) monocytes in 
4T1-Neu mammary tumor implants. Indeed, in vivo T cell assays showed that 
docetaxel-treated monocytes/MDSCs are able to enhance tumor-specific 
cytotoxic T cell responses [183].  
More  specific  macrophage  targeting  came  from  the  administration  of  an  anti-
CD40 antibody in a preclinical model of pancreatic cancer, where alternatively 
activated, M2-like macrophages were re-educated in the tumor 
microenvironment to acquire antigen-presenting capabilities, leading to re-
establishment of tumor immune surveillance and reduction of tumor progression 
[184].  
Finally, recent clinical studies suggest that usage of nonsteroidal anti-
inflammatory drugs, aspirin in particular, is associated with protection against 
occurrence  of  many  tumors  and  metastasis  and  that  this  protective  function 
relies on the inhibition of prostaglandin production [185, 186]. Ineed, PGE2 is 
well-known to have immune-suppressive effects and to favour M2-like 
polarization of TAMs [187, 188]. 
Overall these reports strongly indicate that macrophage-targeting strategies have 
the  potential  to  complement  and  synergize  with  cytoreductive  therapies,  anti-
angiogenic agents and immunotherapy [171].  
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1.5 The transcription factor NF-κB  
NF-κB  family  has  been  considered  the  central  mediator  of  the  inflammatory 
process and a key participant in innate and adaptive immune responses; 
moreover during the last years it has been demonstrated that NF-κB could play a 
crucial role in cancer development [189]. 
NF-κB is evolutionarily conserved and plays a critical role in many biological 
systems, above all the immune system, where it acts as the major orchestrator of 
the  transcriptional  responses  to  many  different  stimuli.  The  engagement  of 
several  immune  receptors  such  as  B  and  T  cell  receptor  (BCR,  TCR),  TLRs, 
Tumor Necrosis Factor Receptor (TNFR) or CD40 [190] triggers NF-κB 
activation  which  in  turn  results  in  the  expression  of  cytokines,  growth  factors 
and effector enzymes. At present, more than 150 genes under control of NF-κB 
have  been  identified,  as  a  demonstration  of  its  vast  spectrum  of  biological 
functions [191, 192].  
Because  NF-κB  activation  drives  expression  of  key  genes  in  inflammation, 
immunity, cell survival and proliferation its mis-regulation, such as constitutive 
activation, could be associated with pathological conditions such as rheumatoid 
arthritis, asthma, intestinal bowel diseases (IBDs), multiple sclerosis and cancer 
[193-196]. Given this great variety of biological roles, a better understanding of 
NF-κB  pathways  could  provide  the  basis  for  the  development  of  therapeutic 
strategies with a relevant impact on human diseases.  
 
1.5.1 NF- κB family and activation 
NF-κB  family  includes  five  members:  RELA  (p65),  RELB,  cREL,  NF-κB1 
(p105-p50)  and  NF-κB2  (p100-p52).  All  these  proteins  possess  a  conserved 
300-amino  acid  REL  homology  domain  (RHD)  that  is  located  toward  the  N-
terminus of the proteins and is responsible for dimerization, binding to 
inhibitors of nuclear factor κB (IκBs) and binding to DNA. Instead, the carboxy-
  34 
terminal non-homologous transactivation domain (TAD), which strongly 
activates the transcription of targeted genes, is present only in cREL, RELB and 
RELA [197, 198]. p50 and p52 are generated by proteolytic degradation of p105 
and p100 precursors  and they lack the transactivation domain, therefore if they 
form  homodimers  they  still  bind  the  DNA  consensus  sites,  but  they  do  not 
activate  transcription  [199,  200].  Each  member  of  NF-κB  family,  except  for 
RELB, can form homodimers as well as heterodimers with one another and the 
main activated form of NF-κB is the heterodimer containing p65 together with 
p50 or p52 (Fig.9) [110].  
 
                       
Figure 9: Mammalian NF- κB-family members.  
NF-kB  family  comprises  five  members:  RELA  (p65),  cREL,  RELB,  p105/p50  and  p100/p52. 
Proteolytic  processing  of  p105  and  p100  at  residues  435  and  405  (as  indicated  by  arrows), 
respectively, generates the p50 and p52 NF-κB proteins. The glycine-rich region (GRR) and the 
carboxy-terminal  sites  of  inducible  phosphorylation  (in  the  DSVCDS  and  EVKEDSAYGS 
sequences  for  p105  and  p100,  respectively)  are  required  for  processing.  Phosphorylation  of 
RELA  at  Ser276,  Ser529  and  Ser536  is  important  for  its  transactivation  activity.  The  size  of 
each human protein is shown on the right (number of amino acids) [110]. 
 
In  resting  conditions,  IκBs  exhert  their  regulatory  function  binding  NF-κB 
proteins masking their Nuclear Localization Sequence (NLS). So, the 
complexes IκBs-NF-κB cannot translocate into the nucleus and are retained in 
  35 
the  cytoplasm  in  inactive  forms.  Triggering  of  many  different  receptors  can 
induce NF-κB activation that is initiated upon phosphorylation of IκBs by IκB 
Kinases (IKK). IKK is a complex made by kinase subunits IKKα and IKKβ and 
the  regulatory  subunit  IKKγ  or  NEMO  (NF-κB  Essencial  Modifier).  Hence, 
upon activation of IKKβ, IκB is phosphorylated and degraded by the 
proteasome,  so  the  released  NF-κB  dimers  can  go  to  the  nucleus  and  activate 
gene transcription [201-204].  
NF-κB could be activated through two different pathways: classical and 
alternative[190]. The classical pathway is particularly involved in innate 
immunity, is activated predominantly by the subunit IKKβ in a NEMO 
dependent  manner  and  is  mainly  mediated  by  Toll  like  receptors  (TLRs), 
scavenger receptors and complement system. Signalling through TLRs leads to 
activation of canonical IKKs complexes, degradation of IκBs and activation of 
RELA and cREL containing NF-κB dimers. The released NF-κB dimers, that in 
this  pathway  are  predominantly  p65-p50  heterodimers,  go  to  the  nucleus  and 
activate  gene  transcription. The  beginning  of  an  inflammatory  response  is 
strictly dependent on NF-κB classical pathway. Signals coming from the 
environment  lead  to  the  recruitment  and  activation  of  effector  cells,  initially 
neutrophils and later macrophages and other leukocytes, resulting in the tissue 
changes characteristic of inflammation – rubor, calor, dolor and tumor 
(redness, heat, pain and swelling, respectively) [199, 203, 205, 206].  
The alternative pathway is particularly active in cells of the adaptive immunity, 
such  as  B  and  T  lymphocytes,  is  independent  of  IKKβ  and  NEMO  but  it  is 
dependent of IKKα homodimers, which selectively phosphorylate p100 
associated  with  RELB.  Therefore,  the  consequence  is  the  release  of  active 
RELB-p52  heterodimers  [207,  208].  Activation  of  NF-κB  downstream  B  cell 
receptor  (BCR)  and  T  cell  receptor  (TCR)  is  a  critical  step  for  mounting 
adaptive immune responses allowing antigen specific maturation and 
proliferation of lymphocytes into effector cells [209].  
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1.5.2 NF- κB and cancer  
Several evidence suggest that NF-κB is a molecular bridge between 
inflammation  and  cancer.  Indeed,  among  all  the  different  signaling  pathways 
activated by inflammation and infection, NF-κB is the major activator of genes 
encoding  for  proteins  important  for  cell  proliferation  (e.g.  cyclin  D1,  c-Myc) 
survival  (BCL-2,  c-FLIP)  adhesion,  and  angiogenesis  (e.g.  CXCL8,  VEGF) 
[210]. 
In fact, as a master regulator of inflammation, NF-κB triggers the transcription 
of  several  proinflammatory  mediators  such  as  IL-1β,  TNFα,  IL-6  and  IL-8. 
These factors are themself able to induce higher NF-κB activation, thus 
providing a positive feedback loop at the site of inflammation. This 
inflammatory environment favours DNA damage, cell proliferation, 
transformation  and  survival  and  consequently  cancer  initiation,  growth  and 
progression [154, 192].  
The pro-inflammatory stimuli, such as bacterial products via Toll-like receptors 
or inflammatory cytokines (e.g. TNFα and IL1β), activate NF-κB that 
translocates  into  the  nucleus  inducing  the  expression  of  cytokines  (such  as 
TNFα and IL6) and chemokines, which contribute to the inflammation-related 
tissue damage. This elevated IKK/ NF-κB activity may also lead to aberrant up-
regulation of certain tumorigenic, adhesion proteins, chemokines, and inhibitors 
of apoptosis that promote cell survival [211].  
Hence, NF-κB is involved not only in tumor development at early stages, but 
also  in  the  migration,  invasion  and  metastasis  of  malignant  cells  [154].  For 
instance,  the  invasive  capacity  of  cancer  cells  can  increase  in  the  presence  of 
inflammatory cytokines such as TNFα, IL-1β and IL6 [3]. In particular, TNFα is 
a  potent  stimulator  of  epithelial-mesenchimal  transition  by  breast  cancer  cells 
for  its  ability  on  activate  NF-κB  activation  [212].  NF-κB  was  also  found  to 
promote metastatization in a genetic mouse model of prostate cancer, in which 
inactivation of IKKα was found to reduce metastatic spread [213]. 
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Moreover, compelling indications demonstrate that in many cancers, NF-κB is 
constitutively active, even if the exact mechanism that sustain this activation is 
not fully understood and several mechanisms have been proposed, such as IL-1β 
and TNFα production, shorter IκBα half life or IκBα mutations [214, 215]. 
For these reasons, NF-κB represents an ideal therapeutic target for the 
development of new anti-tumor strategies.  
 
p50/NF- κB1 
The NF-κB1 gene encodes two functional proteins: p50 and p105. In particular, 
p105 is the precursor of p50, which is the active form of the protein and could 
form dimers with itself or with other NF-κB subunits. The role of p50 and its 
precursor  in  cell  physiology  and  function  is  very  complex.  Indeed,  although 
originally considered a repressor of transcription, p50 could also be a 
transcriptional  activator  and  the  balance  between  pro-  and  anti-  inflammatory 
activity of p50 depends on cell type and environmental conditions [216, 217].  
The  nuclear  translocation  of  p50  homodimers  deeply  controls  functions  of 
myeloid cells in cancer. In fact, it has been demonstrated that in LPS-tolerant 
macrophages increased expression of the p50 subunit of NF-κB directly results 
in  the  downregulation  of  LPS-induced  TNFα  production,  whereas  in  p50 -/- 
macrophages long-term pre-treatment with LPS was unable to induce tolerance 
[100, 218]. Accordingly, as mentioned above, our group has demonstrated that 
TAMs  display  a  defective  NF-κB  activation  in  response  to  the  M1  polarizing 
signals (LPS and TNFα) and that this phenotype is due to the over expression of 
nuclear p50 NF-κB homodimers which inhibits the transcription of pro-
inflammatory genes. On the contrary, we have shown that LPS stimulated p50 -/- 
TAMs recover an M1 (IL-12 highTNFαhighIL-10low) phenotype that correlates, in 
vivo, with tumor growth inhibition [219]. Further, a detailed analysis of the role 
of  p50  NF-κB  homodimer  in  macrophage  functions  revealed  that  its  nuclear 
accumulation, both in TAMs and LPS-tolerant macrophages, not only mediates 
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a  status  of  unresponsiveness  (tolerance)  toward  pro-inflammatory  signals,  but 
actually  plays  a  role  as  key  regulator  of  M2-driven  inflammatory  responses 
[152]. Hence p50 NF-κB regulates the orientation of macrophage polarization, 
playing a crucial role in the control of M1- vs. M2-driven inflammation [100]. 
Moreover,  recently  our  group  demonstrated  that  nuclear  accumulation  of  p50 
NF-κB promotes a tolerogenic phenotype in DCs, affecting both their survival 
and capacity to drive effective activation of effector T cells. In fact, lack of p50 
in  murine  DCs  promoted  increased  lifespan,  enhanced  level  of  maturation 
associated  with  increased  expression  of  the  pro-inflammatory  cytokines  IL-1, 
IL-18  and  IFN-β,  enhanced  capacity  of  activating  and  expanding  CD4+  and 
CD8+ T cells in vivo and decreased ability to induce differentiation of FoxP3 + 
regulatory T cells [220].  
So  targeting  p50  could  represent  a  novel  fascinating  strategy  to  revert  the 
immunosuppressive  phenotype  of  tumor  infiltrating  myeloid  cells  and  boost 
anti-tumor immunity. 
 
1.6 Retinoid-related orphan receptors RORs  
As mentioned above, it is well known that cancer is associated with a profound 
perturbation in myelopoiesis and that circulating hematopoietic stem and 
progenitor cells from patients with solid tumors have “myeloid-biased 
differentiation” [23]. Moreover, while “emergency” myelopoiesis to infection or 
trauma increases rapidly the inflammatory neutrophil and 
monocyte/macrophage pools, chronic cancer inflammation-driven myelopoiesis 
converges in splenic accumulation of immature MDSCs and TAMs recruitment 
at the tumor site [22, 37, 221].  While the pro-tumor functions of MDSCs and 
TAMs are well characterized [20], a large gap remains in our understanding of 
the mechanisms that translate persistent inflammation into reactive “emergency” 
myelopoiesis.  
  39 
IL-17  is  becoming  of  great  interest,  since  in  response  to  inflammation  or 
infection  it  promotes  G-CSF-  and  stem-cell-factor-mediated  neutrophilia  and 
supports  G-CSF-driven  “emergency”  granulopoiesis  [32].  Interestingly,  it  was 
also  shown  that  IL-17  is  required  for  the  development  of  MDSCs  in  tumor-
bearing mice; indeed, a defect in IL-17R reduces the number of MDSCs in the 
blood, spleen, and tumors whereas administration of exogenous IL-17 increases 
the  number  of  MDSCs  in  wild-type  tumor-bearing  mice  [222].  Therefore, 
despite  IL-17  expression  in  tumor  has  been  so  far  greatly  restricted  to  the 
adaptive arm of immunity, TAMs and MDSCs produce the T-helper 17 (Th17)-
driving  cytokines  TGFβ and IL-6  [223],  suggesting  that  adaptive  and  innate 
immunity  share  IL-17-related  molecular  signaling  pathways.  Indeed,  IL-17-
expressing  cells  with  macrophage  morphology  have  been  described  in  cancer 
patients [224]. 
Although  in  literature  it  is  well  described  that  retinoic-acid-related  orphan 
receptor  gamma  (RORγ)  full-length  protein  (RORC1)  and  the  RORCγt  splice 
variant  (RORC2)  are  master  regulators  of  IL-17A  gene  transcription  and  of 
Th17  response  [225-227],  the  signaling  pathways  that  drive  IL-17-producing 
innate  immune  cells  have  been  poorly  investigated.  In  subjects  with  arthritis 
mast  cells  express  a  dual  IL-17A/RORC  finger  print  in  response  to  TLR4 
ligands [228] and a population of RORγt-expressing neutrophils that express IL-
17 in response to IL-6 and IL-23 was recently identified in a model of fungal 
infection  [229].  These  findings  suggest  a  major  role  for  IL-17  and  related 
signaling  cytokines  and  transcription  factors  in  myeloid  lineage  commitment 
and function in inflammatory diseases, including cancer. 
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1.6.1 RORs structure and activity  
RORs, together with receptors for steroid hormones, retinoids, thyroid hormone, 
eicosanoid metabolites, are member of the nuclear receptors (NRs) superfamily 
of  transcription  factors  [230].  The  ROR  family  comprises  three  members: 
RORα (NR1F1), ROR β (NR1F2) and ROR γ (NR1F3); these are considered to 
be ‘orphan’ receptors because their endogenous physiological ligands are either 
unknown or may not exist. Hence, they represent an active area of research due 
to the potential for identification of ligands that may be used to modulate these 
receptors with the goal of developing targeted therapeutics for various diseases 
[231, 232]. 
RORs  exhibit  a  domain  structure  typical  of  NRs  and  contain  an  N-terminal 
domain,  the  function  of  which  has  not  yet  been  clearly  defined,  a  highly 
conserved DNA-binding domain (DBD) consisting of two zinc finger motifs, a 
carboxy-terminal ligand binding domain (LBD) and a hinge domain spacing the 
DBD and LBD [232]. RORs regulate transcription by binding as monomers to 
ROR response elements (RORE), which consist of the core sequence 
“AGGTCA”  preceded  by  an  A/T-rich  sequence,  in  the  regulatory  region  of 
target genes. When bound to this element within the promoters of their target 
genes, RORs constitutively recruit coactivators, leading to continual activation 
of  transcription  of  their  target  genes.  By  using  different  promoters  and/or 
alternative splicing each ROR gene produces several isoforms that vary only in 
their N-terminal region  (Fig. 10) [233].   
RORs display distinct patterns of tissue expression and because of their 
important regulatory roles in many key physiological processes (e.g. 
inflammation,  lipid/glucose  homeostasis  and  insuline  resistance  [234,  235]) 
dysregulation of signaling controlled by these receptors is associated with many 
diseases, including cancer [236].  
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Figure 10: Schematic representation of RORs family members. 
The different RORs isoforms identified in human and mouse are shown on the right (+/-) [233].  
 
 
RORγ- RORγt 
The  RORγ  (RORC)  gene  has  been  found  to  express  two  different  isoforms, 
RORγ1 and RORγt (γ2)/RORC2 (mouse/human) that are expressed in a highly 
tissue-specific  manner.  In  particular,  RORγ1  is  expressed  in  many  tissues, 
including  liver,  adipose,  skeletal  muscle,  and  kidney,  while  the  expression  of 
RORγt is exclusively expressed in few distinct cell types of the immune system 
(i.e.  immature  CD4+/CD8+ thymocys  and  lymphoid  tissue  inducer  (LTi)  cells) 
[233, 237]. 
Mice deficient in RORγ expression lack lymph nodes and Peyer's patches (PPs) 
suggesting that RORγ is essential for lymph node organogenesis and 
development of PPs. RORγt also plays an important regulatory role in 
thymopoiesis,  by  reducing  apoptosis  of  thymocytes  and  promoting  thymocyte 
differentiation into pro-inflammatory Th17 cells [238-240].  
Recent studies indicate also that RORγ provide an important link between the 
circadian clock machinery and its regulation of metabolic genes and metabolic 
syndrome [241, 242]. Accordingly, accumulating evidence indicates that RORγ 
play an important role in the regulation of several metabolic pathways, 
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particularly  lipid  and  steroid  metabolism.  Moreover,  deficiency  in  RORγ  also 
protects against diet-induced insulin resistance [234, 243].  
 
1.6.2 RORγ and cancer 
The  role  of  RORγt/RORC2  (mice/humans)  in  modulating  mouse/human  Th17 
cell  differentiation  under  conditions  such  as  autoimmune  and  inflammatory 
diseases  has  been  widely  investigated;  accordingly,  a  number  of  studies  have 
provided  evidence  for  a  role  of  RORγ  in  cancer  [233,  236,  244,  245].  For 
instance, mice deficient in the expression of RORγ exhibit a high incidence of 
thymic lymphomas that metastasize frequently to liver and spleen; as a 
consequence,  the  lifespan  of  RORγ-/-  mice  is  greatly  reduced.  The  enhanced 
lymphoma formation may be related to the dysregulation of differentiation and 
proliferation in RORγ-/- thymocytes [246].  
Another  potential  link  between  RORγ  and  cancer  is  emerging  from  studies 
showing increased expression of Th17-associated genes, (e.g. RORγ, IL-17 and 
IL-23) in gastric tumors, an increase in the population of circulating Th17 cells 
in gastric cancer patients, and a high incidence of Th17 cells at sites of ovarian 
cancer [247, 248].  
Several  clinical  studies  have  demonstrated  that  both  IL-17  and  RORC2  is 
expressed in tumor-infiltrating immune cells in human lung tissues from chronic 
obstructive pulmonary disease (COPD) patients [249] and that cutaneous T cell 
lymphoma, cervical carcinoma, prostate cancer and ovarian carcinoma 
spontaneously  secrete  IL-17  [250,  251].  Moreover,  RORC2  was  found  to  be 
expressed  in  melanoma  [252]  and  in  non-small  cell  lung  cancer  (NSCLC) 
patients where greatly contributes to tumor cell proliferation [253].   
These findings highlight that RORγ plays critical roles in tumor generation and 
may represent therapeutic targets for many malignancies. 
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2. Outline of the thesis 
“Emergency” hematopoiesis is defined as a modification of the magnitude and 
composition  of  the  hematopoietic  output  that  occurs  during  immunological 
stress, including tumor progression, to ensure proper supply of immune cells to 
increased  demand.  Myeloid  cells,  in  particular,  abundantly  expand  in  tumor 
bearers and infiltrate almost all solid cancers, where microenvironmental signals 
promote their transcriptional reprogramming towards a tumor-promoting 
phenotype.  Although  dynamic  changes  in  myeloid  cell  functions  have  been 
reported to parallel tumor progression, a large gap remains in our understanding 
of the molecular pathways guiding this cancer-driven “emergency” 
myelopoiesis. 
Recent studies reveal that tumor associated macrophages (TAMs) and myeloid 
derived suppressor cells (MDSCs), the two major myeloid populations 
associated  with  cancer  development,  differentiate  from  a  common  myeloid 
progenitor  (CMP)  into  functionally  altered  myeloid  cells.  These  populations 
display functional plasticity and are considered to have a major impact on the 
orchestration  of  cancer-related  inflammation,  promoting  the  construction  of  a 
protumor microenvironment and a protumor host macroenvironment associated 
with increased serum hematopoietic colony-stimulating activity and 
“emergency” hematopoiesis.  
Myeloid cell plasticity is exemplified in the M1 vs M2 extremes of macrophage 
polarization,  which  respectively  express  different  anti-  vs  pro-  inflammatory 
functional  outcomes  in  response  to  polarizing  signals,  including  cytokines. 
Moreover, polarized macrophages (either M1 or M2) reprogram their responses 
towards a subsequent exposure to Th1 (IFN-γ) or Th2 (IL-4) cytokines.  
Cancer fuels myeloid cells heterogeneity by promoting sustained myelopoiesis. 
Investigation of signaling pathways controlling hematopoiesis revealed that G-
CSF-induced “emergency” granulopoiesis is mediated through the transcription 
factors c-EBPβ and STAT3, whereas M-CSF supports monocyte differentiation 
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through  activation  of  the  transcription  factors  PU.1  and  IRF8.  Of  relevance, 
GM- CSF and M-CSF respectively represent prototypical M1 vs M2 polarizing 
signals,  thus  affecting  both  differentiation  and  polarization  of  myeloid  cells. 
Thus, investigation of the molecular networks dictating reciprocal regulation of 
macrophage versus neutrophil/granulocyte differentiation appears to be crucial, 
as it may affect tissue homeostasis during cancerogenesis.  
In this scenario, also IL-17 is becoming of great interest, since in response to 
inflammation or infection it promotes G-CSF-mediated neutrophilia and 
supports  G-CSF-driven  “emergency”  granulopoiesis.  Interestingly,  it  was  also 
shown that IL-17 is required for the development of MDSCs in tumor-bearing 
mice  and  that  TAMs  and  MDSCs  produce  the  Th17-driving  cytokines  TGFβ 
and IL-6; moreover, IL-17-expressing cells with macrophage morphology have 
been described in cancer patients.  
Although  in  literature  it  is  well  described  that  retinoic-acid-related  orphan 
receptor  gamma  (RORγ)  full-length  protein  (RORC1)  and  the  RORCγt  splice 
variant  (RORC2)  are  master  regulators  of  IL-17A  gene  transcription  and  of 
Th17 response, the signaling pathways that drive IL-17-producing innate 
immune  cells  have  been  poorly  investigated.  These  observations  led  us  to 
hypothesize that IL-17 and RORC, might be involved in mediating both 
expansion  and  transcriptional  reprogramming  of  MDSCs  and  TAMs,  through 
modulation of granulo- vs mono/macrophage-lineage commitment, thereby 
contributing  to  tumor  growth.  Hence,  our  challenge  is  to  clarify  the  role  of 
RORC1 in driving myeloid lineage commitment in cancer bearers, in order to 
generate clinically translatable strategies preventing the protumoral commitment 
of myeloid cells. 
Both the recruitment and activation of tumor associated myeloid cells may be 
considered putative targets for therapeutic intervention; accordingly, because of 
their  unique  role  in  linking  the  innate  and  adaptive  immunity,  macrophage-
based immunotherapy is widely considered in clinical trials with cancer 
patients. In particular, current therapeutic approaches affecting TAMs 
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compartment  are  aimed  either  at  reeducating  their  functional  activation  to  an 
antitumor, M1-like, phenotype or inhibiting their recruitment and/or survival in 
tumors.  Several  evidences  indicate  that  massive  presence  of  TAMs  in  solid 
tumor correlates with a poor prognosis. TAMs favor tumor growth and 
progression through the production of anti-inflammatory cytokines that suppress 
anti-tumor adaptive immunity. Moreover, they help invasion, angiogenesis and 
metastasis  since  they  produce  pro-angiogenic  factors  and  matrix  remodelling 
agents. Hence, modulating the recruitment of TAMs in tumors could be 
important to improve anti-tumor therapies. 
We previously reported that, during cancer progression massive nuclear, 
accumulation  of  p50  NF-κB  in  TAMs  results  in  the  lack  of  responsiveness  to 
M1  polarizing  signals,  including  LPS  and  TNF α,  along  with  an  increased 
capacity  to  express  M2  genes  in  response  to  the  M2  polarizing  cytokines, 
correlating with impaired inflammatory functions and tumor promotion. 
Interestingly, similar to the TAMs, p50 NF-κB accumulation in 
monocytes/macrophages is essential for endotoxin tolerance as well as for M2 
polarized activation. Yet, little is known about the forces that drive the 
recruitment of TAMs into tumors, or more generally, of M2 polarized 
macrophages into sites of inflammation. Hence, the challenge is to identify new 
potential anti-tumor targets by studying the mechanisms underlying 
differentiation and recruitment of myeloid cells in neoplastic tissue. Given the 
importance of p50 NF-κB in driving the phenotype of tolerant macrophages, we 
investigated whether p50 controls differentiation and/or recruitment and 
pathogenic roles of macrophage subsets to inflamed tissues, including the tumor 
microenvironment.  
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Abstract 
Tumor associated macrophages (TAMs) share a typical M2-skewed phenotype 
with lipopolysaccharide- (LPS-) tolerant macrophages. Both populations 
display impaired capacity to mount an effective M1 inflammatory response and 
this phenotype, often referred to as “tolerance”, is driven by nuclear 
accumulation  of  p50  NF-κB  inhibitory  homodimers.  It’s  widely  accepted  that 
TAMs  recruitment  into  tumors  correlates  with  poor  prognosis,  however,  the 
detailed  mechanisms  underlying  the  recruitment  of  M2-like  macrophages  to 
inflamed tissues, including the tumor microenvironment, are not fully 
understood. Given  the  importance  of  p50  NF-κB  in  driving  macrophage’s 
tolerance,  we  investigated  whether  nuclear  accumulation  of  p50  may  also 
mediate the recruitment of M2-like macrophages to inflamed tissues. This study 
demonstrates  that  p50  NF-κB  accumulation  is  a  necessary  event  guiding  the 
chemotactic responsiveness of tolerant macrophages to complement 
anaphylatoxins C3a and C5a. By using an in vivo model of LPS-tolerance, we 
demonstrate  a  differential  recruitment  into  the  inflammatory  sites  of  distinct 
F4/80+  macrophage  subsets  characterized  by  different  expression  levels  of 
F4/80  and  the  C5aR  (CD88),  respectively  defined  as  F4/80highCD88high  and 
F4/80lowCD88low. Of relevance, we observed systemic accumulation (blood) of 
the  CD88high mono/macrophage  population  only  in  tolerant  conditions  (LPS-
tolerance  and  sepsis),  both  in  mouse  and  human,  strengthening  the  idea  that 
p50-dependent  induction  of  systemic  tolerance  is  required  for  the  systemic 
expansion  of  F4/80highCD88high  mono/macrophages.  Differential  expansion  of 
the F4/80 lowCD88low and F4/80 highCD88high populations was confirmed also in 
the  preclinical  MN/MCA1  fibrosarcoma  model,  supporting  a  direct  link  with 
conditions of emergency hematopoiesis. Consistent with the LPS-tolerance 
model, ablation of p50 NF-κB resulted in significant impairment of 
F4/80highCD88high  TAMs  accumulation  in  primary  tumors,  which  correlated 
with inhibition of tumor growth and vascularization. Moreover, transcriptome 
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analysis  proved  that  F4/80 high  and  F4/80low  TAMs  express  different  genetic 
programs,  supporting  putative  different  roles  in  tumor  progression.  Thus,  our 
study provides evidence that distinct macrophage subset, arise during infection- 
and  cancer-driven  inflammation,  in  a  p50  NF-κB-dependent  manner  and  that 
complement-mediated  pathways  drives  their  infiltration  of  inflammatory  sites, 
including solid tumors. Future studies will provide the functional 
characterization and roles of these populations in infection and cancer. 
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Introduction 
Leukocyte migration is an indispensable process occurring in several 
physiological and pathological events. Accordingly, inflammatory and immune 
responses mostly involve the recruitment of circulating monocytes into specific 
tissues [1]. Myeloid cells, in particular, abundantly expand in tumor bearers and 
infiltrate  almost  all  solid  cancers,  where  microenvironmental  signals  promote 
their  transcriptional  reprogramming  towards  a  tumor-promoting  phenotype  [2, 
3]. Tumor associated macrophages (TAMs) are the major component of 
leucocytes  infiltrating  tumors  and  extensive  presence  of  TAMs  correlate  with 
poor  prognosis  in  a  widely  variety  of  human  carcinomas  [4-6].  Indeed,  in 
established  cancers,  TAMs  entail  pro-tumor  functions,  since  they  express  an 
M2-skewed phenotype, associated with suppression of adaptive immune 
functions  and  promotion  of  angiogenesis  and  invasion  [3].  However,  due  to 
their  well  known  functional  plasticity,  these  cells  can  also  express  an  M1 
phenotype, associated with anti-tumor activities [7-9].  M1 and M2 functional 
phenotypes  are  the  extremes  of  a  continuum  of  diverse  activation  states  [10], 
hence,  in  response  to  the  complex  tissue-derived  signals  that  macrophages 
receive,  cells  in  different  functional  states  or  with  a  mixed  phenotype  can 
coexist  in  the  same  tumor  [11].  We  previously  reported  that  during  cancer 
progression nuclear accumulation of p50 NF-κB in TAMs results in the lack of 
responsiveness  to  M1  polarizing  signals  (e.g.  IFNγ)  along  with  an  increased 
capacity to express M2 genes in response to the M2 polarizing cytokines (e.g. 
IL-4, IL-10), correlating with impaired inflammatory functions and tumor 
promotion  [12].  Prompted  by  these  evidences,  current  macrophage-centered 
therapeutic approaches are aimed either at activating their antitumor activity or 
inhibiting  their  recruitment  in  tumors  [13-15].  Chemoattractants  involved  in 
monocyte recruitment include chemokines (e.g. CCL2, CCL5, CXCL4) [16-18], 
colony-stimulating factor-1 (CSF-1) [19, 20], and members of the VEGF family 
[21].  Recently,  genetic  evidence  in  the  mouse  suggested  that  complement 
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components play also an important role in accumulation and functional 
polarization of TAMs [22, 23]. Nevertheless, the detailed mechanisms 
underlying the recruitment of M2-like macrophages to inflamed tissues, 
including tumor microenvironment, are not fully understood. 
TAMs  share  nuclear  overexpression  of  p50  NF-κB  and  the  anti-inflammatory 
M2  phenotype  with  lipopolysaccharide-  (LPS-)  tolerant  macrophages.  LPS-
tolerance is a state of hypo-responsiveness acquired after prolonged exposure of 
macrophages to inflammatory agents, including bacterial products such as LPS. 
Tolerant macrophages enter into a transient unresponsive state and are unable to 
respond  to  further  stimulation  with  endotoxin,  but  still  produce  high  level  of 
anti-inflammatory cytokines involved in wound healing, clearing of cell debris 
and pathogens, dampening of the inflammatory response. This phenomenon has 
been observed both in vitro and in vivo in animal models, as well as in humans, 
and  is  mainly  mediated  by  nuclear  accumulation  of  p50  NF-κB  homodimers 
[24-26]. Accordingly, acquisition of a tolerant phenotype could be important in 
protecting the host from a prolonged inflammation and in the resolution of the 
inflammatory  response  and  the  ability  to  recruit  tolerant  macrophages  would 
ameliorate the outcome of pathologies characterized by chronic inflammation.  
Thus, we speculate that more detailed insights into the M2-like macrophages-
recruitment  factors  in  infection  and  cancer  will  provide  new  opportunities  for 
therapeutic intervention.  
By  using  in  vivo  LPS-tolerance  and  tumor  mouse  models,  we  study  new 
mechanisms underling tolerant macrophages recruitment in infection and cancer 
and  we  demonstrated  that  nuclear  accumulation  of  p50  NF-κB  promotes  the 
recruitment  of  specific  F4/80+  macrophage  subset,  expressing  high  level  of 
F4/80  and  complement  receptor  factors  (C5aR  and  C3aR),  into  inflammatory 
sites, including solid tumors. Strikingly, we showed that defect in the 
accumulation of F4/80 high population in the tumor microenvironment correlates 
with an impaired tumor growth. 
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Materials and methods 
Ethics statement.  The study was designed in compliance with: Italian 
Governing  Law  (Legislative  Decree  116  of  Jan.  27,  1992);  EU  directives  and 
guidelines (EEC Council Directive 86/609, OJ L 358, 12/12/1986); Legislative 
Decree  September  19,  1994,  n.  626  (89/391/CEE,  89/654/CEE,  89/655/CEE, 
89/656/CEE,  90/269/CEE,  90/270/CEE,  90/394/CEE,  90/679/CEE);  the  NIH 
Guide for the Care and Use of Laboratory Animals (1996 edition); 
Authorization n. 11/2006-A issued January 23, 2006 by Ministry of Health. The 
study was approved by the scientific board of Humanitas Clinical and Research 
Center. Mice have been monitored daily and euthanized when displaying 
excessive  discomfort.  Septic  patients  were  enrolled  in  the  study  after  signing 
Cancer Research Center Humanitas IRB-approved consent. 
 
Mice.  C57BL/6  mice  were  purchased  from  Charles  River  (Calco,  Italy).  p50 
NF-κB  deficient  mice  on  the  C57BL/6J  background  were  available  in  the 
laboratory [12]. Homozygous C3 mutant mice (B6;129S4-C3tm1Crr/J) were 
obtained from Jackson Laboratories (Bar Harbor, Maine, USA).  
 
MN/MCA1 tumor model. 8 weeks old mice were injected intramuscularly in the 
left leg with 10 5 cells of murine fibrosarcoma (MN/MCA1). Tumor growth was 
monitored three times a week with a caliper, starting from day 14. 
 
Cell  Culture  and  Reagents.  Thioglycollate-elicited  peritoneal  exudate  cells 
(PEC)  were  isolated  from  healthy  mice  as  previously  described  [26].  Briefly, 
mice  were  injected  I.P.  with  1  ml  of  3%  (wt/vol)  with  thioglycollate  medium 
(Difco). Peritoneal exudate cells were harvested 4-5 days after injection. PEC 
were incubated in RPMI medium 1640, containing 10% FBS, 2 mM glutamine, 
and 100 U/mL of penicillin–streptomycin. The concentrations for the different 
treatments  were  as  follows:  LPS  (100  ng/mL)  (LPS  from  Salmonella  Abortus 
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Equi  S-form;  Alexis).  To  induce  LPS  tolerance,  cells  were  incubated  in  the 
presence of LPS for 20 h, washed, and maintained in RPMI medium for 2 h and 
then rechallenged with LPS for 4 h (L/L). To induce M1 activation, cells were 
incubated  in  medium  for  20  h,  washed,  left  in  medium  for  2  h,  and  finally 
stimulated  with  LPS  for  4  h  (M/L).  Control  cells  (M/M)  were  cultured  in 
medium for the entire period of the experiment. 
TAMs  were  isolated  from  tumor  bearing  mice  as  previously  described  [27]. 
Briefly,  when  tumors  reached  a  volume  of  about  2  cm3  (indicatively  3  weeks 
after tumor implantation), mice were sacrified and tumors were processed with 
Trypsin  0,125%.  Cell  suspension  was  plated  in  incomplete  RPMI,  substituted 
after one hour with RPMI containig 10% serum.  
The concentrations for the different treatments in vitro were as follows: C5a and 
C3a (R&D System) were used 100ng/ml, CCL5, CCL2 and MCSF (Peprotech) 
were used 100ng/ml. 
Analysis on tumor-infiltrated cells was performed as follow: tumor tissues were 
cut  into  small  pieces  and  treated  with  collagenase  (type IV,  1 mg/mL,  Sigma-
Aldrich) for 30 min at 37°C. Cell suspensions were stained with the following 
mixture of antibodies. 
 
Flow cytometry. 0.5-1*10 6 cells were re-suspended in HBSS (Hank’s balanced 
salt  solution,  Lonza)  supplemented  with  0.5%  BSA  (Sigma).  Staining  was 
performed at 4°C for 20 minutes, with the following antibodies: anti-
mouse/human  CD11b  (clone  M1/70),  anti-mouse  CD45  (clone  30-F11),  anti-
mouse  CD88  (clone  20/70),  anti-mouse  CD115  (clone  AFS98),  anti-mouse 
CCR5  (clone  HM-CCR5),  anti-mouse  CCR2  (clone  SA203G11),  anti-mouse 
CD31  (clone  MEC  13.3),  anti-human  CD88  (clone  S5/1),  anti-human  Tie2 
(clone 33.1), anti-human CD14 (clone M5E2) (Biolegend San Diego, CA), anti-
mouse  Ly6C  (clone  HK1.4),  anti-mouse  Tie2  (clone  TEK4)  (eBioscience  San 
Diego, CA), anti-human CD15 (clone HI98) (BD biosciences, San Diego, CA), 
anti-mouse HO-1 (clone HO-1-2) (Enzo Life Sciences). Further we used 
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unconjugated  rabbit  monoclonal  anti-mouse  C3aR  (clone  D-20,  Santa  Cruz 
Biotechnology)  followed  by  incubation  with  secondary  goat  anti  rabbit  Alexa 
Fluor® 647 conjugated antibody (Invitrogen, Molecular Probes, Carlsbad, CA). 
For  intracellular  staining  Cytofix/Cytoperm  and  Permwash  staining  kit  (BD 
Pharmigen)  were  used.  Cells  were  detected  using  the  BD  FACS  Canto  II 
cytofluorimeter and analyzed with Flowjo Software. 
 
F4/80high  and F4/80low TAMs  sorting. TAMs  were  isolated  from  tumor  as 
previously  described  and  were  enriched  by  positive  selection  with  CD11b 
microbeads, according to manufacturer's instruction (MACS, Miltenyi). CD11b + 
cells were stained with CD45, F4/80 and CD88 antibodies and sorted with cell 
sorting BD FACS Aria to obtain CD45+F4/80highCD88high population and 
CD45+F4/80lowCD88low population. 
 
Migration assay. PEC and TAMs migration was evaluated using a chemotaxis 
microchamber technique as described previously [28]. Briefly, 30 µl of 
chemoattractant solution (CCL2, CCL5, MCSF, C5a or C3a 100ng/ml in RPMI 
1640 with 1% FBS) or control medium (RPMI 1640 with 1% FBS) was added 
to  the  lower  wells  of  a  chemotaxis  Boyden  chamber  (Neuroprobe)  and  a 
polycarbonate filter (PVP treated, 5 µm pore size; Neuroprobe) was placed into 
the wells and covered with a silicon gasket. The correct concentration for each 
cytokines used was determinated by a dose-response assay both for wt and p50 -/- 
cells (Fig. S1A). 50 µl of cell suspension (4*10 6/ml) were seeded in the upper 
wells  and  the  chamber  was  incubated  at  37°C  for  4  hours.  At  the  end  of  this 
period, filters were removed and stained with Diff- Quik (Baxter) and 10 high-
power oil immersion fields were counted. 
 
Real-Time PCR. Total RNA was extracted with TRIzol (Invitrogen) according 
to the manufacturer’s instructions. 1 µg of total RNA was reverse-transcribed by 
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the  High  Capacity  cDNA  Reverse  Transcription  kit  (Applied  Biosystems), 
amplified using Fast Syber Green Master Mix (Applied Biosystems), and 
detected  by  the  7900HT  Fast  Real-Time  System  (Applied  Biosystems).  The 
sequences of gene-specific primers are available upon request. Data were 
processed using SDS2.2.2 software (Applied Biosystems). Results were 
normalized to the expression of the housekeeping gene β-actin and then 
expressed as fold up-regulation with respect to the control cell population. 
 
Microarray  expression  profiling.  PEC  from  three  independent  experiments 
were stimulated as described above with LPS for 4 or 24 hours. F4/80 high and  
F4/80low TAMs  were  sorting  from  three  biological  replicates.  The  RNA  was 
purified  from  PEC  and  TAMs  using  the  RNeasy  Plus  Mini  Kit,  following 
standard RNA isolation protocol (Qiagen, Italy), and quantified with ND-1000 
UV–Vis Spectrophotometer (NanoDropTechnologies, USA). All the cRNA 
synthesis/sample-labelling,  hybridization,  washing,  and  scanning  steps  were 
conducted  following  the  manufacturer’s  specifications  (Agilent  Technologies 
Inc., Italy). After hybridization, the slides were washed and then scanned with 
the  Agilent  G2565BA  Microarray  Scanner.  The  fluorescence  intensities  of 
scanned images were extracted and pre-processed by Agilent Feature Extraction 
Software (v10.5.1.1). Expression measures were computed using robust 
multiarray average. Principal component analysis was carried out on all genes 
analyzed to assign the general variability in the data to a reduced set of variables 
called principal components. PCA (analysis was applied to the complete 
dataset) is a mathematical algorithm that reduces the dimensionality of the data. 
It accomplishes this reduction by identifying directions, called principal 
components, along which the variation in the data is maximal [29]. In PCA, we 
obtain  a  set  of  orthogonal  axes  oriented  in  the  directions  of  largest  variance 
within  a  set  of  data  points  in  a  high-dimensional  space.  The  first  principal 
component is a vector in the direction of greatest variance, the second principal 
component  is  a  vector  in  the  direction  of  greatest  variance  orthogonal  to  this, 
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and so on. These vectors are in fact eigenvectors of the empirical data 
covariance  matrix.  Values  on  the  x-  and  y-axis  express  a  two-dimensional 
representation  of  greatest  variance  vectors.  Genes  were  defined  as  regulated 
when  characterized  by  a  fold  change  ≥4  and  p  value  ≤  0.05.  We  performed 
enrichment analyses using the databases GO (Biological Process and Molecular 
Function), and KEGG pathways. 
 
Immunoblotting. After the indicated treatments, PEC or TAMs were lysed in 50 
µL  of  lysis  buffer  (20  mM  Tris-HCl,  pH  8;  137  mM  NaCl;  10%  glycerol 
(vol/vol);  1%  Triton  X-100  (vol/vol);  1  mM  Na3VO4;  2  mM  EDTA;  1  mM 
PMSF; 20 µM leupeptin; and 0.15 U/mL aprotinin) for 20 minutes at 4°C. The 
lysates were centrifuged at 13000g at 4°C for 15 minutes and the supernatants 
were run on a 10% (wt/vol) sodium dodecyl sulphate (SDS)-polyacrylamide gel 
electrophoresis (SDS-PAGE; 30 µg protein/lane). Separated proteins were 
transferred onto a nitrocellulose membrane (1 h at 125 mA) and immunoblotted 
for  specific  antibodies  as  per  manufacturer's  instructions.  Blocking  was  done 
with 5% (wt/vol) bovine serum albumin (BSA) in TBS-0.1% Tween (TBST) for 
1 hour at room temperature. All antibody dilutions were prepared in 5% (wt/vol) 
BSA-TBST. Primary antibody was used at 1:2000 dilution for overnight at 4°C. 
HRP-conjugated anti-rabbit secondary antibody (Amersham, USA) was used at 
1:4000 dilution for 1 hour at room temperature. Blots were visualized using an 
enhanced  chemiluminescence  (ECL)  kit  (Amersham,  USA).  The  antibodies 
used  were:  rabbit  anti-mouse  Phospho-p44/42  MAPK  (Erk1/2)  antibody  (Cell 
Signalling  Technologies  Inc,  MA);  goat  anti-mouse  vinculin  antibody  (Santa 
Cruz Biotechnology). 
 
Confocal microscopy. Frozen tissues in OCT were sectioned (8 µm), mounted 
on positively charged slides, air-dried for 30 minutes and fixed with 4% PFA for 
10 minutes at room temperature. Sections were blocked with PBS 0.1% Triton-
X100 (Sigma-Aldrich) plus 5% normal goat serum (Dako Cytomation, 
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Carpinteria,  CA  USA)  and  2%  BSA,  (Amersham  Biosciences,  Piscataway 
Township, NJ USA) for 1 hour. Slides were then incubated with the following 
antibodies: rabbit anti-mouse/human HO-1, rat anti-mouse F4/80 (AbD 
Serotec),  rabbit  anti-mouse  CD31  (PECAM-1,  Pharmingen,  San  Diego,  CA). 
After 1h of incubation, the detection antibodies goat anti-rabbit IgG Alexa® 488 
and  goat  anti-rat  IgG  Alexa®  647  (Invitrogen,  Molecular  Probes)  were  used. 
Nuclei were counterstained with DAPI (Invitrogen, Molecular Probes). Samples 
were mounted with FluorPreserve Reagent (Calbiochem San Diego, CA USA) 
and  analyzed  with  an  Olympus  Fluoview  FV1000  laser  scanning  confocal 
microscope. 
 
In vivo treatments. When the tumor became palpable (day 14), wt mice were 
injected  with  CSFR1  antagonist  (kindly  donated  by  Dr.  Carola  Ries,  Roche 
Diagnostic Gmbh, Penzberg, Germany) as an initial dose of 60mg/kg followed 
by two doses of 30 mg/kg two times a week for a total of 2 weeks.  
To  induce  LPS  tolerance  in  vivo,  6  to  8-week-old  wt  and  p50-/-  mice  were 
injected intraperitoneally with 200 µg of LPS. After 24 hours we collected blood 
and PEC for flow cytometry analysis. 
 
Air pouch model. The air pouch model was performed as described elsewhere 
[30].  Briefly,  wt  and  CD88-/-  mice  were  subcutaneously  injected  on  the  back 
with sterile air (day 0: 5ml; day 3: 3ml). Mice induced tolerant were injected on 
day 5 I.P. with 200 µg of LPS. On day 6, 200 ng of LPS (SIGMA) dissolved in 
1ml carboxymethylcellulose (CMC, SIGMA; 0,5% in PBS) were injected into 
the air pouch. After 24 hours, the animal were sacrified and the pouches were 
washed  with  2  ml  of  PBS  to  recover  the  infiltrating  cells.  Cells  were  washed 
twice to eliminate CMC and used for flow cytometry analysis. 
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Adoptive  transfer.  CD45+F4/80highCD88high  and  CD45+F4/80lowCD88low  cells 
were sorted from wt tumor bearing mice and immediately injected together with 
MN  tumor  cells  into  the  hind  leg  of  wt  or  p50-/-  animals  (10^5  tumor  cells  + 
2*10^5 F4/80high or F4/80 low per mouse). Tumors were measured three times a 
week with a caliper.  
 
Patients. Peripheral blood was collected from healty donors and septic patients 
(n  =  20  patients  and  15  controls)  and  was  analyzed  within  3  hours  after 
collection by FACS-analysis (see section Flow Cytometry). 
 
Statistics. Statistical significance was determined by two-tailed Student’s t test. 
*p value< 0.05; **p value< 0.01; ***p value< 0.001. 
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Results 
p50  NF-κB  modulates  macrophage  migratory  behaviour.  We  previously 
reported  that  nuclear  accumulation  of  p50  NF-κB  is  a  key  event  guiding 
macrophage reprogramming towards an immunosuppressive M2-like phenotype 
[12, 26]. As macrophage functions are dependent on their homing capacity in 
response to chemotactic signals, we decided to investigate the putative role of 
p50 NF-κB on monocyte/macrophage migration. In  vitro migration assay, 
performed in a Boyden chamber, demonstrated that p50-/- peritoneal 
macrophages (PEC) migrate significantly less than their wt counterparts towards 
canonical chemotactic stimuli (i.e. CCL2, CCL5, C5a, C3a) (Fig. 1A-S1A). Of 
note,  flow  cytometry  analysis  (FACS)  on  wt  and  p50 -/-  PEC  revealed  no 
differences in the level of expression of the specific chemotactic receptors (Fig. 
S1B). Since a major pathway involved in myeloid cells migration includes the 
MAPkinases [31], we checked the levels of ERK1/2 phosphorylation in wt and 
p50-/- PEC after stimulation with the chemotactic agents. We observed that in 
response  to  each  different  stimulus,  including  the  positive  control  LPS  [32], 
ERK1/2 phopshorylation in p50 -/- cells was impaired, as compared to wt cells 
(Fig. 1B). Based on this, we next investigated whether and how nuclear 
accumulation  of  p50  NF-κB,  as  occurring  in  LPS-tolerant  macrophages  [26] 
(Fig.  S1C)  could  affect  their  chemotactic  ability.  In  vitro  migration  assay 
demonstrated that PEC activated with LPS for 4 hours (ML) failed to migrate in 
response  to  several  stimuli,  including  CCL2  [28].  Notably,  we  observed  that 
macrophages undergoing LPS-tolerance (LL) were able to recover their 
chemotactic response towards the complement factors C5a and C3a, while their 
migration  in  response  to  CCL2  and  CCL5  remained  impaired  (Fig.  1C).  In 
agreement,  western  blot  analysis  confirmed  that  LPS-tolerant  macrophages 
phosphorylate ERK1/2 only in response to complement factors (C3a and C5a) 
(Fig.  1D).  Altogether,  these  data  indicate  that  lack  of  p50  NF-κB  impairs 
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macrophage  chemotactic  responsiveness  and  that  LPS-tolerant  macrophages 
migrate only in response to complement factors (C5a and C3a). 
 
 
 
Fig.  1:  Role  of  p50  NF-κB  in  macrophage  migration. (A) Wt  and  p50-/- peritoneal 
macrophages (PEC) were used to assemble an in vitro chemotaxis assay in a Boyden chamber, 
in  the  presence  of  100ng/ml  of  each  chemotactic  stimulus.  (B)  Wt  and  p50 -/-  PEC  were 
stimulated with different chemotactic agonists (all used 100ng/ml) for 3 minutes and with LPS 
(positive control) for 15 minutes. Protein lysates were immunoblotted with an antibody against 
phospho-ERK1/2  (p44/42)  (Thr202/Tyr204).  Vinculin  was  used  as  loading  control.  (C)  PEC 
from wt mice were stimulated or not in vitro with LPS (MM=medium; ML=20 hrs medium plus 
4 hrs LPS (activated macrophages); LL= 20 hrs LPS plus 4 hrs restimulation with LPS (tolerant 
macrophages)). Next, cells were harvested and put into a Boyden chamber, in the presence of 
different chemotactic stimuli (all used 100ng/ml). (D) Protein lysates from wt PEC (M/M; M/L 
and L/L) restimulated or not with different chemotactic agents for 3 minutes, were 
immunoblotted  with  anti  phospho-ERK  antibody.  Vinculin  was  used  as  loading  control.  Data 
are expressed as the mean +/- SEM. Graphs are representative of 3 independent experiments.*p 
< 0.05 **p < 0.01 ***p < 0.001. 
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Distinct macrophage subsets are differentially recruited to sites of 
inflammation during systemic LPS-tolerance. To assess the chemotactic 
response of M2-polarized macrophages also in vivo, we performed an air-pouch 
assay in LPS-tolerant wt mice, treated systemically with LPS (10mg/kg), 
according to the scheme described in Fig. S2A. We divided mice in four groups: 
A) ctrl mice injected with only air into the air pouch; B) mice injected with LPS 
(200ng/ml) into the air pouch; C) LPS-tolerant mice (injected I.P. with LPS); D) 
LPS  tolerant  mice  injected  with  LPS  into  the  air  pouch.  As  expected,  FACS 
analysis of the cellular infiltrate collected from the air pouches of the different 
groups  revealed  that  mice  treated  with  LPS  into  the  pouch  (group  B  and  D) 
displayed increased number of CD45 + myeloid cells, compared to control mice 
(Fig. S2B). Interestingly, we observed a differential regulation in the 
accumulation of distinct F4/80+ macrophage subsets. In particular, F4/80+ 
macrophages recruited to the inflammatory site were composed by two subsets 
characterized  by  different  expression  levels  of  F4/80  and  CD88,  respectively 
defined  as  F4/80highCD88high  and  F4/80lowCD88low.  Of  note,  F4/80highCD88high 
macrophages were specifically and exclusively recruited during LPS-tolerance 
(group C and D); in fact, into the air pouches of non-tolerant mice (group A and 
B)  we  observed  only  the  presence  of  F4/80lowCD88low  (Fig.  2A-B).  Because 
LPS-tolerant  macrophages  respond  chemotactically  to  the  complement  factors 
C3a and C5a (Fig. 1C), we performed an air-pouch assay also in CD88 -/- mice. 
Strikingly, the air pouches of CD88 -/- mice showed decreased accumulation of 
F4/80highCD88high cells associated with an increased recruitment of 
F4/80lowCD88low  macrophages  (group  D),  compared  to  wt  (Fig.  2C).  Thus,  a 
specific  subset  of  macrophages  expressing  high  level  of  F4/80  and  CD88 
migrate to sites of inflammation in tolerant conditions. 
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Fig.  2:  F4/80highCD88high  macrophages  migrate  to  sites  of  inflammation  during 
LPS-tolerance. (A) Flow  cytometry  analysis  of  CD45+F4/80+  cells  collected  from  the  air 
pouches of the different groups of wt mice. Group A: ctrl mice injected with only air into the air 
pouch;  Group  B:  mice  injected  with  LPS  into  the  air  pouch;  Group  C:  LPS-tolerant  mice 
(injected  IP  with  LPS  10mg/kg);  Group  D:  LPS  tolerant  mice  injected  with  LPS  into  the  air 
pouch. (B) Percentage of F4/80 high and F4/80 low cells recruited into the air pouch in the different 
groups. (C) Flow cytometry analysis and percentage of F4/80 high and F4/80 low cells recruited into 
the air pouches of group D, in  wt and CD88 -/- mice. Data are expressed as the mean +/- SEM (n 
= 4-5 mice per group). *p < 0.05 
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p50  NF-κB  drives  CD88  expression  and  recruitment  of  F4/80highCD88high 
cells during tolerance. Additional analysis demonstrated that CD88 expression 
is upregulated in concomitance with the induction of tolerance in vivo, in a p50-
dependent manner. In fact, FACS analysis on PEC purified from wt and p50 -/-
mice  at  different  time  points  (4,  8,  16  and  24  hours)  after  I.P.  injection  with 
LPS, showed that while in wt PEC the expression of CD88 increases in parallel 
with the induction of systemic tolerance, macrophages p50 -/- are unable to up-
regulate CD88, even after long exposure to LPS (24 hours) (Fig. 3A). Further, 
specific recruitment of F4/80 highCD88high subset during systemic LPS-tolerance 
was  observed  at  the  site  of  inflammation  (air  pouch,  Fig.  2).  In  order  to 
investigate whether the F4/80highCD88high population could also increase 
systemically,  we  performed  FACS  analysis  of  blood  from  both  wt  and  p50-/- 
mice,  at  different  time  points  (4,  8,  16  and  24  hours)  after  I.P.  injection  with 
LPS (10mg/kg). Notably, the F4/80 high population was detectable in the blood of 
wt mice only after LPS injection. As already reported [26], p50-deficient mice 
do not develop systemic LPS-tolerance. In agreement, these mice did not show 
accumulation  of  the  F4/80 high  population  in  the  blood  of  p50 -/-  mice  after 
prolonged LPS treatment (16-24 hours) (Fig. 3B), suggesting that p50-mediated 
tolerance is required to recruit this population. Interestingly, as compared to the 
F4/80lowCD88low macrophages, the F4/80highCD88high population was 
characterized by higher levels of expression of Tie2, CCR2 and Ly6C (Fig. 3C-
S3B), that increased with similar a kinetic, both in vivo (Fig. 3C) and in vitro 
(Fig. S3A).  
During  the  course  of  human  sepsis,  neutrophils  down-regulate  the  levels  of 
CD88 expression [33, 34]. Strikingly, while we confirmed the CD88 
downregulation on peripheral neutrophils of septic patients, their blood 
monocytes showed a significant upregulation of CD88 and Tie2, as compared to 
healthy controls (Fig. 3D), indicating the expansion of the human 
CD88highTie2high monocytic population in condition of systemic infection.  
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Fig.  3:  p50  NF-κB  controls  expansion  and  recruitment  of  F4/80highCD88high cells 
during tolerance. (A) Wt and p50 -/- mice were injected I.P. with saline or LPS (10mg/kg) and 
PEC were recovered 4-8-16-24 hours after injection. CD88 expression was analyzed by FACS 
as mean of fluorescence intensity (MFI). (B) Blood from wt and p50 -/- mice injected with LPS 
I.P.  was  recovered  at  different  time  points  (4-8-16-24  hours) after  LPS  administration and 
analyzed  by  FACS  for  the  presence  of  F4/80 high  and  F4/80low  populations  and  (C)  for  the 
expression of CD88 and Tie2. Data are expressed as the mean +/- SEM (n = 4 mice per group). 
(D) Neutrophils and monocytes from blood of septic patients were analyzed by FACS for the 
expression of CD88 and Tie2. Healthy donors were used as a control. Data are expressed as the 
mean +/- SEM (n = 20 patients and 15 controls). *p < 0.05 **p < 0.01.  
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Detection  of  F4/80highCD88high and  F4/80lowCD88low TAMs  populations  in 
primary  tumors  and  metastasis.  We  already  published  that  similarly  with 
LPS-tolerant macrophages, tumor associated macrophages (TAMs) display high 
nuclear  accumulation  of  p50  inhibitory  homodimers  [12].  Based  on  this,  we 
functionally and phenotypically analyzed TAMs populations in vitro and in vivo 
in the transplantable MN/MCA1 murine model of fibrosarcoma. First, in vitro 
chemotaxis assay demonstrated that, similarly with LPS-tolerant macrophages, 
TAMs  show  chemotactic  responsiveness  towards  the  complement  factors  C5a 
and C3a (Fig. 4A-B), associated with similar levels of ERK1/2 phosphorylation 
(data not shown). Furthermore, in analogy with LPS-tolerant macrophages (Fig. 
1A),  p50-/-  TAMs  showed  decreased  migration  capacity  to  C5a  and  C3a,  as 
compared to wt TAMs (Fig. 4B). 
 
 
 
Fig. 4: TAMs recapitulate the chemotactic behavior of LPS-tolerant macrophages. 
TAMs  from  wt  (A)  or  wt  and  p50-/-  mice  (B)  were  used  to  assemble  an  in vitro chemotaxis 
assay,  in  comparison  with  untreated,  LPS  activated  or  LPS  tolerant  peritoneal  macrophages. 
Data are expressed as the mean +/- SEM. Graphs are representative of at least 2 independent 
experiments. ***p < 0.001.   
 
 
To assess the phenotypic similarities between TAMs and LPS-tolerance 
macrophages  also  in  vivo,  we  performed  flow  cytometry  analysis  of  TAMs 
purified  from  the  MN/MCA1  fibrosarcoma.  To  this  aim,  10^5  MN/MCA1 
tumor cells were injected in the hind leg of wt mice and after 4 weeks primary 
tumors  and  lung  metastasis  were  recovered,  smashed  to  obtain  single  cell 
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suspension and stained for FACS analysis. We observed that similarly with the 
macrophage populations detected in LPS-tolerant mice (Fig. 2A), TAMs from 
both primary tumors and lung metastasis were composed by two distinct 
F4/80highCD88low and F4/80 lowCD88low populations (Fig. 5A). In further support 
of  this  similarity,  the  F4/80highCD88high  subset  also  expressed  higher  levels  of 
Tie2 (Fig. 5B). Of note, analysis of TAMs populations in wt tumor bearing mice 
subcutaneously injected with B16F10 melanoma cells resulted in similar 
phenotype (Fig. S4A). 
Next, we investigated the role of p50 in the recruitment of TAMs subsets. FACS 
staining on infiltrating TAMs demonstrated that genetic ablation of p50 strongly 
affects F4/80high recruitment in both primary MN/MCA1 tumors and metastasis 
(Fig. 5C-D). To further assess the in  vivo importance of p50 NF-κB in 
macrophage migration, we generated a p50 NF- κB conditional knockout mice 
with selective depletion of p50 in the myeloid compartment 
(p50flox/floxLyzCre), by intercrossing p50 NF- κB floxed mice with LyzM-Cre 
mice.  Strikingly,  we  observed  that  compared  to  littermate  controls,  myeloid-
specific  ablation  of  p50  resulted  in  significant  impairment  of  F4/80high  TAMs 
recruitment in primary tumors, both in MN/MCA1 and B16 model; while, the 
recruitment of F4/80low TAMs was unaffected  (Fig. S4B).  
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Fig.  5:  Distinct  roles  of  p50  in  the  recruitment  of  the  F4/80 highCD88high  and 
F4/80lowCD88low TAMs populations, in primary tumors and metastasis. (A-B) 
MN/MCA1 fibrosarcoma primary tumors and metastasis from wt mice were analyzed by flow 
cytometry analysis for the expression of CD88, Tie2 and F4/80 positive cells. (C-D) Percentage 
of F4/80high and F4/80 low populations in MN/MCA1 primary tumors and metastasis from wt and 
p50-/- mice. Graphs are representative of at least 2 independent experiments. Data are expressed 
as the mean +/- SEM (n = 5 mice per group). *p < 0.05 **p < 0.01 ***p < 0.001. 
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The complement factor C3a controls the selective recruitment of 
F4/80highCD88high TAMs and support tumor development. Additional FACS 
analysis showed that the F4/80highCD88high and F4/80lowCD88low TAMs  
populations  also  differ  for  the  expression  of  several  chemotactic  receptors.  In 
particular,  the  F4/80highCD88high  TAMs  expressed  higher  levels  of  the  C3aR, 
cd115 (M-CSF receptor), CCR2 and CCR5 (Fig.6A-B). Differential expression 
of these chemotactic receptors was functionally associated with increased 
chemotactic  responsiveness  to  specific  chemotactic  agonists.  In  particular,  we 
observed that F480highCD88high TAMs displayed higher chemotactic ability than 
F4/80low in response to C5a, C3a and MCSF (Fig. 6C). 
 
 
 
Fig.6: Chemotacitc response of F4/80 highCD88high and F4/80 lowCD88low TAMs. (A-B) 
TAMs  were  stained  with  an  anti-F4/80  antibody,  along  with  several  antibodies  recognizing 
different chemokine receptors. CD88, CD115, CCR5, CCR2 and C3aR expression are indicated 
as MFI. (C) F4/80 highCD88high and F4/80 lowCD88low TAMs were sorted from MN/MCA1 tumors 
for F4/80 and CD88 expression and used for an in vitro chemotaxis assay. All the chemotactic 
stimuli were used at a concentration of 100ng/ml. Figures are representative of 2 independent 
experiments. Data are expressed as the mean +/- SEM. *p < 0.05 **p < 0.01. 
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It was proposed that M-CSF regulates the recruitment and survival of “resident” 
macrophages  involved  in  tissue  homeostasis  and  several  studies  indicate  that 
CSF-1  inhibition  reduces  the  number  of  tissue  macrophages,  including  TAMs 
[20, 35, 36]. Based on this, we wondered whether antibodies against M-CSFR 
could selectively affect TAMs subsets. To this aim, wt mice were injected with 
10^5 MN/MCA1 tumor cells in the hind leg and 2 weeks later were treated I.P. 
twice a week with vehicle or anti-CSFR1 blocking antibody. During the 
treatment regimen, an initial dose of 60mg/kg was followed by two doses of 30 
mg/kg. Administration of anti-CSFR1 antibody resulted in severe inhibition of 
tumor growth and reduced TAMs accumulation, with a predominant impairment 
of  the  F480highCD88high subset  (Fig.  7A-B).  Of  relevance,  treatment  with  anti-
CSFR antibody significantly reduced the percentage of CD31 expressing cells in 
tumors  (Fig.  7C),  indicating  that  the  ratio  between  the  TAMs  subsets  may  be 
relevant in tumor angiogenesis and tumor growth. Hence, we also investigated 
whether,  in  addition  to  M-CSF1,  the  complement  factors  C3a  and  C5a  could 
play  a  role  in  the  selective  recruitment  of  TAMs  subsets  in  vivo.  Of  note, 
injection of MN/MCA1 cells in C3 deficient mice resulted in significant 
impairment  of  F4/80highCD88high  TAMs  accumulation,  in  both  primary  tumor 
and lung metastasis, while the recruitment of F4/80 low TAMs was unchanged. In 
addition, C3 deficient mice displayed reduced tumor growth and lung metastasis 
formation, as compared to wt mice (Fig. 7D-E).  
Angiogenesis represents a critical process during tumor initiation and 
progression; however, unlike physiological angiogenesis, blood vessel 
development in solid tumors is not tightly controlled but rather occurs 
relentlessly. Consequently, tumor vessels are heterogeneous, branch chaotically 
and  are  aberrant  in  almost  all  aspects  of  their  structure  and  function  [37,  38]. 
Thus, we decided to checked tumor vascularization, in order to further 
characterize the effects of impairing F4/80high cells recruitment on tumor 
growth.  Primary  tumor  lesions  from  C3  deficient  mice  displayed  impaired 
  92 
tumor  vascularization,  assessed  as  reduced  CD31 + cells  density  and  vessels 
length (Fig. 7F).  
Surprisingly, MN/MCA1 tumor growth, metastasis formation and recruitment of 
F480highCD88high and F480lowCD88low subsets were not affected in CD88 -/- mice, 
(Fig. S5A-B). 
 
 
 
Fig.7: Defective recruitment of F4/80 highCD88high TAMs correlates with inhibition 
of tumor growth and tumor angiogenesis. (A) MN/MCA1 tumor-bearing wt mice were 
treated twice a week with vehicle or anti-CSFR1 blocking antibody as indicated. (B) Data on 
F4/80highCD88high and F4/80 lowCD88low TAMs in primary tumors (left) and metastasis (right) are 
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shown. (C) Tumors from vehicle or anti-CSFR1 treated mice were analyzed by FACS for the 
presence  of  CD31+  cells.  (D)  MN/MCA1  tumor  cells  were  injected  in  C3-/-  mice  and  tumor 
growth was measured 3 times a week starting from day 15 after cells injection. Tumor weights 
(left) and number of macroscopic lung metastasis (right) are shown. (E) Mean percentage +/- 
SEM of F4/80 highCD88high and F4/80 lowCD88low TAMs in primary tumors (left) and metastasis 
(right) from wt and C3 -/- tumor bearers. (F) Mean percentage +/- SEM of CD31 + cells of primary 
tumors from wt and C3 -/- tumor bearers (left). Frozen tumor slides from wt (2cm 3 and 3cm 3) and 
C3-/- mice were analyzed by confocal microscopy for the expression of CD31 (green). Analysis 
of vessels length is also performed. Nuclei were counterstained with DAPI (blue). 
Representative images are shown (scale bars are 10 µm). Graphs are representative of at least 2 
independent experiments. Data are expressed as the mean +/- SEM (n = 5 mice per group). *p < 
0.05 **p < 0.01 ***p < 0.001.  
 
 
F4/80highCD88high and F4/80 lowCD88low TAMs play different roles in tumor 
progression. To investigate the specific roles of TAMs subsets, 
F4/80highCD88high  and  F4/80lowCD88low TAMs  were  sorted  from  MN/MCA1 
tumors and adoptively transferred, together with MN/MCA1 tumor cells, in the 
hind leg of wt mice (10^5 tumor cells + 2*10^5 TAMs per mouse). 
Interestingly, as compared to mice receiving only tumor cells, adoptive transfer 
of F4/80lowCD88low TAMs significantly inhibited tumor growth and lung 
metastasis  formation  (Fig.  8A),  as  opposed  to  decreased  vessels  length  (Fig. 
8B).  Conversely,  mice  adoptively  transferred  with  F4/80 highCD88high  TAMs 
displayed increased metastasis formation (Fig. 8A), along with increased tumor 
vessels density and length (Fig. 8B).  
Because  ablation  of  p50  NF-κB  in  tumor  bearing  mice  resulted  in  decreased 
accumulation of F4/80highCD88high TAMs in both primary tumors and 
metastasis,  we  perform  adoptive  transfer  experiments  also  in  p50-/- mice.  As 
expected  [12],  p50 -/- mice  implanted  with  MN/MCA1  cells  displayed  both 
reduced tumor growth and metastasis number as compared to wt mice. 
Strikingly, transfer of wt F4/80 highCD88high TAMs in p50 -/- tumor bearing mice 
resulted  in  restoration  of  tumor  growth,  increased  metastasis  formation  and 
increased tumor vessels density and length (Fig. 8C-D). Our results indicate a 
differential pro- vs antitumor functions of F4/80highCD88high and 
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F4/80lowCD88low subsets respectively, with the F4/80highCD88high TAMs 
strongly supporting tumor angiogenesis. 
 
 
 
Fig.8:  F4/80highCD88high  and  F4/80lowCD88low  TAMs  play  different  roles  in  tumor 
progression. (A) F4/80high and F4/80 low cells were sorted for F4/80 and CD88 expression from 
wt  tumor  bearing  mice  and  next  injected  together  with  MN/MCA1  tumor  cells  into  wt  mice 
(10^5  tumor  cells  +  2*10^5  F4/80highCD88high  and  F4/80lowCD88low  TAMs  per  mouse).  (B) 
Frozen  tumor  sections  were  analyzed  by  confocal  microscopy  for  the  expression  of  CD31. 
Analysis of vessels length is also shown. (C) F4/80 high cells sorted from wt tumor-bearing mice 
were injected together with MN/MCA1 tumor cells into p50 -/- mice. Tumor weights (center) and 
number of metastasis (right) are shown. (D) Frozen tumor sections were analyzed by confocal 
microscopy for the expression of CD31 (green). Analysis of vessels length is also performed. 
Nuclei were counterstained with DAPI (blue). Representative images are shown (scale bars are 
10 µm). Graphs are representative of at least 2 independent experiments. Data are expressed as 
the mean +/- SEM (n = 5 mice per group). *p < 0.05 **p < 0.01 ***p < 0.001.  
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F4/80highCD88high and F4/80lowCD88low TAMs express distinct 
transcriptional programs. As macrophage polarization plays a crucial role in 
tumor development [7] and since we observed distinct roles of the 
F4/80highCD88high  and  F4/80lowCD88low  TAMs  subsets,  we  performed  genome 
wide analysis through the Agilent DNA microarray platform, comparing global 
gene profiling of F4/80 high TAMs, F4/80 low TAMs, PEC untreated (M/M), LPS-
activated  PEC  (M/L)  and  LPS-tolerant  PEC  (L/M).  To  identify  sources  of 
variability among these entire databases, a PCA was performed [29]. The results 
showed  that  F4/80high and  F4/80low TAMs  are  distinct  in  terms  of  global  gene 
expression. Moreover, their global profiling is closer to that of L-M than M-L 
PEC (Fig. 9A). Real Time qPCR analysis confirmed the differential expression 
of  several  pro-  and  anti-inflammatory  cytokines  by  these  two  populations  of 
TAMs.  Indeed,  F4/80highCD88high TAMs  express  for  example  CXCL10,  IL10, 
MsrII  (Macrophage  scavenger  receptor  II),  at  higher  levels  as  compared  to 
F480lowCD88low TAMs. On the contrary, F4/80 lowCD88low TAMs express Arg1, 
GrzB (Granzyme B) at higher levels (Fig. S6A).  
Interestingly, gene ontology analysis showed that F480highCD88high TAMs 
preferentially expressed clusters of genes involved in immunity, inflammation, 
leukocyte migration and activation. In contrast, F4/80lowCD88low TAMs 
expressed  preferentially  clusters  of  genes  involved  in  metabolism/catabolism 
and  regulation  of  apoptosis  (Fig.  9B),  confirming  profound  differences  in  the 
gene expression profiles. Strikingly, we showed differential expression of genes 
involved in iron metabolism, by both gene ontology (Fig. 9C) and Real Time 
qPCR analysis (Fig. 9D).  
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Fig.9: F4/80highCD88high and F4/80lowCD88low TAMs express distinct 
transcriptional profiles. (A) mRNA was prepared from F480highCD88high and 
F480lowCD88low TAMs sorted from MN/MCA1 tumors and  was analyzed by the Agilent DNA 
microarray platform, in comparison with untreated, LPS activated and LPS tolerant PEC. Global 
gene profiling comparison performed among the TAMs and PEC dataset by PCA is shown . (B) 
Gene  ontology  [39]  enrichment  analysis  of  differentially  expressed  genes.  (left)  Top  enriched 
GO  terms  for  genes  with  higher  expression  in  F4/80low  TAMs  versus  F4/80high  TAMs.  (right) 
Top  enriched  GO  terms  for  genes  with  higher  expression  in  F4/80high  TAMs  versus  F4/80low 
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TAMs. Enrichment score (-log(Pvalue)) is shown. (C) Iron related gene expression analysis of 
F4/80high and F4/80 low TAMs. Results (mean of three independent experiments) are fold-increase 
relative to unstimulated PEC. (D) mRNA expression levels of selected cytokines were analyzed 
by real-time PCR. Wt PEC were used as a control cells. Graphs are representative of at least 3 
independent experiments. Data are expressed as the mean +/- SEM. **p < 0.01 ***p < 0.001. 
 
 
Of relevance, F4/80highCD88high TAMs expressed high levels of the heme 
oxygenase-1  gene  (HO-1  encoded  by  HMOX1),  which  encodes  for  a  heme-
catabolizing enzyme with cytoprotective and antiapoptotic properties. HO-1 acts 
by  extracting  iron  from  protoporphyrin  and  generates  equimolar  amounts  of 
biliverdin and CO, and is high expression in different tumor cells (e.g. prostate 
cancers,  brain  tumors,  adenocarcinoma,  squamous  carcinoma,  melanoma  and 
pancreatic carcinoma) is associated with tumor progression and increased tumor 
angiogenesis [40, 41]. High expression of HO-1 in F4/80highCD88high TAMs was 
confirmed by both Real Time qPCR (Fig. 9D) and FACS analysis (Fig. 10A). 
Due  to  the  preferential  expression  of  HO-1  by  the  F4/80highCD88high  TAMs 
population,  we  used  this  enzyme  to  evaluate  the  preferential  localization  of 
TAMs subsets into the tumor lesions. Confocal microscopy analysis on 
MN/MCA1 tumor thick-sections stained with anti-HO-1 and anti-F4/80 
antibodies indicated that F4/80 +HO-1+ TAMs were specifically enriched at the 
tumor  margin,  while  F4/80+HO-1- TAMs  localized  preferentially  in  the  inner 
areas of tumors (Fig. 10B).  
 
 
 
 
 
 
 
 
 
  98 
 
 
Fig.10: HO-1 is specifically expressed by F4/80highCD88high TAMs and 
preferentially localize at the peripheral margin of tumors. (A) F4/80 highCD88high and 
F4/80lowCD88low TAMs  were stained with an anti-HO-1 antibody and analyzed by FACS. (B) 
Frozen wt MN/MCA1 tumor sections were analyzed by confocal microscopy for the expression 
of F4/80 (red) and HO-1 (green). Nuclei were counterstained with DAPI (blue). Representative 
images are shown (scale bars are 10 µm). Graphs are representative of at least 2 independent 
experiments. Data are expressed as the mean +/- SEM (n = 5 mice per group). **p < 0.01 ***p 
< 0.001. 
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Discussion 
Inflammatory and immune responses mostly involve the recruitment of 
circulating monocytes to specific contexts. In particular, macrophages 
infiltrating tumors are a major leukocyte component of many cancer types and 
extensive evidence indicates that TAMs recruitment into tumors correlates with 
a poor prognosis [2, 42-45]. Thus, strategies aimed either to “re-educate” TAMs 
towards  an  M1  phenotype  or  to  inhibit  their  recruitment  in  tumors  represent 
attractive anti-tumor approaches. This work has identified p50 NF-κB also as an 
important  regulator  of  macrophage  migration.  In  particular  we  demonstrated 
that lack of p50 NF-κB impairs macrophage chemotactic responsiveness. 
Accordingly,  nuclear  accumulation  of  p50  NF-κB  not  only  drives  phenotypic 
traits of TAMs and LPS-tolerant macrophages, including the expression of anti-
inflammatory  M2  polarized  genes  [26],  but  also  promotes  their  chemotactic 
response  to  complement  anaphylatoxins  C5a  and  C3a.    Our  group  already 
published  that  monocytes  stimulated  with  LPS  for  short  periods  (till  6  hours) 
display a dramatic drop in migration in response to CCL2, due to the 
inactivation of CCR2 function [28]. We demonstrated here that tolerant 
macrophages  are  able  to  migrate  only  in  response  to  complement  factors  C5a 
and C3a, while migration to CCL2 remained impaired.  
Distinct F4/80+ macrophage subsets characterized by different expression levels 
of F4/80 and the C5aR (CD88), respectively defined as F4/80 highCD88high and 
F4/80lowCD88low,  differentially  accumulate  into  the  inflammatory  sites,  in  in 
vivo model of LPS-tolerance. Of relevance, p50-dependent induction of 
systemic tolerance [26] is a necessary event driving systemic accumulation of 
F4/80highCD88high  mono/macrophages,  both  in  mouse  and  human.  This  result, 
along with the differential expansion of the F4/80lowCD88low and 
F4/80highCD88high populations, observed also in the preclinical MN/MCA1 
fibrosarcoma and B16 melanoma model, indicates that expansion of 
F4/80highCD88high macrophages is promoted through emergency hematopoiesis. 
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Moreover, in line with the LPS-tolerance model, ablation of p50 NF-κB resulted 
in significant impairment of F4/80 highCD88high TAMs accumulation in primary 
tumors, which correlated with inhibition of tumor growth [12] and 
vascularization.  
Consistent with other reports where lack of complement factors (C3 or C5aR) in 
tumor bearers resulted in impaired MDSCs accumulation, as well as in 
resistance to tumor development and metastasis formation [46-50], we observed 
that reduced fibrosarcoma growth and lung metastasis formation in C3 -/- mice, 
as compared to wt mice, was paralleled by significant impairment recruitment of 
F4/80high  TAMs,  in  both  primary  tumor  and  lung  metastasis.  This  result  was 
mimicked by treatment with an anti-CSFR1 antibody, indicating that blocking 
accumulation of F4/80 high macrophages in the tumor microenvironment impairs 
tumor growth and tumor angiogenesis.  
Strikingly,  adoptive  transfer  of  F4/80 low  TAMs  in  wt  tumor  bearing  mice 
resulted in inhibition of tumor growth and in reduced formation of lung 
metastasis,  while,  conversely,  transfer  of  wt  F4/80high  TAMs  in  p50-/-  tumor 
bearing  mice  caused  restoration  of  tumor  growth  and  increased  metastasis 
formation.  Accordingly,  transfer  of  F4/80high  TAMs  also  increased  tumor 
vessels  density  and  length,  indicating  that  the  ratio  between  the  F4/80high  and 
F4/80low TAMs critically controls the angiogenic switch in growing tumors [51]. 
A distinct role of F4/80 high and F4/80 low TAMs in tumor development was also 
confirmed by analysis of their transcriptomes, showing that distinct gene 
profiles  characterize  the  transcriptional  programs  of  these  populations.  These 
data are in line with findings that macrophages in different functional states or 
with  a  mixed  phenotype  can  coexist  in  the  same  tumor  and  that  they  could 
preferentially localize in different tumor regions [52-54]. 
Thus, we show that distinct macrophage subsets with different functions arise 
during  infection-  and  cancer-driven  inflammation,  in  a  p50  NF-κB-dependent 
manner and that complement-mediated pathways selectively drive their 
infiltration  of  inflammatory  sites,  including  solid  tumors.  Interestingly,  we 
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describe a novel role of p50 NF-kB in guiding expansion, recruitment and the 
tumor promoting functions of the M2-like F4/80high TAMs subset. 
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Supplemental data 
 
Fig.  S1.  (A)  Wt  and  p50-/- PEC  were  used  to  assemble  an  in vitro  dose-response  chemotaxis 
assay  in  a  Boyden  chamber,  in  the  presence  of  different  indicated  concentrations  of  each 
chemotactic  stimulus.  Data  are  expressed  as  the  mean  +/-  SEM.  (B)  Wt  and  p50-/- PEC  were 
stained  with  several  antibodies  recognizing  different  chemokine  receptors.  CD88,  CD115, 
CCR5,  CCR2  and  C3aR  expression  are  indicated  as  MFI.  (C)  Protein  lysates  from  wt  PEC 
(M/M;  M/L  and  L/L)  were immunoblotted with anti  p50  NF-κB  antibody.  Actin  was used as 
loading control. Graphs are representative of 3 independent experiments.*p < 0.05 **p < 0.01 
***p < 0.001. 
 
 
 
 
 
Fig. S2 . (A) Air pouch model scheme: wt mice were injected at day 0 subcutaneously with 5cc 
of sterile air. The injection was repeated at day 3. 48 hrs after the second injection of air, mice 
belonging  to  groups  C  and  D  were  injected  IP  with  LPS  10mg/Kg  to  induce  systemic  LPS-
tolerance. After additional 24 hrs mice from group B and D were injected with LPS 200ng/ml 
into the air pouch. At day 7 cells recruited into the air pouch were collected and analyzed by 
flow cytometry. (B) Number of total CD45 + cells recruited into the air pouch in the different 
groups is shown. Data are expressed as the mean +/- SEM (n = 4-5 mice per group). *p < 0.05. 
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Fig.  S3.  (A)  PEC  from  wt  mice  were  stimulated  or  not  in  vitro  with  LPS  (MM=medium; 
ML=20  hrs  medium  plus  4  hrs  LPS  (activated  macrophages);  LL=  20  hrs  LPS  plus  4  hrs 
restimulation  with  LPS  (tolerant  macrophages));  after  stimulation  cells  were  harvested  and 
analyzed by flow cytometry for the expression (MFI) of F4\80, CD88, Tie2, CCr2 and Ly6C. 
Data are expressed as the mean +/- SEM. Graphs are representative of 3 independent 
experiments. *p < 0.05 **p < 0.01. 
 
 
 
 
 
Fig. S4 . (A) B16 melanoma tumors from wt tumor-bearing mice were analyzed by FACS for 
the  presence  of  F4/80 high  and  F4/80low  populations  and  for  expression  of  CD88.  (B)  Mean 
percentage of F4/80 highCD88high and F4/80 lowCD88low TAMs in primary tumors from p50 Flox and 
p50LyzCre tumor bearers (MN/MCA1 (left) and B16 (right)). Data are expressed as the mean +/- 
SEM (n = 4-5 mice per group). *p < 0.05. 
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Fig.  S5.  (A)  MN/MCA1  tumor  cells  were  injected  in  CD88-/-  mice  and  tumor  growth  was 
measured  3  times  a  week  starting  from  day  14  after  cells  injection.  (B)  Mean  percentage  of 
F4/80highCD88high  and  F4/80lowCD88low  TAMs  in  primary  tumors  (left)  and  metastasis  (right) 
from wt and CD88 -/- tumor bearers.  Data are expressed as the mean +/- SEM (n = 4-5 mice per 
group). 
 
 
 
 
 
Fig.  S6:  (A)  Total  RNA  was  prepared  from  F4/80highCD88high  and  F4/80lowCD88low  TAMs 
sorted from MN/MCA1 tumors. mRNA expression levels of seleceted cytokines were analyzed 
by real-time PCR. Wt PEC were used as a control cells. Graphs are representative of at least 3 
independent experiments. Data are expressed as the mean +/- SEM. ***p < 0.001. 
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Supplemental materials and methods 
Mice. The targeting construct to generate a NFKB1flox/flox (p50 Flox) mice was 
designed  as  follows:  the  eighth  exon  of  NFKB1  gene  was  flanked  with  loxP 
sites  and  the  neomycin  resistance  gene,  flanked  with  Flippase  Recognition 
Target (FRT) sites to permit its excision, was inserted in the seventh intron. This 
construct was introduced by electroporation into mouse ES cells. Homologous 
recombination was confirmed by southern blot and ES cells carrying NFKB1fl-
neo  allele  were  injected  into  C57  blastocysts  to  generate  germ-line  chimeras. 
The  neomycin  resistance  cassette  in  the  targeting  construct  was  removed  by 
crossing heterozygous NFKB1+/fl-neo mice with mice carrying the FLP 
recombinase under the control of the actin promoter (kindly provided by Rolf 
Sprengel)  to  produce  mice  carrying  the  NFKB1  floxed  allele  (p50F/F  mice). 
p50Flox  mice  were  crossed  with  B6.129P2-Lyz2tm1(cre)Ifo/J  mice  (Jackson 
Laboratories,  Bar  Harbor,  Maine,  USA)  to  generate  p50fl/fl;  LyzCre  mice. 
Homozygous  CD88  (C5aR1)  mutant  mice  were  kindly  donated  by  Dr.  J.D. 
Lambris  (Pathology  and  Laboratory  Medicine,  University  of  Pennsylvania, 
USA). 
 
B16 tumor model. 8 weeks old wt, p50Flox and p50LyzCre mice were injected 
subcutaneously  with  5*10^5  cells  of  melanoma  (B16)/200 µl  saline  solution 
into the right flank. Tumor growth was monitored 3 times a week with a caliper, 
starting from day 13.  
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Graphical abstract 
 
 
 
 
Significance  
Preclinical  data  show  that  MDSCs  and  TAMs  orchestrate  tumor-promoting 
conditions, suggesting these cells as attractive therapeutic targets. MDSCs and 
TAMs generation is tightly associated with the altered hematopoietic output that 
occurs in cancer, defined as ‘‘emergency hematopoiesis.’’ Here we report that 
RORC1  is  a  key  driver  of  emergency  hematopoiesis  in  tumor  bearers,  in 
response to colony-stimulating factors (G-CSF, GM-CSF, and M-CSF), and that 
RORC1-expressing  myeloid  cells  mark  advanced  cancer  inflammation.  We 
demonstrate that ablation of RORC1 in the myeloid compartment impairs tumor 
development and the generation of suppressive MDSCs while promoting 
generation  of  antitumor  M1-polarized  TAMs.  Thus,  inhibition  of  RORC1-
dependent  myelopoiesis  may  represent  a  therapeutic  approach  to  prevent  the 
induction of the tumor-promoting host macro- and microenvironments.  
 
 
In brief  
Strauss et al. show that RORC1 
orchestrates myelopoiesis and 
supports tumor-promoting 
innate immunity. Importantly, 
ablation of RORC1 in the 
myeloid compartment inhibits 
tumor  growth  and  metastasis, 
suggesting a cancer therapeutic 
approach.  
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Abstract 
Cancer-driven granulo-monocytopoiesis stimulates expansion of tumor 
promoting myeloid populations, mostly myeloid-derived suppressor cells 
(MDSCs) and tumor-associated macrophages (TAMs). We identified subsets of 
MDSCs  and  TAMs  based  on  the  expression  of  retinoic-acid-related  orphan 
receptor (RORC1/ROR γ) in human and mouse tumor bearers. RORC1 
orchestrates myelopoiesis by suppressing negative (Socs3 and Bcl3) and 
promoting  positive  (C/EBPb)  regulators  of  granulopoiesis,  as  well  as  the  key 
transcriptional mediators of myeloid progenitor commitment and differentiation 
to  the  monocytic/macrophage  lineage  (IRF8  and  PU.1).  RORC1  supported 
tumor-promoting innate immunity by protecting MDSCs from apoptosis, 
mediating TAMs differentiation and M2 polarization, and limiting tumor 
infiltration  by  mature  neutrophils.  Accordingly,  ablation  of  RORC1  in  the 
hematopoietic compartment prevented cancer-driven myelopoiesis, resulting in 
inhibition of tumor growth and metastasis.  
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Introduction 
Immunologic stress, such as infection and cancer, modifies the magnitude and 
composition of the hematopoietic output, a feature of immune regulation 
defined as ‘‘emergency’’ hematopoiesis, to guarantee proper supply of immune 
cells to increased demand [1]. Tumors can reprogram myeloid cells to promote 
disease  progression  [2].  However,  the  molecular  pathways  guiding  cancer-
driven ‘‘emer- gency’’ myelopoiesis remain largely unknown. Colony-
stimulating factors (CSFs) are major orchestrators of hematopoietic 
development. Among these, granulocyte CSF (G-CSF) and granulocyte-
macrophage  CSF  (GM-CSF)  drive  ‘‘emergency’’  myelopoiesis  by  securing 
supply of neutrophils and macrophages from bone marrow (BM) and 
hematopoietic stem cell niches (HSCs) [1, 3]. Further, the macrophage CSF (M-
CSF) promotes macrophage differentiation from medullar precursors and 
differentiation  of  tissue  macrophages  involved  in  tissue  homeostasis  [4]  and 
tumor  progression  [5].  Recent  studies  reveal  that  monocytic  and  granulocytic 
myeloid-derived suppressor cells (M-MDSCs and PMN-MDSCs, respectively) 
and  tumor-associated  macrophages  (TAMs),  the  major  myeloid  populations 
associated with cancer development [2], differentiate from a common myeloid 
progenitor (CMP) [6]. Importantly, reciprocal regulation of macrophage versus 
neutrophil/granulocyte differentiation might control tissue homeostasis. 
Depletion of tissue macrophages leads to exacerbated G-CSF-mediated 
granulopoiesis [7, 8], and tissue macrophages regulate HSC niche homeostasis 
[9, 10]. Thus, investigation of the molecular networks that dictate this reciprocal 
regulation  appears  to  be  crucial,  as  it  may  affect  tissue  homeostasis  during 
cancerogenesis. 
G-CSF-induced granulopoiesis is mediated through the transcription factors c-
EBPb [11] and STAT3 [12], whereas M-CSF supports monocyte differentiation 
through the transcription factors PU.1 and IRF8 [13]. Of relevance, interleukin-
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17A  (IL-17A)  promotes  G-CSF-  and  stem-cell-factor-mediated  neutrophilia 
[14] and supports G-CSF-driven ‘‘emergency’’ myelopoiesis [15]. 
Despite the fact that IL-17 expression in cancer has been so far mainly restricted 
to the adaptive immunity [16] and its role in cancer remains controversial [17], 
TAMs  and  MDSCs  produce  the  Th17-driving  cytokines  TGFb  and  IL-6  [18], 
and IL- 17-expressing cells with macrophage morphology have been described 
in cancer patients [19]. Although the Th17 response is controlled by the nuclear 
receptor retinoic-acid-related orphan receptor gamma (RORγ) full-length 
protein (RORC1) and the RORC γt splice variant (RORC2) [20], the signaling 
pathways  that  drive  IL-17-producing  innate  immune  cells  have  been  poorly 
investigated. IL-17A-expressing myeloid cells have been reported in 
inflammation  [19,  21,  22].  In  arthritis  patients,  mast  cells  express  a  dual 
RORC1/IL-17A fingerprint in response to TLR4 ligands [23], and a population 
of  RORγt-expressing  neutrophils  that  produce  IL-17  was  identified  in  fungal 
infection  [21].  We  explored  the  role  of  the  IL-17/RORC1  axis  in  myeloid 
lineage differentiation and commitment associated with cancer development. 
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Experimental procedures  
 
More-detailed procedures can be found in the Supplemental Experimental 
Procedures.  
 
Ethics statement. The study was approved by the scientific board of Humanitas 
Clinical and Research Center and designed in compliance with Italian governing 
law, EU directives and guidelines, and the NIH Guide for the Care and Use of 
Laboratory  Animals.  Mice  have  been  monitored  daily  and  euthanized  when 
displaying excessive discomfort. Cancer patients were enrolled in the study after 
signing Cancer Research Center Humanitas IRB-approved consent.  
 
Mice. C57BL/6 mice were purchased from Charles River. RORC1 mutant mice 
(B6.129P2(Cg)-Rorctm1Litt/J)  [24]  were  donated  by  Dr.  Dan  Littman  (New 
York  University).  MMTV-PyMT  mice  [25]  were  donated  by  Professor  Guido 
Forni (University of Turin) and mated with C57BL/6 females to obtain the F1 
C57BL/6-MMTV-PyMT  strain.  IL-17A-deficient  mice  were  donated  by  Dr. 
Burkhard Becher (University of Zurich). All animal work was conducted under 
the approval of the Humanitas Clinical and Research Center, in accordance with 
Italian and EU directives and guidelines.  
 
BM  transplantation.  5*106  CD45.2  RORC1-deficient  (Rorc1-/-),  IL-17A-/-,  or 
WT  BM  cells  were  injected  intravenously  into  8-week-old  lethally  irradiated 
(two doses of 475 cGy) CD45.1 C57BL/6 WT male or C57BL/6-MMTV-PyMT 
female mice. 8 weeks later, BM engraftment was checked by staining of blood 
cells with PerCP-conjugated CD45.1 antibody and PE-conjugated CD45.2 
antibody (BD Biosciences) and subsequent FACS analysis.  
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Tumor  models.  10 5  murine  fibrosarcoma  (MN/MCA1)  cells  were  injected 
intramuscularly in the left hind limb. Tumor growth was monitored three times 
a week with a caliper, starting from day 14. The models of chemically induce 
fibrosarcoma  and  mammary  tumor  virus-polyoma  middle  T  antigen  (MMTV-
PyMT) transgenic mice are described in the Supplemental Experimental 
Procedures.  
 
Cell  culture  and  Reagents.  Lineage  cell  separation  from  BM,  isolation  of 
myeloid  cells,  and  cell-culture  conditions  are  described  in  the  Supplemental 
Experimental Procedures.  
 
Mixed-Lymphocyte  Reaction.  Mixed-lymphocyte  reaction  was  performed  as 
previously  reported  [26]  and  as  described  in  the  Supplemental  Experimental 
Procedures. 
 
Patients. Ten patients with T2 or T3 CRC did not receive radiation or 
chemotherapy before sample collection. 
 
Flow  Cytometry.  Detailed  conditions  and  antibodies  used  in  flow  cytometry 
analysis are described in the Supplemental Experimental Procedures 
 
Gating strategy. Gating strategy for the identification of human MDSCs, 
neutrophils,  and  mono-  cytes  is  described  in  the  Supplemental  Experimental 
Procedures. 
 
Histopathological  analysis.  Histopathological  analysis  was  performed  on  BM 
and spleens from WT, Rorc1 -/-, and chimeric mice on sections routinely stained 
with  H&E.  Single-  and  double-marker  immunohistochemistry  on  mouse  and 
human tissue spec- imens were performed as previously reported [27] and are 
described in detail in the Supplemental Experimental Procedures. 
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Confocal Microscopy. Confocal Microscopy was performed as previously 
reported [28] and as described in the Supplemental Experimental Procedures. 
 
Statistics. Statistical significance was determined by a two-tailed Student’s t test 
(*p <0.05, ** p <0.01, *** p <0.001). 
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Results 
Divergent RORC1/IL-17A Fingerprint in Tumor-Associated Myeloid Cells. 
To  clarify  the  role  of  IL-17A+  innate  immune  cells  in  tumor  progression,  we 
screened the myeloid compartment of fibrosarcoma (MN/MCA1)-bearing 
C57BL/6 mice. A tumor volume of <1.5 cm 3 and few lung metastases (fewer 
than five), at days 21–23 after tumor cell injection, was defined as early-stage 
disease  (ED),  whereas  tumors  larger  than  2  cm3  and  a  higher  number  of  lung 
metastases (more than 15; days 25–28) was defined as advanced-stage disease 
(AD) (Fig. S1). In AD, few blood and spleen CD45 +CD3+ T cells expressed IL-
17A (data not shown), whereas IL-17A was significantly expressed by CD45 + 
CD3- cells in the blood (30% ± 3%) and spleen (12% ± 1.5%) (Fig. 1A). Few 
CD45+ CD3-  cells  expressed  IL-17A  in  non-tumor  bearers  (NTs)  and  ED, 
suggesting that IL-17A+ myeloid cells mark advanced cancer-associated 
inflammation.  FACS  analysis  of  the  CD45 + CD3- cell  pool  confirmed  that 
Gr1+CD11b+  MDSCs  represent  the  major  splenic  myeloid  population  in  AD 
(Fig. 1B), comprising a predominant polymorphonuclear 
CD11b+Gr1+Ly6GhighLy6C low (PMN-MDSCs)  population  and  side  monocytic 
CD11b+Gr1+Ly6ChighLy6Glow (M-MDSCs) and CD11b+F4/80+ macrophage 
populations. IL-17A was significantly expressed by PMN-MDSCs in the blood 
and spleen of AD mice (Fig. 1C), although these cells failed to release IL-17 in 
response to degranulating signals, including CD16/32 (FCII/III) antibody-
mediated cross-linkage and C5a (data not shown) [29]. In contrast, IL-17A was 
poorly or not expressed by M-MDSCs (Fig. 1C) and CD11b+F4/80+ 
macrophages (data not shown).  
RORC1  and  its  splice  variant  RORC2  are  master  regulators  of  IL-17A  gene 
transcription  in  Th17  cells  [20],  innate  lymphocytes  [30], γδ T  cells  [31],  and 
natural killer T cells [32]. Hence, we tested by FACS whether IL-17 expression 
in myeloid cells was associated with RORC1. In keeping with IL-17A 
expression,  the  majority  of  blood  and  spleen  PMN-MDSCs  from  AD  mice 
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expressed RORC1, while its expression was restricted to a minor subset of IL-
17A M-MDSCs (Fig. 1D, left). Nevertheless, as compared to PMN-MDSCs, M-
MDSCs  expressed  higher  levels  of  RORC1,  estimated  as  mean  fluorescence 
intensity  (MFI)  (Fig.  1D,  right).  It  is  noteworthy  that  RORC1  was  highly 
expressed  by  splenic  IL-17A  CD11b+F4/80+  macrophages  in  AD  mice  (Fig. 
1E), by F4/80+ TAMs (>90%) and thyoglicollate-elicited peritoneal 
macrophages (PECs) from both tumor-free (NT-PEC) and AD (AD-PEC) mice 
(Fig. 1E).  
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Fig. 1: Myeloid-specific IL-17A +/RORC1+ cells mark advanced cancer-associated 
inflammation . (A) Expression of IL-17A by CD45 +CD3- hematopoietic cells in blood (left) or 
spleens (right) from tumor-free (NT) or MN/MCA1-bearing mice, at both early tumor disease 
(ED) and advanced tumor disease (AD). Mean percentages ± SEM of IL-17A + cells within the 
CD45+CD4-CD3- gate were measured by fluorescence-activated cell sorting (FACS). (B) 
Myeloid subsets in spleens from tumor-bearing mice. Mean percentages ± SEM of Gr1 +CD11b+ 
(total MDSCs), CD11b +Gr1+Ly6ChighLy6G low (M-MDSCs), CD11b +Gr1+Ly6G+Ly6C low (PMN-
MDSCs)  and  CD11b+F4/80+  cells  in  spleen  from  NT,  ED,  or  AD  mice  measured  within  the 
CD45+ gate. (C) Mean percentages ± SEM of IL-17A-expressing M-MDSCs and PMN-MDSCs 
in  blood  or  spleens  from  NT,  ED,  or  AD  mice.  (D)  Mean  percentages  and  MFI  ±  SEM  of 
RORC1-expressing  M-MDSCs  and  PMN-MDSCs  in  blood  or  spleens  from  NT  or  tumor-
bearing mice. (E) RORC1-expressing splenic CD11b +F4/80+ cells obtained from NT, ED, and 
AD mice (left) or RORC1-expressing PECs obtained from NT (NT-PECs) and AD (AD-PECs) 
mice and RORC1-expressing TAMs isolated from AD tumors (MN/MCA1) (right). Results are 
shown  as  mean  percentages  ±  SEM.  Expression  of  IL-17A  and  RORC1  in  myeloid  cells  was 
determined  within  the  CD11b +CD45+  gate.  Results  of  a  representative  experiment  of  six 
independent experiments with six mice/group are shown. Statistical analysis: *p < 0.05, **p < 
0.01, ***p < 0.001 (Student’s t test). See also Figure S1.  
 
 
To corroborate the evidence that ED stages already promote emergency 
hematopoiesis, we performed histopathological and immunohistochemical 
analysis of both spleens and BM from mice bearing early- and late-stage tumor 
(Fig. 2A). Histopathological analysis of the BM parenchyma of wild-type and 
Rorc1-/-  tumor-free  and  tumor-bearing  mice  (including  ED  and  AD  tumor 
stages)  showed  a  significant  expansion  of  the  granulocytic  compartment  (Fig. 
2A,  top),  which  associated  with  a  progressive  contraction  of  the  erythroid 
colonies (blue arrows) and with signs of dysmegakaryopoiesis (i.e., 
megakaryocytes with bulbous and/or hypolobated nuclei and prominent 
pleiomorphism; red arrows). Notably, at late time points (AD), the BM 
granulocytic  hyperplasia  of  tumor-associated  emergency  hematopoiesis  was 
characterized by the enrichment in immature myeloid precursors (Fig. 2A, top, 
dashed lines), which were more conspicuous in WT than in Rorc1 -/- mice. As 
expected, tumor-free mice showed a normal composition of the hematopoietic 
parenchyma  in  the  BM  with  preserved  myeloid/erythroid  ratio  and  normal 
maturation  of  the  myeloid  elements.  Spleen  histopathology  performed  on  the 
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same animals demonstrated signs of tumor-associated emergency hematopoiesis 
in the spleen parenchyma of ED and AD tumor-bearing WT and Rorc1 -/- mice, 
in the form of red pulp hyperplasia underlying splenomegaly (Fig. 2A, bottom). 
The enhanced myelopoiesis of WT mice featured the progressive (i.e., from ED 
to  AD)  accumulation  of  clusters  of  morphologically  immature  granulocytes 
(Fig. 2A, bottom, arrows and dashed lines; right H&E insets) that intermingled 
with erythroid precursor islets, megakaryocytes, and polymorphonuclear 
granulocytes.  Despite  a  comparable  degree  of  red  pulp  hyperplasia  due  to  the 
consistent  increase  in  polymorphonuclear  granulocytes,  erythroid  precursors, 
and megakaryocyte clusters, Rorc1-/- mice showed less clusters of 
morphologically immature myeloid cells as compared with their WT 
counterparts  (Fig.  2A,  bottom,  arrows  and  dashed  lines;  right  H&E  insets). 
Immunohistochemical analysis of the MDSC- associated IL-4R marker 
highlighted IL-4R+ myeloid cells with monocytoid or granulocytic morphology 
populating the myeloid cell aggregates differently enriched within the expanded 
red pulp of tumor-bearing WT and Rorc1 -/- mice (Fig. 2A). Overall, these results 
demonstrate  that  Rorc1-/-  mice  effectively  instruct  BM  and  splenic  emergency 
hematopoiesis along cancer development while displaying a defective induction 
of specific MDSC-related myeloid populations. With the gating strategy used to 
determine  IL-17A  and  RORC1  shown  in  Fig.  2B,  our  results  suggest  that 
RORC1  expression  is  uncoupled  from  IL-17A  in  the  monocytic/macrophage 
compartment, while it is co-expressed in the granulocytic cells of tumor-bearing 
mice.  
To validate this finding in cancer patients, we analyzed the MDSC populations 
in  PBMCs  from  healthy  donors  (HDs;  n  =  10)  or  patients  with  advanced 
colorectal cancer (CRC; stage II/III; n = 10) using the gating strategy of Fig. 2C. 
It is noteworthy that the number of RORC1+ M-MDSCs (HLA-DRlow/-
CD14+CD33high) and PMN-MDSCs (HLA-DR low/-CD15+CD33high) increased in 
CRC  patients  and  dominated  in  the  human  PMN-MDSC  subset  (Fig.  2D). 
Expansion of MDSC populations in cancer patients was paralleled by 
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increased number of circulating neutrophils and monocytes (Fig. 2D). Also in 
analogy  to  the  murine  setting  (Fig.  1D),  the  human  M-MDSCs  population 
showed higher mean fluorescence intensity of RORC1+. In contrast, IL-17A was 
detected  neither  in  human  blood  M-MDSCs  nor  in  PMN-MDSCs  (data  not 
shown).  These  results  indicate  that  expression  of  RORC1  by  myeloid  subsets 
constitutes a hallmark of tumor-promoting ‘‘emergency’’ myelopoiesis. 
 
 
RORC1  Promotes  Expansion  of  MDSCs  and  TAMs.  To  investigate  the  in 
vivo  relevance  of  RORC1-expressing  myeloid  cells,  we  transplanted  donor 
RORC1-deficient BM cells into lethally irradiated C57BL/6 WT recipient mice 
(Rorc1-/- >WT), to be compared to WT>WT mice. Eight weeks later, mice were 
injected  with  MN/MCA1  cells  and  monitored  for  tumor  development.  Tumor 
growth  and  metastasis  were  significantly  reduced  in  Rorc1-/->WT  mice  (Fig. 
3A). The effect of RORC1 deficiency in BM cells was tested in two additional 
tumor models. Rorc1 -/- BM was transplanted into mouse mammary tumor virus-
polyoma middle T antigen (MMTV-PyMT; a spontaneous mammary 
carcinoma)  transgenic  mice  and  into  C57BL/6  mice  that  were  exposed  to 
methylcholanthrene-induced cancerogenesis and subsequently developed 
fibrosarcoma [33] (Fig. 3B). Consistently, RORC1 deficiency in the BM 
resulted  in  tumor  growth  inhibition  in  both  models  (Fig.  3B).  FACS  analysis 
(data  not  shown)  confirmed  the  IL-17/RORC1  expression  pattern  observed  in 
the  MN/MCA1  model  (Fig.  1).  Rorc1 -/->WT  tumor-bearing  mice  showed  a 
significant reduction of splenic M-MDSCs and PMN-MDSCs, in comparison to 
WT>WT mice (Fig. 3C).  
To estimate the suppressive activity of M-MDSCs, we activated cells with IFN-
γ [6], loaded them with ovalbumin, and then co-cultured them for 3 days with 
total  splenocytes  purified  from  OT-1  transgenic  mice  expressing  the  T  cell 
receptor specific for the ovalbumin antigen. Rorc1-/- M-MDSCs displayed 
reduced  suppressive  activity,  estimated  as  proliferation  of  co-cultured  OT1 
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splenocytes (Fig. 3D). It is noteworthy that, at the tumor site, we observed an 
increase  of  PMN-MDSCs  (Fig.  3E),  as  opposed  to  a  significant  decrease  of 
CD11b+Ly6C lowF4/80+ TAMs (Fig. 3F).  
Histological  analysis  of  spleens  from  Rorc1-deficient  tumor  bearers  showed  a 
dramatic reduction in IL-4R + MDSCs [34] and strongly reduced expression of 
IL-17A  (Fig.  3G)  in  comparison  to  WT  counterpart.  These  results  are  further 
confirmative  of  the  IL-4R  expression  analyses  on  WT  and  Rorc1-/- BM  (Fig. 
2A)  and  imply  that  RORC1  promotes  the  expansion  of  splenic  MDSCs  and 
TAMs.  To  confirm  this  conclusion,  we  treated  tumor-free  or  MN/MCA1-
bearing WT mice with the RORC1 agonist SR1078 [35]. SR1078 increased the 
AD lung metastatic burden (Fig. S2A), as well as splenic M-MDSCs and PMN-
MDSCs (Fig. S2B, left). Despite the fact that CD11b +F4/80+ macrophages were 
not modified (data not shown), SR1078 increased RORC1 expression in splenic 
macrophages,  as  well  as  in  M-MDSCs  and  PMN-MDSCs  (Fig.  S2B).  By 
contrast,  IL-17A  expression  was  selectively  induced  in  PMN-MDSCs  (Fig. 
S2B, right). Of note, SR1078 did not affect steady-state myelopoiesis in tumor-
free mice (Fig. S2C), confirming RORC1 as a positive regulator of 
myelopoiesis in cancer. 
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Fig.  2:  Effects  of  RORC1  on  emergency  hematopoiesis  associated  with  cancer 
development. (A) Top: BM histopathological analysis of WT (left) and Rorc1 -/- (right) tumor-
free  (NT)  and  tumor-bearing  mice  with  early  (ED)  and  advanced  (AD)  disease,  showing  the 
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progressive  changes  in  BM  hematopoietic  parenchyma  along  tumor  development  in  the  two 
strains. While tumor-free mice displayed a normal hematopoietic composition with no 
detectable  differences  between  WT  and  Rorc1-/-  strains,  ED  and  AD  BM  samples  showed  a 
progressive expansion of the myeloid granulocytic lineage, which was paralleled by the 
contraction of the erythroid (blue arrows) and megakaryocytic (red arrows) compartments and 
was similarly observed in WT and Rorc1 -/- mice. In AD samples, the myeloid pool expansion 
was  also  characterized  by  the  increase  in  morphologically  immature  myeloid  cell  clusters 
(dashed lines), which was consistent with the enhanced myelopoietic activitiy of stress-adapted 
(i.e.,  cancer-associated)  myelopoiesis.  The  immature  myeloid  cell  clusters  characterizing  AD 
samples  were  more  prominent  in  WT  than  in  Rorc1-/-  mice.  Original  magnifications  of  H&E 
panels  are  3400.  Bottom:  spleen  histopathological  analysis  of  WT  (left)  and  Rorc1-/-  (right, 
composite panels) tumor-free (upper panels) and tumor-bearing (ED, middle composite panels; 
AD, lower composite panels) mice showing the progressive increase in red pulp (RP) 
hematopoietic function along tumor development in the two strains. In tumor-free mice, white 
pulp (WP) areas are predominant over RP, the latter being mainly populated by erythroid cells 
with  scattered  myeloid  and  megakaryocytic  elements  (upper  H&E  panels  and  upper  H&E 
insets). In ED and AD samples, RP hyperplasia was evident and consequent to the increase of 
hematopoietic foci. In particular, the RP WT mice showed an increase in immature myeloid cell 
figures (left middle and lower H&E panels, arrows and dashed lines) showing granulocytic or 
monocytoid morphology (left middle and lower H&E insets, arrows), along with an increase in 
megakaryocyte and erythroid precursor clusters. In Rorc1 -/- mice, despite a comparable degree 
of  RP  hyperplasia  mainly  consequent  to  megakaryocyte  and  polymorphonuclear  granulocyte 
expansion  and  clustering,  foci  of  morphologically  immature  myeloid  cells  were  less  evident 
(right  middle  and  lower  H&E  panels  and  insets,  arrows  and  dashed  lines).  Within  the  RP 
myeloid  cell  clusters  that  were  differently  expanded  in  WT  and  Rorc1 -/-  mice,  cells  with 
granulocytic  or  monocytoid  morphology  expressing  the  MDSC  marker  IL-4R  were  detected 
(IHC  insets,  red  signal). (B)  Gating  strategy  used  to  determine  the  different  mouse  myeloid 
subsets. (C)  Gating  strategy  used  to  determine  the  different  human  myeloid  subsets.  (D) 
Cytofluorimetric analysis of RORC1 expression in the circulating MDSC subsets, neutrophils, 
and monocytes from CRC patients as indicated. MDSC analysis was performed on PBMCs, and 
analysis  of  neutrophils  and  monocytes  was  carried  out  in  whole  blood.  Mean  percentages  ± 
SEM of M-MDSCs (HLA-DR - CD332+CD14+), PMN-MDSCs (HLA-DR - CD332+CD15+), 
monocytes (HLA-DR+CD14+CD15low/ -CD16-CD332+), and neutrophils (HLA-DR -CD14-
CD15+CD16+CD33+) in blood from healthy donors (HD; n = 10) and CRC patients (n = 10) are 
shown.  Statistical  analysis:  *p  <  0.05,  **p  <  0.01,  ***p  <  0.001  (Student’s  t  test).  Below,  a 
representative flow-cytometry analysis of RORC1 + M-MDSCs and RORC1 + PMN-MDSCs from 
cancer patients is also shown. 
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Fig.  3:  Role  of  RORC1  in  the  expansion  of  MDSCs  and  TAMs  during  tumor-
driven  emergency  myelopoiesis. (A)  MN/MCA1  cells  were  injected  into  the  indicated 
hematopoietic  reconstituted  mice.  Starting  from  day  14  after  MN/MCA1  cell  injection,  tumor 
volume (cm 3) was monitored. At day 28, mice were sacrificed, the weight of the tumors (g) was 
estimated  (left),  and  the  number  and  weight  of  macroscopic  lung  metastases  was  measured 
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(right). Data are shown are the mean ± SEM of at least 12 mice/group. Statistical analysis: *p < 
0.05, **p < 0.01, ***p < 0.001 (Student’s t test).  (B) Rorc1 -/- BM was transplanted into MMTV-
PyMT transgenic mice (left) or C57Bl/6 mice, which were subsequently exposed to 
methylcholanthrene to induce fibrosarcoma (right). Mean tumor volumes (cm 3) ± SEM from six 
WT>WT and Rorc1 -/->WT chimeras are shown. Statistical analysis: *p < 0.05, **p < 0.01, ***p 
<  0.001  (Student’s  t  test). (C)  Mean  percentages  ±  SEM  of  M-MDSCs  and  PMN-MDSCs  in 
spleens from WT>WT and Rorc1 -/->WT tumor (MN/MCA1) bearers. Statistical analysis: *p < 
0.05,  **p  <  0.01,  ***p  <  0.001  (Student’s  t  test).  (D)  Decreased  antigen-specific  (OVA) 
suppressive  activity  of  Rorc1 -/-  M-MDSCs  in  response  to  IFN- γ  at  different  MDSC:OT1 
splenocyte  ratios.  Data  shown  are  the  mean  ±  SEM  of  a  representative  experiment  done  in 
triplicate. Statistical analysis: *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test).  (E) Mean 
percentages ± SEM of M-MDSCs and PMN-MDSCs in primary AD tumors (MN/MCA1) from 
WT>WT and Rorc1 -/->WT mice (AD). Statistical analysis: *p < 0.05, **p < 0.01, ***p < 0.001 
(Student’s  t  test). (F)  Mean  percentages  ±  SEM  of  F4/80+  TAMs  in  primary  tumors  from 
WT>WT  and  Rorc1 -/->WT  tumor  bearers  (MN/MCA1).  Myeloid  cell  percentage  in  Rorc1 -/-
>WT chimeras (white bar) is represented as relative value as compared to WT>WT chimeras 
(100%)  (black  bar).  Data  from  a  representative  experiment,  of  six  independent  experiments, 
with n = 6 mice per group is shown. Statistical analysis: *p < 0.05, **p < 0.01, ***p < 0.001 
(Student’s  t  test).  (G)  Histological  analysis  of  IL-17A +  and  IL-4R+  in  the  splenic  MDSCs 
population in WT and Rorc1 -/- tumor-bearing mice.  
 
 
To explain the reduction of MDSCs in Rorc1-/- tumor-bearing mice, we 
considered  two  possible  mechanisms:  RORC1  regulates  the  differentiation  of 
hematopoietic  precursors  in  the  BM  (Fig.    4)  and/or  RORC1  regulates  the 
survival and maturation of MDSCs (Fig. S3). We first analyzed by FACS the 
commitment of common hematopoietic progenitors in tumor-bearing WT>WT 
and Rorc1 -/->WT chimeras. Although in the spleen few Lin -c-kit+Sca-1+ (LSK) 
cells were measured (data not shown), LSK cells were significantly increased in 
the  BM  from  Rorc1-/->WT  mice  (Fig.  4A).  Analysis  of  myeloid  progenitors 
revealed increased number of CMPs in the BM of Rorc1 -/->WT chimeras and, in 
accordance,  a  decrease  of  granulocyte/macrophage  progenitors  (GMPs)  (Fig. 
4A). These findings reveal a blockage in differentiation of early hematopoietic 
progenitors in Rorc1-/->WT chimeras and suggest a relevance of RORC1 
directly  in  the  BM  during  the  early  steps  of  myeloid  cell  differentiation. 
Corroborating  this  hypothesis,  RORC1  was  expressed  by  immature  (c-kit +) 
granulocytes  and  monocytes  in  the  BM  of  naive  mice  (Fig.  4B).  In  the  same 
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myeloid cell subsets, IL-17 was found produced mainly by immature 
neutrophils  (Fig.  4B).  Next,  we  tested  the  in  situ  expression  of  IL-17A  and 
RORC1  in  BM  parenchyma  of  patients  undergoing  a  biopsy  for  staging  of 
Hodgkin’s lymphoma. Consistently, IL-17A staining was localized within 
myeloid cells with immature morphology, within the precursor-rich areas lining 
the bone trabeculae (Fig. 4C, black arrows). By contrast, mature granulocytes 
with  segmented  nuclei  barely  expressed  or  did  not  express  IL-17A.  Indeed,  a 
neat decreasing gradient was observed in IL-17A expression from para-
trabecular areas rich in precursors toward inter-trabecular spaces mainly 
populated by mature elements (Fig. 4C). Notably, double-marker 
immunohistochemical analysis confirmed that IL-17A + hematopoietic cells did 
not correspond to Th-17 cells, as they were distinct from the CD3 + T elements 
populating the BM niche (Fig. 4D, black arrows). Within the same BM 
hematopoietic parenchyma, RORC1 (ROR γ) expression was detected mostly in 
myeloid  cells  with  combined  cytoplasmatic  and  nuclear  localization  (Fig.  4E, 
black arrows). These results in human samples further support that the RORC1/ 
IL-17A  program  takes  part  in  the  regulation  of  the  precursor  compartment 
during myelopoiesis. To test whether RORC1 regulates myelopoiesis, lineage-
negative [36] cells isolated from WT and Rorc1 -/- BM were treated in vitro with 
G-CSF  or  GM-CSF  and  tested,  5  days  later,  for  granulocyte  or  monocyte 
differentiation by flow cytometry (Fig. 4F). In response to GM-CSF, Lin - cells 
from Rorc1 -/- mice failed to differentiate in macrophages, displaying increased 
differentiation  into  GR-1high  granulocytes.  On  the  contrary,  G-CSF  treatment 
resulted in reduced GR-1high granulocyte production by RORC1 -/-Lin- cells. This 
contrasts  with  the  steady-state  condition,  where  in  absence  of  any  specific 
stimulus the rate of differentiation of Lin - cells was identical between WT and 
Rorc1-/- BM  sources.  These  results  indicated  a  key  role  of  RORC1  in  the 
myelopoietic activity of G-CSF and GM-CSF. Fig. S3A underlies the different 
effects of G-CSF and GM-CSF on the differentiation of Ly6G+ subsets, 
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indicating  that  GM-CSF  promotes  a  larger  expansion  of  double  Ly6G+Ly6C+ 
monocytic cells. 
We  next  determined  whether  RORC1  might  control  MDSC  survival  [37]  and 
maturation. Small differences were observed in survival of WT versus Rorc1 -/- 
BM-derived MDSCs at steady-state conditions (medium) (Fig. S3B). In 
contrast, increased AnxV + binding was observed in both M-MDSCs and PMN-
MDSCs after 48 hr, which was reduced in the presence of either tumor 
supernatant  (TSN)  or  combination  of  GM-CSF/G-CSF  in  both  subsets  (Fig. 
S3B), indicating that RORC1 is crucial for MDSCs survival. The protective role 
of both TSN and GM-CSF/G-CSF against apoptosis was partially lost in 
RORC1-deficient M-MDSCs, while RORC1-deficient PMN-MDSCs suffered a 
massive  apoptosis  (Fig.  S3B).  These  results  confirm  the  protective  role  of 
RORC1 in CSF-mediated M-MSDCs and PMN-MDSCs survival, highlighting a 
tighter dependence of PMN-MDSCs survival from RORC1 expression levels. 
Neutrophil activation and maturation is paralleled by upregulation of the FC γII 
and FCγIII receptors (CD32 and CD16, respectively) [38] and of the 
complement  C5a  receptor  (C5aR)  [39].  Splenic  PMN-MDSCs  from  WT>WT 
tumor  bearers  expressed  lower  CD16/CD32  and  C5aR  levels  than  did  PMN-
MDSCs from Rorc1-/->WT mice (Fig. S3C). Furthermore, WT splenic immature 
PMN-MDSCs expressed lower levels of CD16/CD32 and C5aR, as opposed to 
higher  RORC1,  when  compared  to  mature  thioglycollate-elicited  neutrophils 
(Neu-PECs) (Fig. S3D). These observations indicate that RORC1 might 
suppress  neutrophil  maturation,  favoring  immature  PMN-MDSCs  to  support 
tumor promotion. 
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Fig. 4: RORC1 regulates myeloid commitment of BM precursors. (A) Frequency of 
hematopoietic stem cells (LSK) and myeloid progenitors (CMP, GMP, and MEP) in the BM of 
WT and Rorc1 -/- mice. Mean percentages ± SEM is shown. Statistical analysis: *p < 0.05, **p < 
0.01, ***p < 0.001 n = 6 (Student’s t test). (B) Flow-cytometry analysis for the expression of 
RORC1 and IL-17 in different myeloid cells identified by staining of BM cells with monoclonal 
antibodies to CD11b, CD117, GR-1, and F4/80. For RORC1 expression, BM cells from Rorc1 -/- 
mice  were  set  as  a  negative  control.  Immature  granulocytes  (myeloblasts)  were  identified 
according to their co-expression of GR-1 and c-kit. Mature granulocytes were GR-1 high and c-
kit-,  whereas  monocytes/macrophages  were  CD11b+Gr-1-F4/80+.  For  further  checking  of  their 
phenotype, these populations were sorted and stained with Giemsa. Representative pictures are 
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shown. (C–E) In situ expression of IL-17A and RORC1 (ROR γ) within the hematopoietic BM 
parenchyma  of  patients  undergoing  BM  biopsy  for  staining  of  Hodgkin's  lymphoma  (HL). 
Representative pictures show that both IL-17A (C) and RORC1 (E) are produced by immature 
BM cells lining the endosteal nuche, whereas IL-17A is not expressed by CD3 + cells in the BM 
(D). (F) Lin - cells were isolated from the BM of WT and Rorc1 -/- mice and treated as indicated. 
The  frequency  of  differentiated  myeloid  cell  subsets  was  calculated  within  the  gate  of  viable 
cells  (7-AAD -).  Data  shown  are  the  mean  ±  SEM  of  two  different  experiments.  Statistical 
analysis: *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test). See also Fig. S3.   
 
 
RORC1  Controls  Critical  Regulators  of  Myelopoiesis.  To  determine  the 
tumor-derived factor/s that activate RORC1, we analyzed MN/MCA1 
supernatants from AD mice for myeloid growth factors. TSNs were enriched in 
G-CSF, GM-CSF, and M-CSF and partially in IL-1b (Fig. 5A). Of note, 48 hr of 
treatment with either a combination of GM-CSF and G-CSF or TSN induced IL-
17A  expression  in  BM-derived  PMN-MDSCs  and,  to  a  lower  extent,  in  M-
MDSCs  (Fig.  5B,  left).  BM-derived  M-MDSCs  and  PMN-MDSCs  expressed 
basal RORC1 levels (Fig. 5B, right), plausibly induced by GM-CSF and G-CSF 
used for their in vitro generation [40], which was increased by combination of 
GM-CSF and G-CSF (Fig. 5B, right). Confocal microscopy demonstrated that 
RORC1 expression and nuclear translocation was induced in naive PECs 
challenged for 72 hr with lipopolysaccharide (LPS), IL- 1b, G-CSF, GM-CSF, 
and M-CSF, but not by IFN- γ (Fig. 5C) or IL-6 (data not shown). Of note, we 
found increased levels of G-CSF and GM-CSF in the sera of AD mice (data not 
shown), as compared to ED mice, suggesting that RORC1-dependent 
emergency hematopoiesis is controlled by the extent of cancer-associated 
inflammation. 
Finally, we determined the mRNA levels for RORC1 and RORC2 [20, 41] in 
PECs and in thymocytes [24] from healthy WT mice (Fig. S4A). It is 
noteworthy  that  LPS-stimulated  (72  hr)  PECs  expressed  Rorc1  mRNA  levels 
similar to those of WT thymocytes, but not Rorc2 mRNA. These data confirm 
that in cancer, the monocyte-macrophage lineage expresses a selective RORC1 
fingerprint  unlinked  from  IL-17A,  whereas  the  granulocyte/neutrophil  lineage 
expresses  a  dual  RORC1/IL-17A  signature.  In  support  of  RORC1  as  a  key 
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driver of ‘‘emergency’’ granulo-monocytopoiesis, BM-CD11b+Gr1+ 
granulocytes  and  BM-CD11b+Ly6C+  monocytes  from  both  LPS-  and  M-CSF-
treated mice significantly increased RORC1 expression (Fig. S4B). To 
determine the in vivo role of myeloid growth factor/s, we treated MN/MCA1-
bearing  mice  with  neutralizing  antibodies  to  G-CSF,  GM-CSF,  or  the  M-CSF 
receptor (M-CSFR/CSFR1) [4]. Inhibition of G-CSF and GM-CSF limited the 
accumulation of splenic PMN-MDSCs with no effect on M-MDSCs (Fig. 5D, 
left).  In  contrast,  the  anti-CSFR1  antibody  decreased  the  number  of  F4/80+ 
spleen macrophages whereas, surprisingly, it induced a strong increase in 
splenic PMN-MDSCs. At contrast, the anti-G-CSF antibody significantly 
increased the CD11b +F4/80+ spleen macrophages. Confirming the relevance of 
myelopoiesis to cancer inflammation, neutralization of GM-CSF, G-CSF, or M-
CSFR resulted in inhibition of tumor growth and metastasis (Fig. 5D, center and 
right). These findings suggest a reciprocal antagonistic regulation of the 
polymorphonuclear and monocytic lineages in CSF-driven ‘‘emergency’’ 
myelopoiesis in cancer.  
To  shed  light  on  the  mechanisms  of  RORC1-driven  emergency  myelopoiesis, 
we evaluated positive and negative transcriptional regulators in BM and spleens 
from WT>WT and Rorc1-/->WT tumor bearers. CCAAT/enhancer binding 
protein β  (C/EBPβ)  is  a  major  positive  regulator  of  G-CSF-  and  GM-CSF-
driven ‘‘emergency’’ myelopoiesis [11], whereas C/EBP α appears to be a major 
regulator of ‘‘steady-state’’ granulopoiesis and cooperates with PU.1 to 
‘‘emergency’’ granulo-monocytopoiesis [42, 43]. We observed a mild but 
significant  decrease  of  mRNA  expression  of  PU.1,  C/EBPβ,  and  C/EBPα  in 
spleens  and  BM  from  Rorc1 -/->WT  tumor  bearers,  paralleled  by  decreased 
C/EBPβ  protein  levels  in  splenic  PMN-MDSCs  and  M-MDSCs  (Fig.  6A). 
Importantly,  BM  and  spleens  from  Rorc1 -/->WT  MN/MCA1  tumor  bearers 
displayed  increased  mRNA  levels  of  the  suppressor  of  cytokine  signaling-3 
(Socs3) and the transcriptional co-regulator B cell leukemia/lymphoma 3 (Bcl3) 
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(Fig.  6B),  both  potent  inhibitors  of  G-CSF-driven  granulopoiesis  [44,  45].  In 
agreement  with  the  IFN-γ-mediated  inhibition  of  G-CSF-driven  neutrophilia 
[46],  IFN-γ  induced  a  strong  increase  of  Socs3  and  Bcl3  mRNA  in  splenic 
PMN-MDSCs from Rorc1-/- tumor bearers (Fig. 6B, right). Finally, in 
accordance  with  the  decreased  number  of  macrophages  found  in  spleen  and 
tumor of Rorc1 -/->WT chimeras (Fig. 6C), we observed a decreased number of 
IRF8-expressing  CD11b +F4/80+CD115+  macrophages  (Fig.  6D),  which  was 
confirmed  by  confocal  microscopy  in  tumor  tissues  of  Rorc1-/->WT  chimeras 
(data not shown). As M-CSFR/CD115 [5] is a marker of terminally 
differentiated macrophages [47], this result indicates that RORC1 is required for 
the modulation of cell-fate switching factor(s) driving maturation of 
macrophages [13]. 
 
 
  135 
 
Fig.  5:  CSF-,  LPS-,  and  IL-1β-mediated  induction  of  RORC1  in  innate  immune 
cells. (A)  Expression  levels  of  GM-CSF,  G-CSF,  M-CSF,  and  IL-1b  in  the  MN/MCA1 
supernatants  (TSN)  from  advanced  disease  were  determined  by  ELISA.  Data  shown  are  the 
mean  ±  SEM  of  three  independent  experiments. (B)  BM-MDSCs  were  left  untreated  or  were 
treated with either TSN (MN/MCA1) or a combination of recombinant GM-CSF (40 ng/ml) and 
G-CSF  (40  ng/ml)  for  48  hr.  Expression  of  IL-17A  and  RORC1  in  M-MDSCs  and  PMN-
MDSCs was evaluated by FACS analysis. Mean fluorescence intensity (MFI) ± SEM of three 
representative experiments is shown. Statistical analysis: *p < 0.05, **p < 0.01, ***p < 0.001 
(Student’s t test).  (C) Expression and nuclear translocation of RORC1 in PECs exposed to IFN-
g (200 U/ml), LPS (100 ng/ml), IL-1 β (20 ng/ml), G-CSF (40 ng/ml), GM-CSF (40 ng/ml), and 
M-CSF  (40  ng/ml).  After  72  hr  of  in  vitro  activation,  PECs  were  stained  with  anti-RORC1 
antibody (red) or irrelevant rat immunoglobulin G (IgG). Nuclei were counterstained with DAPI 
(blue).  Representative  images  are  shown.  Confocal  microscopy  analysis  of  RORC1  nuclear 
fluorescence  intensity  (nuclear  coefficient)  is  shown  on  the  right.  Mean  ±  SEM  from  three 
independent  experiments  is  shown.  Statistical  analysis:  *p  <  0.05,  **p  <  0.01,  ***p  <  0.001 
(Student’s  t  test).  (D)  MN/MCA1  tumor-bearing  mice  were  treated  with  blocking  antibodies 
against G-CSF, GM-CSF, M-CSFR/CSFR1, or isotype control antibody as indicated. Data on 
M-MDSCs, PMN-MDSCs, and CD11b +F4/80+ cells in spleens from mice with AD within the 
CD45+  gate  (left)  and  primary  tumor  growth  (center)  are  shown  as  the  mean  ±  SEM.  The 
number  of  macroscopic  lung  metastases  (right)  is  shown  as  the  mean  ±  SD.  A  representative 
experiment with six mice/ group is shown. Statistical analysis: *p < 0.05, **p < 0.01, ***p < 
0.001 (Student’s t test).  See also Figure S4.  
 
 
RORC1 controls polarization of myeloid cells. M-CSFR signaling modulates 
macrophage survival and differentiation [5] and induces M2 macrophage 
polarization, a condition supporting tumor progression [48]. To evaluate 
RORC1 in the macrophage polarization, we analyzed the mRNA expression of 
prototypical  M1  and  M2  genes  in  AD-PECs,  cells  displaying  an  intermediate 
PEC versus a TAM phenotype and representing a good model to study M1-M2 
polarization in cancer [49, 50] from tumor-bearing WT>WT and Rorc1 -/->WT 
chimeras.  AD-PECs  were  isolated  from  tumor-  bearing  WT>WT  and  Rorc1-/-
>WT chimeras and treated with 100 ng LPS (M/L) or 200 U/ml IFN- γ for 4 hr 
to induce M1 polarization or exposed to LPS for 20 hr (L/M) to induce LPS-
tolerant  M2-like  polarization  [51].  In  addition,  spleen  PMN-  MDSCs  were 
stimulated 4 hr in vitro with IFN- γ, LPS, or IFN-  γ plus LPS. RORC1-deficient 
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AD-PECs  displayed  enhanced  expression  of  M1  (IL-12p40,  tumor  necrosis 
factor  alpha  (TNF-α),  IL-1β)  and  decreased  expression  of  M2  (IL-10,  TGFβ, 
chitinase-3-like protein 3/Ym1) genes under M/L and L/M conditions (Fig 7A). 
Simiarly, RORC1-deficient PMN-MDSCs showed increased TNF- α and IL-1  β 
mRNA  levels  and  IL-1β  secretion  in  response  to  LPS/IFN-γ  (Fig.  7B).  Thus, 
RORC1 acts as negative regulator of M1 and promoter of M2 cytokine genes.  
This  observation  was  supported  by  the  increased  levels  of  pro-inflammatory 
cytokines (TNF-α and IL-1β) and growth factors (G-CSF, GM-CSF, and 
VEGF)  in  MN/MCA1  superna-  tants  from  Rorc1-/->WT  (Fig.  7C),  correlating 
with  marked  splenomegalia  observed  in  Rorc1 -/->WT  chimeras  bearing  the 
MN/MCA1 and MMTV-PyMT tumors (Fig. 7D). Moreover, we found 
increased splenic CD4+IFN-γ+ and F4/80+TNF-α+ cells in tumor-free and 
tumor-bearing  Rorc1 -/->WT  mice  (Fig.  S5A),  while  total  CD45 +CD4+  cells 
decreased as described (Fig. S5A) [52]. In contrast, tumor-infiltrating CD4 +IFN-
γ+ and total CD45 +CD4+ T cells increased in Rorc1 -/->WT chimeras (Fig. S5A). 
Furthermore, F4/80+TNF-α+ macrophages increased in spleens and tumors from 
Rorc1-/->WT mice (Fig. S5A). Supporting the inhibitory role of RORC1, 
CD4+Foxp3+  T  regulatory  cells  significantly  decreased  in  the  spleen  from 
Rorc1-/->WT mice (Fig. S5A). 
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Fig.  6:  Influence  of  RORC1  on  the  expression  of  transcriptional  regulators  of 
myeloid cell maturation. (A) Total RNA from BM (left) and splenocytes (center) obtained 
from  MN/MCA1-bearing  WT>WT  and  Rorc1-/->WT  mice  was  analyzed  by  RT-PCR  for  the 
expression of the C/EBP β, C/EBPα, and PU.1 transcription factors. Results are given as the fold 
increase over the mRNA level expressed by WT and are representative of at least three different 
experiments. Mean percentages ± SEM of C/EBP β protein expression in M- and PMN-MDSC 
subsets in c-kit low BM and splenocytes from WT>WT and Rorc1 -/->WT tumor-bearing chimeras 
were measured by FACS analysis (right). The mean ± SD of three independent experiments is 
shown. (B) mRNA levels of Socs3 and Bcl3 in BM and splenocytes (left) or in unstimulated (-) 
and  IFN-γ-activated  PMN-MDSCs  (CD11b +Ly6G+)  isolated  from  the  spleen  (right)  obtained 
from  MN/MCA1-bearing  WT>WT  and  Rorc1-/->WT  mice.  Results  are  shown  as  the  mean  ± 
SEM from triplicate values. (C) Splenic CD11b+F4/80+CD115+ macrophages (left) and 
CD11b+F4/80+CD115+ TAMs (right). Macrophage percentage in Rorc1 -/->WT chimeras (white 
bar)  is  represented  as  relative  value  as  compared  to  WT>WT  chimeras  (100%)  (black  bar). 
Results are shown as the mean ± SEM from triplicate values.  (D) The mean count ± SEM of 
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IRF8+F4/80+ cells in spleens and MN/MCA1 from WT>WT and Rorc1 -/->WT chimeras 
analyzed  within  the  CD11b +F4/80+  gate  is  shown.  The  mean  ±  SEM  of  three  independent 
experiments is shown. Statistical analysis: *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test). 
 
 
 
 
 
Fig.  7.  Effects  of  RORC1  on  macrophage  polarization. (A)  Total  RNA  from  control 
(medium),  activated  (IFN-γ),  M1-activated  (M/L),  and  M2-like  LPS-tolerant  (L/M)  AD-PECs 
  139 
harvested  from  MN/MCA1  from  WT>WT  (black  bar)  or  Rorc1-/->WT  (white  bar)  chimeras 
were  analyzed  by  RT-PCR  for  the  expression  of  representative  M1  genes  (IL-12p40,  TNF-α, 
and IL-1 β) and M2 genes (IL-10, TGF β, and Ym1). Statistical analysis: *p < 0.05, **p < 0.01, 
***p  <  0.001;  n=3  (Student’s  t  test).  Results  are  representative  of  at  least  three  different 
experiments  and  are  shown  as  the  mean  ±  SEM  from  triplicate  values. (B)  Total  RNA  from 
control (medium) and activated (IFN- γ, LPS, or LPS+IFN- γ) PMN-MDSCs obtained from the 
spleen  from  MN/MCA1-bearing  WT>WT  and  Rorc1-/->WT  chimeras  were  analyzed  by  RT-
PCR  for  the  expression  of  representative  M1  genes  (IL-1β  and  TNF-α).  Secretion  of  IL-1β 
(pg/ml) was determined by ELISA. Cells were activated as indicated for 24 hr. Results are given 
as  the  fold  increase  over  the  mRNA  level  expressed  by  untreated  cells  (medium)  and  are 
representative of at least three different experiments; shown are the mean ± SEM from triplicate 
values. For ELISA, results are the average of three independent experiments ± SD. Statistical 
analysis: *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test).  (C) Expression levels (pg/ml) of 
cytokines/growth  factors  in  tumor  supernatants  (MN/MCA1)  harvested  from  WT>WT  and 
Rorc1 -/->WT  chimeras.  Results  are  the  average  of  three  independent  experiments  ±  SEM. 
Statistical  analysis:  *p  <  0.05,  **p  <  0.01,  ***p  <  0.001  (Student’s  t  test). (D)  Mean  spleen 
weights  (g)  ±  SEM  in  MN/MCA1-bearing  (n=10)  and  MMTV-PyMT  (n=6)  mice.  Statistical 
analysis: *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test). See also Figure S5.  
 
 
Antagonistic regulation of the polymorphonuclear and monocytic lineages. 
A decreased number of tissue macrophages in tumors from Rorc1 -/->WT mice 
(Fig. 3F) correlated with increased PMN-MDSCs infiltration (Fig. 3E), 
suggesting that pathways leading to terminal differentiation and M2 polarization 
of TAMs hamper neutrophil accumulation in tumors. To prove this assumption, 
we  treated  MN/MCA1-bearing  WT  mice  with  an  anti-CSFR1  antibody  [53], 
which significantly depleted the CD11b +F4/80+CD115+ TAMs population, co-
expressing high RORC1 levels (Fig. 8A). Macrophage depletion was paralleled 
by the inhibition of immature RORC1 + M-MDSCs and PMN-MDSCs (Fig. 8B) 
and increased tumor infiltration of mature (C5ahighCD16/32high) (Fig. 8C) 
RORC1  Ly6Ghigh  neutrophils  (Fig.  8B).  In  agreement,  RORC1  was  highly 
expressed  in  F4/80+/CD115+  macrophages,  in  comparison  to  reduced  RORC1 
levels in Ly6G low granulocytes and negativity in mature inflammatory Ly6G high 
granulocytes  (Fig.  8D),  indicating  that  TAMs  infiltration  is  accompanied  by 
infiltration of immature MDSC populations, at the expense of mature 
neutrophils. Of relevance, anti-M-CSF treatment resulted in a similar increase of 
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C5ahighCD16/32high  mature  neutrophils  in  the  spleen  (Fig.  S6A),  indicating  its 
systemic  effects.  These  results  are  in  agreement  with  Fig.  5D  and  together 
suggest a competition between the monocytic and granulocytic commitment of 
myeloid  precursors.  As  mature  RORC1  PMN-MDSCs  display  a  pronounced 
inflammatory  phenotype  (Fig.  7B),  their  inhibition  most  likely  contributes  to 
maintaining  the  tumor-promoting  microenvironment.  Furthermore,  while  M-
CSF induced RORC1 expression in splenic (data not shown) and medullar (Fig. 
S4B)  monocyte  precursors,  treatment  with  anti-CSFR1  resulted  in  reduced 
monocyte/macrophage precursors (population C + D) and in increased 
granulocyte progenitors (population A + B) (Fig. 8E). Supporting the role for 
reciprocal  negative  regulation  of  monocytes/macrophages  and  granulocytes  in 
cancer inflammation, treatment with anti-G-CSF antibody increased the number 
of  splenic  F4/80 +TNF-α+  M1-like  macrophages,  paralleled  by  elevation  of 
CD4+IFN-γ+ Th1 cells (Fig. 8F). As the increase in CD4+IFN-γ+ and 
F4/80+TNF-α+ cells observed in Rorc1 -/- tumor-bearing mice was phenocopied 
by the anti-G-CSF treatment of MN/MCA1 tumor-bearing mice, we questioned 
whether  G-CSF  might  work  through  RORC.  To  address  this  question,  we 
treated WT and Rorc1 -/- tumor-bearing mice with anti-G-CSF and monitored the 
expansion of both CD4+IFN-γ+ and F4/80+TNF-α+ cells. As a result, the anti-G-
CSF treatment significantly decreased RORC1 expression in PMN-MDSCs and 
partially  in  M-  MDSCs  and  F4/80+  macrophages  (Fig.  S6B).  Moreover,  the 
increase  of  tumor-infiltrating  F4/80+TNF-α+  macrophages  and  CD4+IFN-γ+  T 
cells in response to anti-G-CSF, observed in WT mice, was significantly 
reduced  in  Rorc1-/-  mice  (Fig.  S6C),  strengthening  the  hypothesis  that  G-CSF 
works through the induction of RORC1. Finally, to assess the role of myeloid-
specific  RORC1  in  adaptive  immunity  against  cancer,  we  depleted  CD4+ and 
CD8+  T  cells  in  both  WT  and  Rorc1-/-  tumor-bearing  mice.  As  a  result,  we 
observed  a  significant  increase  of  lung  metastasis  in  Rorc1-/-  tumor-bearing 
mice treated with the anti-CD4/anti-CD8 antibodies (Fig. S6D), suggesting that 
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the  protumor  activity  of  RORC1  acts  through  both  the  innate  and  adaptive 
immunity.  
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Fig.  8:  Reciprocal  negative  regulation  of  monocytes/macrophages  and  granulocytes  in 
cancer-associated inflammation. (A) Mean counts ± SEM of CD115 - and RORC1-expressing 
F4/80+  macrophages  in  the  MN/MCA1  tissue  from  untreated  (isotype  IgG  control)  and  anti-
CSFR1-treated tumor-bearing WT mice. (B) Mean counts ± SEM of RORC1+ and RORC1 M-
MDSC and PMN-MDSC subsets. (C) Mean fluorescence intensity (MFI) ± SEM for 
CD16/CD32 and C5aR expression in PMN-MDSCs in MN/MCA1 from WT mice treated with 
isotype IgG or ant-CSFR1 antibody. (A–C) Statistical analysis: *p < 0.05, **p < 0.01, ***p < 
0.001; n = 3 (Student’s t test). (D) FACS analysis of RORC1 expression levels in Ly6G high and 
Ly6G low granulocytes and in F4/80 +/CD115+ macrophages. (E) FACS dot plots for granulocyte 
(A), monocyte/macrophage (C), and macrophage (D) progenitor subsets in BM and spleen from 
one  representative  MN/MCA1-  bearing  WT  mouse  treated  with  IgG  isotype  and  one  treated 
with anti-CSFR1 antibody, both with AD, are shown. The mean ± SD of five mice/experimental 
group is shown (t test, *p < 0.05; n=5). Statistical analysis: *p < 0.05, **p < 0.01, ***p < 0.001 
(Student’s t test). (F) Total CD4 + and CD4+IFN-γ+ and total F4/80+ and F4/80+TNF-α+ subsets in 
MN/MCA1 tumors from tumor-bearing mice treated with isotype control antibody (white bar) 
or  anti-G-CSF  antibody  (black  bars).  The  mean  ±  SEM  of  six  mice/experimental  group  is 
shown.  Statistical  analysis:  *p  <  0.05,  **p  <  0.01,  ***p  <  0.001  (Student’s  t  test). See  also 
Figure S6.  
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Discussion 
We demonstrate that RORC1 fuels cancer-promoting inflammation by 
enhancing  survival  and  expansion  of  CD16/32low/  C5aRlow  immature  MDSCs, 
with  reduced  expression  of  M1  cytokines  (IL-1β  and  TNF-α)  and  increased 
suppressive  activity,  and  promoting  terminal  macrophage  differentiation.  Our 
study indicates that RORC1 impinges on cancer-driven myelopoiesis by 
suppressing negative (Socs3 and Bcl3) [44, 45] and promoting positive 
(C/EBPb) [42] transcriptional regulators of ‘‘emergency’’ granulopoiesis, while 
instating the expression of macrophage-specific tran- scription factors IRF8 and 
PU.1 [13]. Depletion of RORC1+F4/80+CD115+ TAMs with anti-CSFR1 
antibody enhanced the recruitment of mature (CD16/CD32high) RORC1  
inflammatory neutrophils, with diminished expansion of immature 
RORC1+(CD16low/CD32low) PMN-MDSCs. This result, along with the observed 
competition between the commitment of myeloid precursors for the monocytic 
versus  granulocytic  lineage,  observed  with  the  anti-G-CSF  and  anti-CSFR1 
treatments, respectively, may indicate that blocking M-CSF-dependent 
myelopoiesis unleashes expansion and maturation of granulocytic cells, which 
would favor the increase of tumor-infiltrating neutrophils. These events deflect 
the inflammatory microenvironment to adverse the tumor, increasing infiltration 
of  CD4+  IFN-γ+  T  cells  and  F4/80+TNF-α+  M1  polarized  macrophages.  Our 
results indicate that high RORC1 expression acts as pro- resolving mediator of 
myeloid inflammation and that antagonists to RORC1 might hold the potential 
to prevent tumor-promoting myeloid differentiation. We also report that IL-17 
expression is disjointed from RORC1 in the monocyte/macrophage lineage (M-
MDSCs  and  CD11b+F4/80+  TAMs).  Wu  et  al.  have  recently  described  that 
tumor-infiltrating inflammatory dendritic cells activate IL-17-producing ROR γt+ 
γδT17 cells to secrete IL-8, TNF-α, and GM-CSF cells and sustain the 
subsequent  intratumor  accumulation  of  immunosuppressive  PMN-MDSCs  in 
colorectal cancer [54]. Further, an inflammatory cascade encompassing the IL-
  144 
1β-mediated  production  by  IL-17  in γδT  cells  resulted  in  systemic  G-CSF-
dependent expansion of suppressive neutrophils and formation of breast cancer 
metastasis  [55].  Our  observation  that  IL-17  is  selectively  expressed,  but  not 
secreted by immature granulocyte/neutrophil subsets, does not support a direct 
role  of  myeloid-cell-derived  IL-17  in  the  expansion  of  MDSCs  during  cancer 
development, but rather indicates that IL-17A is a hallmark of immature 
myeloid  responses  in  cancer  bearers.  This  notion  is  further  supported  by  the 
observation that expression of IL-17 and RORC1 localizes within the immature 
myeloid  cells  precursor-rich  areas  lining  the  bone  trabeculae  of  BM  biopsies 
from patients under diagnosis of Hodgkin’s lymphoma. Moreover, in contrast to 
Rorc1-/- BM  transplantation,  chimeric  mice  receiving  the  Il17a-/- BM  had  no 
defect in developing tumor-associated myeloid cells, in both the BM and spleen 
(data  not  shown).  It  remains  to  be  established  whether  IL-17A  expression  by 
circulating MDSCs is dependent on the disease stage, as we did not observe its 
expression in blood from T2/T3 CRC patients. 
Along with other reports, our observation highlights the relevance of members 
of the nuclear receptor superfamily in regulation of inflammation [56, 57] and 
suggests RORC1 as central regulator of cancer associated myelopoiesis and key 
driver of the protumor differentiation of MDSCs and TAMs. 
 
Author contributions 
L.S.  and  A.S.  conceived  the  ideas  and  designed  the  experiments.  L.S.,  S.S., 
F.M.C.,  G.S.,  S.M.,  M.G.T.,  C.P.,  A.A.,  S.T.,  A.D.,  F.Z.,  and  C.T.  performed 
the experiments. L.S., S.S., C.T., M.P.C., and A.S. analyzed the data. L.S. and 
A.S. wrote the paper. 
 
Acknowledgments 
This work was supported by Associazione Italiana Ricerca sul Cancro (AIRC; 
Program  Innovative  Tools  for  Cancer  Risk  Assessment  and  Diagnosis,  5  per 
  145 
mille  number  12162  and  IG  number  2014-15585),  Fondazione  Cariplo,  and 
Ministero Universita` Ricerca (MIUR). 
 
References 
 
1. Ueha,  S.,  F.H.  Shand,  and  K.  Matsushima,  Myeloid  cell  population 
dynamics  in  healthy  and  tumor-bearing  mice.  Int  Immunopharmacol, 
2011. 11(7): p. 783-8. 
2. Sica, A. and V. Bronte, Altered macrophage differentiation and immune 
dysfunction in tumor development. J Clin Invest, 2007. 117(5): p. 1155-
66. 
3. Metcalf, D., Hematopoietic cytokines. Blood, 2008. 111(2): p. 485-91. 
4. Hume, D.A. and K.P.A. MacDonald, Therapeutic applications of 
macrophage  colony-stimulating  factor-1  (CSF-1)  and  antagonists  of 
CSF-1 receptor (CSF-1R) signaling. Blood, 2012. 119(8): p. 1810-1820. 
5. Qian,  B.Z.  and  J.W.  Pollard,  Macrophage  diversity  enhances  tumor 
progression and metastasis. Cell, 2010. 141(1): p. 39-51. 
6. Gabrilovich,  D.I.,  S.  Ostrand-Rosenberg,  and  V.  Bronte,  Coordinated 
regulation of myeloid cells by tumours. Nat Rev Immunol, 2012. 12(4): 
p. 253-68. 
7. Gordy,  C.,  et  al.,  Regulation of steady-state neutrophil homeostasis by 
macrophages. Blood, 2011. 117(2): p. 618-29. 
8. Goren,  I.,  et  al.,  A Transgenic Mouse Model of Inducible Macrophage 
Depletion Effects of Diphtheria Toxin-Driven Lysozyme M-Specific Cell 
Lineage Ablation on Wound Inflammatory, Angiogenic, and Contractive 
Processes. American Journal of Pathology, 2009. 175(1): p. 132-147. 
9. Chow,  A.,  et  al.,  Bone  marrow  CD169(+)  macrophages  promote  the 
retention of hematopoietic stem and progenitor cells in the mesenchymal 
  146 
stem cell niche. Journal of Experimental Medicine, 2011. 208(2): p. 261-
271. 
10. Winkler, I.G., et al., Bone marrow macrophages maintain hematopoietic 
stem cell (HSC) niches and their depletion mobilizes HSCs. Blood, 2010. 
116(23): p. 4815-4828. 
11. Akagi, T., et al., Impaired  response  to  GM-CSF  and  G-CSF,  and 
enhanced apoptosis in C/EBP beta-deficient hematopoietic cells. Blood, 
2008. 111(6): p. 2999-3004. 
12. Zhang,  H.,  et  al.,  STAT3  controls  myeloid  progenitor  growth  during 
emergency granulopoiesis. Blood, 2010. 116(14): p. 2462-71. 
13. Friedman,  A.D.,  Transcriptional  control  of  granulocyte  and  monocyte 
development. Oncogene, 2007. 26(47): p. 6816-28. 
14. Liu, B., et al., IL-17 is a potent synergistic factor with GM-CSF in mice 
in stimulating myelopoiesis, dendritic cell expansion, proliferation, and 
functional enhancement. Exp Hematol, 2010. 38(10): p. 877-884 e1. 
15. Schwarzenberger, P., et al., Requirement of endogenous stem cell factor 
and granulocyte-colony-stimulating factor for IL-17-mediated 
granulopoiesis. J Immunol, 2000. 164(9): p. 4783-9. 
16. Iwakura,  Y.,  et  al.,  Functional Specialization of Interleukin-17 Family 
Members. Immunity, 2011. 34(2): p. 149-162. 
17. Toomer, K.H. and Z.B. Chen, Autoimmunity as a double agent in tumor 
killing and cancer promotion.  Frontiers  in  Immunology,  2014.  5:  p.  1-
14. 
18. Zamarron,  B.F.  and  W.  Chen,  Dual  roles  of  immune  cells  and  their 
factors  in  cancer  development  and  progression.  Int  J  Biol  Sci,  2011. 
7(5): p. 651-8. 
19. Zhu, X., et al., IL-17 expression by breast-cancer-associated 
macrophages:  IL-17  promotes  invasiveness  of  breast  cancer  cell  lines. 
Breast Cancer Res, 2008. 10(6): p. R95. 
  147 
20. Ivanov,  II,  et  al.,  The orphan nuclear receptor RORgammat directs the 
differentiation program of proinflammatory IL-17+ T helper cells. Cell, 
2006. 126(6): p. 1121-33. 
21. Taylor,  P.R.,  et  al.,  Activation  of  neutrophils  by  autocrine  IL-17A-IL-
17RC  interactions  during  fungal  infection  is  regulated  by  IL-6,  IL-23, 
RORgammat and dectin-2. Nat Immunol, 2014. 15(2): p. 143-51. 
22. Zhuang, Y., et al., CD8(+) T Cells That Produce Interleukin-17 
Regulate  Myeloid-Derived  Suppressor  Cells  and  Are  Associated  With 
Survival Time of Patients With Gastric Cancer. Gastroenterology, 2012. 
143(4): p. 951-+. 
23. Hueber,  A.J.,  et  al.,  Mast cells express IL-17A in rheumatoid arthritis 
synovium. J Immunol, 2010. 184(7): p. 3336-40. 
24. Sun,  Z.M.,  et  al.,  Requirement  for  ROR  gamma  in  thymocyte  survival 
and lymphoid organ development.  Science,  2000.  288(5475):  p.  2369-
2373. 
25. Guy, C.T.C., R.D.; and Muller, W.J., Induction of mammary tumors by 
expression  of  polyomavirus  middle  T  oncogene:  a  transgenic  mouse 
model for metastatic disease. Mol Biol Cell, 1992. 12: p. 954-961. 
26. Larghi,  P.,  et  al.,  The p50 subunit of NF-kappaB orchestrates dendritic 
cell lifespan and activation of adaptive immunity. PLoS One, 2012. 7(9): 
p. e45279. 
27. Tripodo, C., et al., Stromal SPARC contributes to the detrimental 
fibrotic changes associated with myeloproliferation whereas its 
deficiency favors myeloid cell expansion. Blood, 2012. 120(17): p. 3541-
3554. 
28. Moalli,  F.,  et  al.,  Role of complement and Fc gamma receptors in the 
protective activity of the long pentraxin PTX3 against Aspergillus 
fumigatus. Blood, 2010. 116(24): p. 5170-5180. 
  148 
29. Mantovani,  A.,  et  al.,  Neutrophils  in  the  activation  and  regulation  of 
innate and adaptive immunity.  Nat  Rev  Immunol,  2011.  11(8):  p.  519-
31. 
30. Sawa,  S.,  et  al.,  Lineage  Relationship  Analysis  of  ROR  gamma  t(+) 
Innate Lymphoid Cells. Science, 2010. 330(6004): p. 665-669. 
31. Gray, E.E., K. Suzuki, and J.G. Cyster, Cutting Edge: Identification of a 
Motile IL-17-Producing gamma delta T Cell Population in the Dermis. 
Journal of Immunology, 2011. 186(11): p. 6091-6095. 
32. Rachitskaya, A.V., et al., Cutting edge: NKT cells constitutively express 
IL-23  receptor  and  ROR  gamma  t  and  rapidly  produce  IL-17  upon 
receptor ligation in an IL-6-independent fashion. Journal of 
Immunology, 2008. 180(8): p. 5167-5171. 
33. Stutman, O., Tumor development after 3-methylcholanthrene in 
immunologically  deficient  athymic-nude  mice.  Science,  1974.  183:  p. 
534-536. 
34. Marigo,  I.,  et  al.,  Tumor-induced  tolerance  and  immune  suppression 
depend on the C/EBPbeta transcription factor.  Immunity,  2010.  32(6): 
p. 790-802. 
35. Kojetin, D.J. and T.P. Burris, REV-ERB and ROR nuclear receptors as 
drug targets. Nature Reviews Drug Discovery, 2014. 13(3): p. 197-216. 
36. Markiewski, M.M., et al., Modulation of the antitumor immune response 
by complement. Nature Immunology, 2008. 9(11): p. 1225-1235. 
37. Sinha,  P.,  et  al.,  Myeloid-derived  suppressor  cells  express  the  death 
receptor Fas and apoptose in response to T cell-expressed FasL. Blood, 
2011. 117(20): p. 5381-5390. 
38. Hogarth,  P.M.,  Fc  receptors  are  major  mediators  of  antibody  based 
inflammation in autoimmunity.  Current  Opinion  in  Immunology,  2002. 
14(6): p. 798-802. 
39. Guo,  R.F.  and  P.A.  Ward,  Role  of  C5A  in  inflammatory  responses. 
Annual Review of Immunology, 2005. 23: p. 821-852. 
  149 
40. Peranzoni, E., et al., Myeloid-derived suppressor cell heterogeneity and 
subset definition. Current Opinion in Immunology, 2010. 22(2): p. 238-
244. 
41. Yang, X.O., et al., T helper 17 lineage differentiation is programmed by 
orphan nuclear receptors ROR alpha and ROR gamma. Immunity, 2008. 
28(1): p. 29-39. 
42. Hirai, H., et al., C/EBP beta is required for 'emergency' granulopoiesis. 
Nature Immunology, 2006. 7(7): p. 732-739. 
43. Jin, F.L., et al., PU.1 and C/EBP alpha synergistically program distinct 
response to NF-kappa B activation through establishing monocyte 
specific enhancers. Proceedings of the National Academy of Sciences of 
the United States of America, 2011. 108(13): p. 5290-5295. 
44. Croker, B.A., et al., SOCS3 is a critical physiological negative regulator 
of  G-CSF  signaling  and  emergency  granulopoiesis.  Immunity,  2004. 
20(2): p. 153-65. 
45. Kreisel, D., et al., Bcl3 prevents acute inflammatory lung injury in mice 
by restraining emergency granulopoiesis. J Clin Invest, 2011. 121(1): p. 
265-76. 
46. Ulich, T.R.d.C., J.; and Souza, L., Kinetics and mechanisms of 
recombinant human granulocyte-colony stimulating factor-induced 
neutrophilia. Am J Pathol, 1988. 133: p. 630-638. 
47. Auffray, C., M.H. Sieweke, and F. Geissmann, Blood  Monocytes: 
Development,  Heterogeneity,  and  Relationship  with  Dendritic  Cells. 
Annual Review of Immunology, 2009. 27: p. 669-692. 
48. Mantovani, A. and A. Sica, Macrophages, innate immunity and cancer: 
balance, tolerance, and diversity.  Curr  Opin  Immunol,  2010.  22(2):  p. 
231-7. 
49. Sica,  A.,  et  al.,  Autocrine production of IL-10 mediates defective IL-12 
production and NF-kappa B activation in tumor-associated 
macrophages. J Immunol, 2000. 164(2): p. 762-7. 
  150 
50. Torroella-Kouri, M., et al., Identification of a Subpopulation of 
Macrophages  in  Mammary  Tumor-Bearing  Mice  That  Are  Neither  M1 
nor M2 and Are Less Differentiated. Cancer Research, 2009. 69(11): p. 
4800-4809. 
51. Porta, C., et al., Tolerance and M2 (alternative) macrophage 
polarization  are  related  processes  orchestrated  by  p50  nuclear  factor 
kappaB. Proc Natl Acad Sci U S A, 2009. 106(35): p. 14978-83. 
52. Harrington,  L.E.,  et  al.,  Interleukin  17-producing  CD4(+)  effector  T 
cells  develop  via  a  lineage  distinct  from  the  T  helper  type  1  and  2 
lineages. Nature Immunology, 2005. 6(11): p. 1123-1132. 
53. Ries,  C.H.,  et  al.,  Targeting  tumor-associated  macrophages  with  anti-
CSF-1R  antibody  reveals  a  strategy  for  cancer  therapy.  Cancer  Cell, 
2014. 25(6): p. 846-59. 
54. Wu,  W.C.,  et  al.,  Circulating hematopoietic stem and progenitor cells 
are myeloid-biased in cancer patients. Proc Natl Acad Sci U S A, 2014. 
111(11): p. 4221-6. 
55. Coffelt, S.B., et al., IL-17-producing gammadelta T cells and 
neutrophils conspire to promote breast cancer metastasis. Nature, 2015. 
522(7556): p. 345-8. 
56. Gerbal-Chaloin,  S.,  et  al.,  Nuclear  receptors  in  the  cross-talk  of  drug 
metabolism and inflammation. Drug Metab Rev, 2013. 45(1): p. 122-44. 
57. Wittke,  A.,  et  al.,  Vitamin  D  receptor-deficient  mice  fail  to  develop 
experimental allergic asthma. J Immunol, 2004. 173(5): p. 3432-6. 
 
 
 
 
 
 
 
  151 
Supplemental Data 
 
 
 
Fig. S1. (Related to Fig 1):  Classification of MN/MCA1 bearing mice into early- (ED) and 
late-stage  (AD)  tumor  bearers.  Data  are  mean  ±  SEM  in  30  mice.  (Left)  After  tumor  cell 
injection (day 0), tumor volume (cm 3) was measured starting from day 14 until day 28. (Right) 
Mean counts ± SEM of macroscopic lung metastases in 30 mice are shown.  
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Fig. S2. (Related to Fig. 3):  The RORC1 agonist SR1078 promotes metastasis formation and 
expansion of tumor promoting myeloid populations in tumor bearing mice. (A) Mean counts ± 
SEM of macroscopic lung metastases in untreated (PBS receivers) and SR1078 treated mice. (B) 
Data are mean percentages ± SEM of M-MDSC, PMN-MDSC; RORC1+M-MDSC, 
RORC1+PMN-MDSC, RORC1+CD11b+F4/80+; IL-17A+PMN-MDSC in spleen from 
MN/MCA1 bearing mice receiving PBS or SR1078. (C) Mean percentages ± SEM of M-MDSC, 
PMN-MDSC and CD11b +F4/80+ in spleen from tumor free mice receiving PBS or SR1078. The 
mean  prevalence  of  myeloid  subsets  measured  in  mice  treated  with  SR1078  is  represented  as 
relative value of the mean obtained in PBS-treated control mice, defined as 100%. 6 
animals/group are shown. Statistical analysis: *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t 
test). 
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Fig. S3. (Related to Fig. 4):  Role of RORC1 in M- and PMN-MDSC survival. (A) Different 
ratio of induction of the Gr1 +Ly6C - vs Gr1 +Ly6C+ myeloid populations, from the progenitors in 
response to G-CSF and GM-CFS. (B) FACS analysis of AnnexinV-binding (AnxV) to in vitro 
generated  BM-derived  M-MDSC  and  PMN-MDSC,  from  WT  and  Rorc1-/- mice,  as  indicated. 
AnxV binding was determined in response to 48 hr of culture with media, TSN (MN/MCA1) or 
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combination  of  recombinant  GM-CSF  (40  ng/ml)  and  G-CSF  (40  ng/ml).  Mean  ±  SD  of  3 
independent experiments is shown. (C and D) Effect of RORC1 on neutrophil maturation. (C) 
The  histogram  bars  show  the  mean  percentages  ±  SEM  of  CD16/CD32+  and  C5aR+  PMN-
MDSCs separated from the spleen of MN/MCA1 bearing WT>WT and Rorc1 -/->WT chimeras. 
(D)  The  histogram  bars  show  the  mean  ±  SEM  of  the  relative  mean  fluorescence  (MFI)  for 
CD16/CD32,  C5aR  and  RORC1  in  PMN-MDSC  harvested  from  the  spleen  of  MN/MCA1 
bearers  and  in  thioglycollate  elicited  peritoneal  neutrophils  (Neu-PEC)  from  tumor  free  mice. 
Data  from  6  independent  experiments  are  shown.  Statistical  analysis:  *p  <  0.05,  **p  <  0.01, 
***p < 0.001 (Student’s t test). 
 
 
 
 
 
 
 
Fig.  S4.  (Related  to  Fig.  5):  RORC1  expression  by  myeloid  cells.  (A)  RORC1  mRNA 
expression  in  peritoneal  macrophages  (PEC).  mRNA  expression  levels  for  Rorc1  (left)  and 
Rorc2  (right)  in  LPS  stimulated  (48  or  72  hr)  PEC  were  compared  to  constitutive  levels 
expressed by unstimulated thymocytes. Mean ± SEM from 3 independent experiments is shown. 
(B) RORC1 is expressed during “emergency” granulo-monocytopoiesis. RORC1 expression in 
bone marrow CD11b +GR1+ granulocytic and CD11b +Ly6C+ monocytes from both LPS- and M-
CSF-treated mice was analysed by FACS. Data shown are mean ± SEM of 6 mice. Statistical 
analysis: *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test). 
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Fig.  S5.  (Related  to  Fig.  7):  Influence  of  RORC1  on  type  I  innate  and  adaptive  effector 
responses. (A) Total CD4 + and CD4 +IFN-γ+ within the CD45 + gate (upper histograms) and total 
F4/80+ and F4/80 +TNFα+ subsets within the CD11b +CD45+ gate (lower histograms), in spleen 
from  tumor  free  (Left),  spleen  from  tumor  bearers  (Center)  and  from  MN/MCA1  tumors 
(Right),  in  chimeric  mice  as  indicated.  The  mean  prevalence  of  CD4  and  F4/80  subsets 
measured  in  Rorc1-/->WT  chimeras  is  represented  as  relative  value  of  the  mean  obtained  in 
WT>WT  chimeras  (defined  as  100%).  Mean  ±  SEM  of  a  representative  experiment,  of  6 
independent experiments, with 6 mice/group is shown. (B) FACS-DOT PLOTs for CD4 +IFN-γ+ 
and  F4/80+TNFα+  subsets  in  MN/MCA1  of  one  representative  WT>WT  and  Rorc1 -/->WT 
chimera with AD are shown. HISTO PLOTS of the relative mean fluorescence (MFI) of TNFa 
expression by F4/80 + MN/MCA1 infiltrating macrophages of one representative WT>WT and 
Rorc1 -/->WT chimera with AD are shown. Statistical analysis: *p < 0.05, **p < 0.01, ***p < 
0.001 (Student’s t test). 
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Fig.  S6.  (Related  to  Fig.  8):  (A)  Modulation  of  mature  splenic  neutrophils  in  anti-CSFR1 
treated  tumor  bearing  mice.  Data  are  mean  percentage  ±  SD  for  CD16/CD32  and  C5aR 
expression  in  PMN-MDSC  in  MN/MCA1  from  WT  mice,  treated  with  isotype  IgG  or  ant-
CSFR1  antibody,  is  shown.  (B)  Flow  cytometry  analysis  of  RORC1  expression  in  tumor 
infiltrating  (MN/MCA1)  M-MDSC,  PMN-MDSC  and  F4/80  macrophages,  in  anti-G-  CSF 
treated tumor bearing WT mice. Mean ± SD is shown. (C) Flow cytometry analysis of tumor 
infiltrating TNF α+F4/80+ macrophages and IFN- γ+CD4+ T lymphocytes in anti-G-CSF treated 
tumor bearing WT and Rorc1 -/- mice. Mean ± SD is shown. (D) Number of lung metastasis in 
WT  and  Rorc1-/-  tumor  bearing  mice  treated  with  anti-CD4+  and  anti-CD8+  T  cell  depleting 
antibodies. Mean ± SEM of 7 animals/group are shown. Statistical analysis in panels A-D: *p < 
0.05, **p < 0.01, ***p < 0.001 n=6 (Student’s t test) 
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Supplemental Experimental Procedures 
 
Ethics  Statement.    The  study  was  designed  in  compliance  with  principles  set 
out in the following laws, regulations and policies governing the care and use of 
laboratory animals: Italian Governing Law (Legislative Decree 116 of Jan. 27, 
1992); EU directives and guidelines (EEC Council Directive 86/609, OJ L 358, 
12/12/1986);  Legislative  Decree  September  19,  1994,  n.  626  (89/391/CEE, 
89/654/CEE, 89/655/CEE, 89/656/CEE, 90/269/CEE, 90/270/CEE, 
90/394/CEE, 90/679/CEE); the NIH Guide for the Care and Use of Laboratory 
Animals (1996 edition); Authorization n. 11/2006-A issued January 23, 2006 by 
Ministry of Health. The study was approved by the scientific board of 
Humanitas  Clinical  and  Research  Center.  Humanitas  Clinical  and  Research 
Center Institutional Regulations and Policies providing internal authorization for 
persons conducting animal experiments. 
 
Animals.  C57BL/6  mice  were  purchased  from  Charles  River  (Calco,  Italy). 
Homozygous RORC1 mutant mice (B6.129P2(Cg)-Rorctm1Litt/J) [1] were 
donated by Prof. Dr. Dan Littman (New York University). Male MMTV-PyMT 
mice [2], were donated by Prof. Guido Forni (University of Turin, Orbassano, 
Italy)  and  mated  with  C57BL/6  females  to  obtain  the  F1  C57BL/6-MMTV-
PyMT strain. IL-17A-deficient mice were donated by Prof. Dr. Burkhard 
Becher (University of Zuerich, CH). 
 
Bone marrow Transplantation (BMT). 8 weeks old mice were lethally 
irradiated with two dose of 475 cGy before bone marrow transplantation 
(BMT).  5*106  CD45.2  RORC1  deficient  (Rorc1 -/-),  IL-17A-/-,  or  WT  bone 
marrow (BM) cells were injected intravenously into CD45.1 C57BL/6 WT male 
or  C57BL/6-MMTV-PyMT  female  mice.  8  weeks  later,  BM  engraftment  was 
checked  by  staining  blood  cells  with  PerCP-conjugated  CD45.1  antibody  and 
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PE-conjugated CD45.2 antibody (BD Biosciences) and subsequent FACS 
analysis. Then, 105 murine fibrosarcoma (MN/MCA1) cells were injected 
intramuscularly in the left hind limb. Tumor growth was monitored 3 times a 
week with a caliper, starting from day 14. To chemically induce fibrosarcoma, 8 
weeks  after  BMT  mice  received  a  single  subcutaneous  injection  of  200  µg 
methylcholanthrene in corn oil. 12 weeks later tumor growth was monitored 3 
times a week. 6-8 weeks after BMT, C57BL/6-MMTV-PyMT mice were 
monitored 3 times a week for breast carcinoma development. 
 
Cell Culture and Reagents.  TAMs and thioglycollate-elicited peritoneal 
exudate  cells  (PEC)  were  isolated  from  healthy  or  tumor  bearing  mice  as 
previously described [3]. PEC and TAMs were incubated in RPMI 1640 
containing 10% FCS, 2 mmol/L glutamine and 100 units/mL penicillin-
streptomycin. BM-MDSCs were generated from bone marrow (BM) cells 
isolated from naïve WT or Rorc1 -/- mice as previously described [4]. BM cells 
were  cultured  for  4  days  in  RPMI  containing  10%  FBS,  supplemented  with 
40ng/ml of murine recombinant IL-6, GM-CSF and G-CSF (Peprotech). Spleen-
derived  MDSCs  were  isolated  by  MACS  cell  separation  according  to  the 
manufacturer’s  instructions  (Miltenyi  Biotech).  In  details,  MDSCs  were  first 
enriched by consequent serial negative selections with CD19 and CD11c 
microbeads (130-052-201 and 130-052-001 respectively), followed by positive 
selection  with  LY6G  microbeads  kit  (130-092-332)  (PMN-MDSCs).  Finally, 
remaining  cells  were  positively  selected  with  CD11b+  microbeads  (130-049-
601),  which  all  stained  positive  for  Ly6C  marker  (M-MDSC).  The  purity  of 
both BM-MDSCs and spleen-derived M-MDSCs (CD11b+Ly6C+Ly6Glow), 
PMN-MDSC (CD11b+Ly6G+Ly6Clow) populations was >90%, as determined by 
flow cytometry, and the viability as determined by AnxV-binding (Immunostep) 
was >95% for WT>WT MDSCs subsets, whereas in contrast MDSCs isolated 
form Rorc1 -/->WT animals showed a decreased viability (as stated in the text). 
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BM-MDSCs  were  cultured  in  RPMI  1640  containing  5%  FCS,  2  mmol/L 
glutamine,  100  units/mL  penicillin-streptomycin,  10  mM  Hepes  and  20  mM 
beta-mercaptoethanol and M-MDSCs and PMN-MDSCs subsets were cultured 
in DMEM containing 5% FCS, 2 mmol/L glutamine, 100 units/mL penicillin-
streptomycin, 10 mM Hepes and 20 µM beta-mercaptoethanol. The 
concentration for the different in vitro, treatments were as follows: 100 ng/mL 
LPS  from  Salmonella  Abortus,  Equi  S-form  (Alexis),  200  U/mL  IFN-γ,  40 
ng/mL  GM-CSF,  40  ng/mL  G-CSF,  40  ng/mL  IL-1β  (all  from  Peprotech)  or 
MN/MCA1 tumor supernatant (TSN) diluted 1:1 in culture media. 
 
Lineage cell separation from BM. Isolation of lineage-negative cells (depleted 
from mature hematopoietic cells such as T cells, B cells, 
monocytes/macrophages,  granulocytes  and  erythrocytes)  from  BM  harvested 
from naïve WT or Rorc -/- mice was performed by using the murine lineage cell 
separation  kit  from  Miltenyi  (130-090-858)  as  indicated  by  the  manufacturers 
protocol. Separated lineage–negative progenitor cells were cultured in the 
presence of recombinant murine GM-CSF (40 ng/mL), G-CSF (40 ng/mL) (all 
from Peprotech) or culture media alone for up to 7-10 days. Then, to evaluate 
ckit+  macrophage/monocyte  and  granulocyte  progenitors,  cells  were  stained 
with  anti-CD117  (ckit),  CD11b,  Ly6C,  Ly6G,  Gr1,  and  F4/80  antibodies  (all 
from eBioscience) and analyzed by flow cytometry. 
 
In vivo treatments.  When the tumor became palpable (day 14) WT>WT and 
Rorc1-/->WT  mice  were  treated  with  the  following  drugs:  RORα/ γ  Agonist 
(SR1078, Calbiochem) was administered at the dose of 10mg/kg intra 
peritoneally  (i.p.)  four  times  a  week  for  2  weeks,  control  mice  received  PBS 
injections; CSFR1 antagonist (kindly donated by Dr. Carola Ries, Roche 
Diagnostic Gmbh, Penzberg, Germany) were administered as an initial dose of 
60mg/kg followed by two doses of 30 mg/kg two times a week for a total of 2 
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weeks;  anti-GCSF  MAB  414  (R&D  Systems),  anti-  GM-CSF  415NA  (R&D 
Systems)  were  administered  1  mg/mouse  i.p.  daily  for  a  total  of  2  weeks; 
control mice were injected with isotype antibody 0,3 mg of both the anti-CD4 
(Rat  Anti-Mouse  CD4  Monoclonal  Antibody,  Unconjugated,  Clone  GK1.5, 
BioXcell)  and  the  anti-CD8  (Rat  Anti-Mouse  CD8a  Monoclonal  Antibody, 
Unconjugated, Clone 2.43, BioXcell) antibodies were injected IP once a week. 
 
Patients. 10 patients with T2 or T3 CRC were enrolled in the study after signing 
Cancer  Research  Center  Humanitas  IRB-approved  consent.  Patients  did  not 
receive  radiation  or  chemotherapy  before  sample  collection.  Peripheral  blood 
was collected at the time of surgery from all patients. All blood samples were 
analyzed  within  3  hr  after  collection  by  FACS-analysis  (see  section  Flow 
Cytometry). 
 
MLR. M-MDSCs (CD11b+Ly6C+Ly6Glow) populations were isolated from 
MN/MCA1  bearing  WT>WT  or  Rorc1-/->WT  chimeric  mice  by  Milteny  bead 
separation as described above. Serial dilutions of M-MDSC starting from 2*10 5 
cells were plated in 96 well plates in 100µL of RPMI medium (2*10 5, 1*10 5, 
5*104, 2.5*104 or 12.5*104). Cells were then stimulated with IFN- γ (200 U/mL) 
or kept in culture media alone for 72 hr. Then, TSNs were harvested and tested 
for nitrite production (as control) and 2*10 5 splenocytes from OT1 mice were 
added. Cells were incubated in DMEM containing 5% FCS, 2 mmol/L 
glutamine,  100  units/mL  penicillin-streptomycin,  10  mM  Hepes  and  20  µM 
beta-mercaptoethanol and pulsed with ovalbumin peptide (OVA257–264) (250 
µg/mL)  for  additional  72  hr.  H3  thymidine  was  added  for  the  last  16  hr  of 
culture and its incorporation was analyzed by MicroBeta plate counter (Perkin 
Elmer).  As  controls  OT-1  splenocytes  alone  were  pulsed  with  OVA  peptide 
(250  µg/mL),  ConA  (5  µg/mL)  or  kept  in  culture  media.  All  conditions  were 
evaluated in triplicates. 
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Flow cytometry. 5*10 5 cells were re-suspended in HBSS (Hank’s balanced salt 
solution, Lonza) supplemented with 0.5% BSA (Sigma). Staining was 
performed  at  4°C  for  20  minutes,  with  the  following  antibodies:  anti-mouse 
CD45-PerCP, CD11b-PE, FITC or –APC, Gr1-PE or -APC, F4/80-PE or -APC, 
CD115  (CSFR1)-PE  C5aR-PE  and  IFN-γ-PE  (all  from  BD  Biosciences;  San 
Diego,  CA);  Ly6G-FITC  and  Ly6C-FITC  or  –PE  (from  Miltenyi  Biotech; 
Teterow, Germany); FCII/IIIR –PE or –APC (CD16/CD32) (from Bio Legend; 
San  Diego,  SA);  lineage  markers  (PE-CD3,  -CD4,  -CD8,  –Mac-1,  –Gr-1,  -
Ter119, and -B220), hematopoietic progenitor markers (Sca-1, c-Kit (CD117), 
IL7Rα, CD34,) IL-17A-APC, TNF α-Alexa647 and anti-mouse/human RORC1-
APC  (from  eBioscience;  San  Diego,  CA);  anti-human  CD14-PE,  HLADR- 
Pacific  Blue,  CD15-FITC  (BD  Bioscience;  San  Diego,  CA)  and  IL-17A-PE 
(BioLegend San Diego, CA). Further we used unconjugated CEBP/β (Millipore; 
Billerica,  Massachusetts)  and  unconjugated  IRF8  antibody  (Cell  Signaling) 
followed  by  incubation  with  secondary  goat  anti  rabbit  Alexa  Fluor®  488 
conjugated  antibody  (Invitrogen,  Molecular  Probes,  Carlsbad,  CA).  For  the 
gating of viable cells we used viability staining solution (7-ADD eBiosciences). 
For  intra-cellular  staining  Cytofix/Cytoperm  and  Permwash  staining  kit  (BD 
Pharmigen) were used according to the manufacturer’s instruction. Cells were 
detected  using  the  BD  FACS  Canto  cytofluorimeter  and  analyzed  with  BD 
FACS Diva Software. 
 
Gating  strategy  for  the  identification  of  human  MDSCs,  neutrophils  and 
monocytes.  Cells  were  stained  with  a  cocktail  of  mABs  to  HLA-DR  (clone 
L243), CD14 (clone M5E2), CD16 (Anti-human CD16 (PE-Cy7), Clone: CB16, 
eBioscience San Diego, CA), CD15 (clone HI98) (BD biosciences, San Diego, 
CA)  and  CD33  (clone  WM53,  BioLegend  San  Diego,  CA).  Identification  of 
monocytes and neutrophils was carried out in whole blood from healthy or CR 
patients, by an immunophenotypic analysis through multiparameter flow 
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cytometry. The analysis was performed according to WHO criteria on antigens 
that  are  expressed  by  human  monocytes  and  neutrophils.  Neutrophils  were 
identified as HLA-DR-CD14-CD15+CD16+CD33+ cells, whereas monocytes 
were HLA-DR+CD14+CD15low/- CD16-CD33++. Analysis of MDSCs 
populations  was  performed  on  PBMC  from  healthy  or  CR  patients.  MDSCs 
were identified within the gate of HLA-DR - cells as CD33 high cells. Next within 
the CD33high gate, the two subsets were resolved according to their expression 
of  CD14  (M-MDSCs)  or  CD15  (G-MDSCs).  Interestingly,  differently  from 
CD14+  mature  monocytes  that  retain  HLA-DR  expression,  a  condition  that 
allow distinguishing them from M-MDSCs, granulocytes and G-MDSCs were 
both negative for HLA-DR expression. Therefore, in the whole blood, to further 
distinguish granulocytes from G-MDSCs we evaluated the level of expression 
of  CD33  that  were  higher  in  G-MDSCs  and  almost  negative  in  granulocytes. 
Notably  according  to  other  literature  data  we  found  that  CD33  mAb  that 
certainly marks M-MDSCs also stain circulating CD14+ monocytes, a 
population  that  is  also  increased  in  advance  colorectal  cancer  patients.  In 
summary  in  PBMC  from  colorectal  cancer  patients  we  defined  M-MDSCs  as 
HLA-DR-CD14+CD33high whereas G-MDSC were HLA-DR-CD15+CD33high. 
 
Histopathology  and  Immunohistochemistry.  Histopathological  analysis  was 
performed on BM and spleens from WT, Rorc1 -/- and chimeric mice on sections 
routinely  stained  with  Haematoxylin  and  Eosin.  Single-  and  double-marker 
immunohistochemistry on mouse and human tissue specimens were performed 
as  previously  described  [5].  Briefly,  four-micrometers  thick  sections  were  cut 
from  formalin-fixed  and  paraffin-embedded  tissue  specimens  and  put  onto 
slides; sections were deparaffinized through alcohol gradients and rehydrated to 
water.  Antigenic  retrieval  was  performed  using  TRIS-  EDTA  pH9  buffer  in 
thermostatic bath at 98°C for 30 minutes. Mouse spleen sections were incubated 
with  anti-mouse  IL4R  (Biolegend)  and  anti-mouse  IL17A  (Abcam)  primary 
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antibodies and the binding was revealed using specific secondary antibodies and 
the streptavidin-biotin-peroxidase complex method. Sections from BM biopsies 
of patients with early-stage Hodgkin’s lymphoma and uninvolved marrow (n=8) 
were incubated with anti-human IL-17A (LifeSpan, Biosciences, Inc.) or anti-
human RORγ (LifeSpan, Biosciences, Inc.) and the binding was revealed by the 
means of specific secondary antibody and the alkaline-phosphatase anti-
alkaline-phosphatase method (APAAP, Dako). Double-marker 
immunohistochemistry  for  IL-17A  and  CD3  was  performed  on  sections  from 
the same specimens by two sequential rounds of single-marker 
immunohistochemistry  using  the  two  different  revelation  systems  mentioned 
above.  Stained  sections  were  analyzed  by  an  expert  pathologist  (CT)  using  a 
Leica DM2000 optical microscope and microphotographs were collected with a 
Leica DFC320 digital camera using the Leica IM50 imaging software. 
 
Real-Time PCR. Total RNA was extracted with TRIzol (Invitrogen) according 
to the manufacturer’s instructions. 1 µg of total RNA was reverse-transcribed by 
the  High  Capacity  cDNA  Reverse  Transcription  kit  (Applied  Biosystems), 
amplified using Fast Syber Green Master Mix (Applied Biosystems), and 
detected  by  the  7900HT  Fast  Real-Time  System  (Applied  Biosystems).  The 
sequences of gene-specific primers are available upon request. Data were 
processed using SDS2.2.2 software (Applied Biosystems). Results were 
normalized to the expression of the housekeeping gene β-actin and then 
expressed as fold up-regulation with respect to the control cell population. 
 
ELISA. MN/MCA1 supernatants were tested in sandwich ELISA (R&D 
Systems). Tumor cell-free supernatants were tested for the indicated 
cytokines/growth factors: Murine TNF α, GM-CSF, G-CSF, M-CSF, IL-1 β, IL-
17A and VEGFA (Duoset Elisa kit, R&D). 
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Confocal  Microscopy  analysis.  Cells  were  seeded  on  Poly-L-Lysine  (Sigma-
Aldrich) coated sterile rounded glasses at 2x10 5 cells/ml in medium and fixed 
with  4%  PFA  for  10  minutes  at  room  temperature.  Cell  permeabilization  was 
obtained  after  1  hr  incubation  with  PBS  0.1%  Triton-X100  (Sigma-Aldrich) 
plus 5% normal goat serum (Dako Cytomation, Carpinteria, CA USA) and 2% 
BSA,  (Amersham  Biosciences,  Piscataway  Township,  NJ  USA).  Cells  were 
then incubated with anti-mouse/human RORC1-APC (Clone: AFKJS-9, 
eBioscience;  San  Diego,  CA)  or  rat  IgG2a  K  isotype  APC  as  control.  Nuclei 
were counterstained with DAPI (Invitrogen, Molecular Probes). Samples were 
mounted  with  FluorPreserve  Reagent  (Calbiochem  San  Diego,  CA  USA)  and 
analyzed with an Olympus Fluoview FV1000 laser scanning confocal 
microscope operating with lasers with 405 and 647 nm excitations. The 
resulting fluorescence emission was collected using a 460-to-490 nm (for DAPI) 
and 620-750 nm (for APC) band-pass filters. Samples were imaged with an oil 
immersion objective (40×1.30 NA Plan-Apochromat; Olympus). 
 
Statistics. Statistical significance was determined by a two-tailed Student’s t test 
(*p <0.05, ** p <0.01, *** p <0.001). 
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5. Discussion 
Both  recruitment  and  activation  of  tumor  associated  myeloid  cells  may  be 
considered putative targets for therapeutic intervention; accordingly, because of 
their  unique  role  in  linking  innate  and  adaptive  immunity,  macrophage-based 
immunotherapy is widely considered in clinical trials of cancer patients. 
Chemoattractants  involved  in  monocyte  recruitment  include  chemokines  (e.g. 
CCL2,  CCL5,  CXCL4)  [1-3],  colony-stimulating  factor-1  (CSF-1)  [4,  5],  and 
members  of  the  VEGF  family  [6].  Recently,  genetic  evidence  in  the  mouse 
suggested that complement components play an important role in the 
accumulation  and  functional  polarization  of  TAMs  [7,  8].  We  identified  p50 
NF-κB also as an important regulator of macrophage migration. In particular we 
demonstrated that lack of p50 NF-κB impairs macrophage chemotactic 
responsiveness.  Accordingly,  nuclear  accumulation  of  p50  NF-κB  not  only 
drives phenotypic traits of TAMs and LPS-tolerant macrophages, including the 
expression of anti-inflammatory M2 polarized genes [9], but also promotes their 
chemotactic  response  to  complement  anaphylatoxins  C5a  and  C3a.  Distinct 
F4/80+  macrophage  subsets  characterized  by  different  expression  levels  of 
F4/80  and  the  C5aR  (CD88),  respectively  defined  as  F4/80highCD88high  and 
F4/80lowCD88low,  differentially  accumulate  into  the  inflammatory  sites,  in  in 
vivo model of LPS-tolerance. Of relevance, p50-dependent induction of 
systemic  tolerance  [9]  is  a  necessary  event  driving  systemic  accumulation  of 
F4/80highCD88high  mono/macrophages,  both  in  mouse  and  human.  This  result, 
along with the differential expansion of the F4/80lowCD88low and 
F4/80highCD88high populations, observed also in the preclinical MN/MCA1 
fibrosarcoma and B16 melanoma model, indicates that expansion of 
F4/80highCD88high macrophages is promoted through emergency hematopoiesis. 
Moreover, in line with the LPS-tolerance model, ablation of p50 NF-κB resulted 
in significant impairment of F4/80 highCD88high TAMs accumulation in primary 
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tumors, which correlated with inhibition of tumor growth [10] and 
vascularization.  
Consistent with other reports where lack of complement factors (C3 or C5aR) in 
tumor bearers resulted in impaired MDSCs accumulation, as well as in 
resistance to tumor development and metastasis formation [11-15], we observed 
that reduced fibrosarcoma growth and lung metastasis formation in C3 -/- mice, 
as compared to wt mice, was paralleled by significant impairment recruitment of 
F4/80high TAMs,  in  both  primary  tumor  and  lung  metastasis.  This  result  was 
mimicked by treatment with an anti-CSFR1 antibody, indicating that blocking 
accumulation of F4/80 high macrophages in the tumor microenvironment impairs 
tumor growth and tumor angiogenesis.  
Strikingly, adoptive transfer of F4/80low TAMs in wt tumor bearing mice 
resulted in inhibition of tumor growth and in reduced formation of lung 
metastasis,  while,  conversely,  transfer  of  wt  F4/80high  TAMs  in  p50-/-  tumor 
bearing  mice  caused  restoration  of  tumor  growth  and  increased  metastasis 
formation. Accordingly, transfer of F4/80 high TAMs also increased tumor vessels 
density and length, indicating that the ratio between the F4/80 high and F4/80 low 
TAMs  critically  controls  the  angiogenic  switch  in  growing  tumors  [16].  A 
distinct  role  of  F4/80high  and  F4/80low  TAMs  in  tumor  development  was  also 
confirmed by analysis of their transcriptomes, showing that distinct gene 
profiles characterize the transcriptional programs of these populations.  
Thus, we show that distinct macrophage subsets with different functions arise 
during  infection-  and  cancer-driven  inflammation,  in  a  p50  NF-κB-dependent 
manner and that complement-mediated pathways selectively drive their 
infiltration of inflammatory sites, including solid tumors. 
 
In addition, we demonstrate that the retinoic-acid-related orphan receptor 
(RORC1/RORγ)  fuels  cancer-promoting  inflammation  by  enhancing  survival 
and expansion of CD16/32low/ C5aRlow immature MDSCs, with reduced 
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expression  of  M1  cytokines  (IL-1 β  and  TNF-α)  and  increased  suppressive 
activity, and promoting terminal macrophage differentiation. Our study 
indicates that RORC1 impinges on cancer-driven myelopoiesis by suppressing 
negative  (Socs3  and  Bcl3)  [17,  18]  and  promoting  positive  (C/EBP β)  [19] 
transcriptional  regulators  of  ‘‘emergency’’  granulopoiesis,  while  instating  the 
expression of macrophage-specific tran- scription factors IRF8 and PU.1 [20]. 
Depletion of RORC1+F4/80+CD115+ TAMs with anti-CSFR1 antibody 
enhanced  the  recruitment  of  mature  (CD16/CD32high)  RORC1  inflammatory 
neutrophils, with diminished expansion of immature 
RORC1+(CD16low/CD32low) PMN-MDSCs. This result, along with the observed 
competition between the commitment of myeloid precursors for the monocytic 
versus  granulocytic  lineage,  observed  with  the  anti-G-CSF  and  anti-CSFR1 
treatments, respectively, may indicate that blocking M-CSF-dependent 
myelopoiesis unleashes expansion and maturation of granulocytic cells, which 
would favor the increase of tumor-infiltrating neutrophils. These events deflect 
the inflammatory microenvironment to adverse the tumor, increasing infiltration 
of  CD4+  IFN-γ+  T  cells  and  F4/80+TNF-α+  M1  polarized  macrophages.  Our 
results indicate that high RORC1 expression acts as pro- resolving mediator of 
myeloid inflammation and that antagonists to RORC1 might hold the potential 
to prevent tumor-promoting myeloid differentiation. We also report that IL-17 
expression is disjointed from RORC1 in the monocyte/macrophage lineage (M-
MDSCs  and  CD11b+F4/80+  TAMs).  Wu  et  al.  have  recently  described  that 
tumor-infiltrating inflammatory dendritic cells activate IL-17-producing ROR γt+ 
γδT17 cells to secrete IL-8, TNF-α, and GM-CSF cells and sustain the 
subsequent  intratumor  accumulation  of  immunosuppressive  PMN-MDSCs  in 
colorectal cancer [21]. Further, an inflammatory cascade encompassing the IL-
1β-mediated  production  by  IL-17  in γδT  cells  resulted  in  systemic  G-CSF-
dependent expansion of suppressive neutrophils and formation of breast cancer 
metastasis  [22].  Our  observation  that  IL-17  is  selectively  expressed,  but  not 
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secreted by immature granulocyte/neutrophil subsets, does not support a direct 
role  of  myeloid-cell-derived  IL-17  in  the  expansion  of  MDSCs  during  cancer 
development, but rather indicates that IL-17A is a hallmark of immature 
myeloid  responses  in  cancer  bearers.  This  notion  is  further  supported  by  the 
observation that expression of IL-17 and RORC1 localizes within the immature 
myeloid  cells  precursor-rich  areas  lining  the  bone  trabeculae  of  BM  biopsies 
from patients under diagnosis of Hodgkin’s lymphoma. Moreover, in contrast to 
Rorc1-/- BM  transplantation,  chimeric  mice  receiving  the  Il17a-/- BM  had  no 
defect in developing tumor-associated myeloid cells, in both the BM and spleen 
(data  not  shown).  It  remains  to  be  established  whether  IL-17A  expression  by 
circulating MDSCs is dependent on the disease stage, as we did not observe its 
expression in blood from T2/T3 CRC patients. 
Along with other reports, our observation highlights the relevance of members 
of the nuclear receptor superfamily in regulation of inflammation [23, 24] and 
suggests RORC1 as central regulator of cancer associated myelopoiesis and key 
driver of the protumor differentiation of MDSCs and TAMs. 
 
Nowadays  anticancer  therapies  are  not  only  directed  against  cancer  cells,  but 
different  approaches  have  been  investigated  to  harness  the  potency  of  the 
immune system to target cancer. These have been essentially focused on 
enhancing the immunogenicity of the tumor or on the induction and expansion 
of immune effector cells to potentially target and eradicate the tumor. However, 
immune-modulating activities of chemotherapeutic agents are often very 
complex to understand, due to the fact that same molecules may play opposite 
roles  depending  on  tumor  type,  immune  contexts  and/or  precise  therapeutic 
strategy. Accordingly, the tight balance between immune activating and 
immune suppressive events plays a crucial role in defining the clinical outcome 
of  cancer  patients.  These  complexities  highlight  the  need  for  an  ever  more 
profound comprehension of the dynamic changes in the tumor 
microenvironment and in systemic immune response, as tumors evolve, 
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progress and respond to therapy. An improved knowledge of these aspects will 
facilitate the rational design of highly efficient, synergistic regimens that 
combine anticancer agents and immunotherapies [25]. 
In this scenario, our studies are intended to shed light on novel key pathways 
driving lineage commitment of myeloid precursors during cancer-related 
"emergency"  myelopoiesis,  their  recruitment  and  functional  transcription  in 
cancer bearers, in order to estimate whether they may represent novel prognostic 
indicators  and  targetable  elements  in  anticancer  immunotherapy.  Collectively 
our data identify RORC1 as key orchestrator of pathological differentiation of 
myeloid suppressor cells in cancer bearers and describe a novel role of p50 NF-
κB in guiding expansion, recruitment and the tumor promoting functions of the 
M2-like F4/80high TAMs subset. Hence, RORC1 and p50 provide a new axis of 
cancer associated myelopoiesis that drive the protumor differentiation of 
MDSCs and TAMs.  
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